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Abstract
There is now convincing neurochemical and neurophysiological evidence to 
suggest that increased excitatory neurotransmission is involved in epilepsy. 
Antagonists of JV-methyl-D-aspartate (NMDA)-type glutamate receptors are 
powerful anticonvulsants in many animal models of epilepsy. Early attempts to 
pharmacologically modulate glutamatergic transmission resulted in 
anticonvulsant compounds such as dizocilpine (MK801) and phencyclidine. 
Preclinical testing of these agents generally showed efficacy but also 
demonstrated severe side effects. A clinical application of pure glutamate 
antagonists has yet to be established.
Remacemide hydrochloride (RMD) is an anticonvulsant compound which 
exhibits efficacy in a wide range of seizure models. Both RMD and its active 
metabolite, desglycinyl-remacemide (DGR), are said to have inhibitory actions 
on voltage-gated sodium channels and NMDA glutamate receptors with DGR 
possessing greater potency at both sites. The following studies were designed 
to further investigate the pharmacology of RMD and DGR in various 
neurochemical and epilepsy models. Clinical trial results reported while this 
project was in progress demonstrated that the drug did not perform well as 
monotherapy. It was initially believed that the additional action on NMDA 
receptors would result in RMD possessing an improved clinical profile 
compared to standard Na+ channel blockers such as carbamazepine (CBZ) and 
phenytoin (PHT). Further investigations as to why a drug with such a
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promising preclinical portfolio performed so poorly in the clinical environment 
were therefore conducted.
Pharmacokinetic studies suggested that although some conversion of RMD to 
DGR does occur in the peripheral tissues the majority of DGR generation 
occurs at the blood/brain barrier, resulting in an accumulation of DGR in the 
brain. The pharmacokinetics of DGR were seen to outlast those of the parent 
compound both in serum and brain.
The effects of hepatic enzyme induction on the pharmacokinetics and 
pharmacodynamics of RMD were investigated. Administration of 
phenobarbital (PB), a known hepatic enzyme inducer, resulted in a significant 
increase in both the content and activity of cytochrome P450 enzymes in the 
livers of mice. This increase in hepatic enzyme activity was shown to 
significantly decrease the brain concentrations of RMD and DGR although the 
effects on DGR concentrations were more pronounced. The efficacy of RMD 
against maximal electroshock (MES)-induced seizures was seen to decrease in 
induced animals when compared to saline-treated controls.
In vitro investigations in the hippocampal slice permitted the effects of RMD 
and DGR to be studied separately. CBZ and ARR-15896, a putative NMDA 
antagonist, were employed for comparative purposes. RMD was found to 
have no effect on zero Mg2+ / 4-aminopyridine (4-AP) induced epileptiform 
burst firing in the rat hippocampal slice. In contrast, DGR, CBZ and ARR-
15896 all significantly reduced epileptiform activity. These results suggested
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that blockade of voltage-gated Na+ channels and the NMDA receptor protect 
against paroxysmal discharges in this model. The relatively low potency of 
RMD at these pharmacological targets may explain its lack of efficacy in this 
regard.
A neurochemical study investigating the effects of RMD and DGR on sodium 
channel activity was conducted in rat brain synaptosomes. RMD and DGR 
were seen to reduce voltage-gated sodium channel activity in a concentration- 
related manner in agreement with previous electrophysiological investigations 
and confirmed the reported separation in potency at this site.
Several antiepileptic drugs (AEDs) have effects on y-aminobutyric acid 
(GABA)/glutamate homeostasis. Previous studies have reported that DGR has 
effects on GABA-transaminase (GABA-T) and glutamic acid decarboxylase 
(GAD) following chronic administration to mice. The effects of RMD and DGR 
on the activity of glutamate dehydrogenase, one of the enzymes responsible for 
glutamate homeostasis, were analysed in rat brain mitochondria. RMD and DGR 
were shown to significantly reduce the formation of glutamate from a- 
ketoglutarate (a-KG) via an action on the enzyme glutamate dehydrogenase in rat 
brain mitchondria. It is possible that this action may contribute to the 
anticonvulsant properties of the compounds although further investigations are 
required.
There is growing evidence to suggest that monoamines have an important role
in epilepsy. The effects of RMD and DGR on the reuptake processes of
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serotonin (5-HT), norephinephrine (NE) and dopamine (DA) were 
investigated in rat brain synaptosomes. RMD was seen to significantly reduce 
the reuptake of DA at therapeutically relevant concentrations while DGR 
reduced the reuptake of 5-HT and NE at therapeutic concentrations. Further 
investigations are required to assess the mechanism and importance of the 
results obtained to RMD pharmacology in terms of epilepsy and possibly 
affective disorders.
In conclusion, observations from the above studies indicate that there are 
differences in the pharmacology of RMD and DGR. Pharmacokinetic studies 
demonstrated that DGR is present in the brain at higher concentrations than 
the parent compound. The increased susceptibility of DGR to hepatic enzyme 
induction and a subsequent change in the ratio of RMD to DGR in the brain 
may have contributed to the decrease in pharmacological effect observed in 
MES investigations. Alternatively, the concentrations of RMD and DGR may 
have simply decreased to sub-effective levels. Results from hippocampal slice 
studies suggest that blockade of sodium channels or inhibition of NMDA 
receptors is sufficient to decrease epileptiform bursting in the zero Mg2+/4-AP 
model. It appears, therefore, that RMD, in contrast to DGR, does not exert a 
blockade at either of these two sites of action sufficient to decrease burst 
firing. Results obtained for both compounds with regards to monoamine 
uptake and glutamate dehydrogenase activity may influence the anticonvulsant 
activities of RMD in vivo although further investigations are required to 
assess their importance.
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In conclusion, it is suggested that RMD monotherapy results in NMDA 
receptor blockade by DGR at concentrations lower than those required to 
block Na+ channels. In induced patients, where DGR levels are lower, the 
block of Na+ channels exerted by RMD results in an improved antiepileptic 
profile. As a result it is suggested that NMDA receptor blockade is not as 
important a mechanism of action for an antiepileptic compound to possess as 
first believed. This suggestion has possible implications for the future 
development of NMDA receptor antagonists as AEDs.
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1 INTRODUCTION
1.1 Epilepsy
Epilepsy is one of the most common neurological disorders in man. With a 
prevalence of approximately 0.5 - 1%, it is estimated that 50 million people world 
wide may have the disorder (Brodie et al, 1997). Incidence rates of the disease are 
highest in childhood and the elderly, with a plateau observed between the ages of 
15-65 (Brodie and Dichter, 1997). Epilepsy is not a single disease, but rather a 
collection of diverse syndromes, some of which are secondary to brain 
derangements, and some of which are primarily genetic (Chadwick, 1990).
1.1.1 Definition
The characteristic event of all epileptic disorders is a seizure. These episodes are 
associated with high frequency discharges by a group of neurons in the brain 
(Rang et al, 1995). This transitory disturbance in brain function develops 
suddenly, ceases spontaneously and may be caused by a number of different 
provocations (Barker et al, 2000). The particular symptoms produced by a seizure 
depend on the region of the brain that is affected. Thus, involvement of the 
motor-cortex causes convulsions, involvement of the hypothalamus causes 
peripheral autonomic discharges, and involvement of the reticular formation in the 
upper brainstem leads to loss of consciousness (Rang et al, 1995). Seizures which 
begin as a local abnormal discharge may then spread to other regions of the brain.
30
1.1.2 Classification of seizure types
According to the classification established by the International League against 
Epilepsy, seizures can be divided into two groups, partial and generalised (Table 
1; Brodie and Schachter, 2001).
Partial seizures are those in which the discharge remains localised. When 
consciousness is not impaired the seizure is classified as a simple partial seizure.
In episodes where consciousness is affected, the seizure is termed complex partial. 
Simple partial seizures can develop into complex partial seizures. A partial seizure 
can progress into a generalised motor seizure (Commission, 1981).
Generalised seizures are those which involve both brain hemispheres. Immediate 
loss of consciousness is characteristic of generalised seizures. The main categories 
are tonic-clonic seizures, absences and myoclonic seizures. A tonic-clonic seizure 
consists of an initial strong contraction of the whole musculature, causing a rigid 
spasm. Respiration stops and defaecation, micturition and salivation often occur. 
This tonic phase is followed by a series of violent, synchronous jerks which 
gradually diminish over 2 - 4  minutes. Absence seizures usually occur in children. 
This seizure type is less severe than tonic-clonic seizures although their frequency 
is often much higher. Patients abruptly cease what they are doing, and stare 
vacantly for a few seconds with little or no motor disturbance. Recovery is rapid 
with the patient often suffering no ill-effects (Rang et al, 1995).
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International classification of epileptic seizure types
0 Partial seizures (beginning locally)
• Simple seizures (without impaired consciousness)
• with motor symptoms
• with somatosensory or special sensory symptoms
• with autonomic symptoms
• with psychological symptoms
• Complex partial seizures (with impaired consciousness)
• simple partial onset followed by impaired consciousness
• impaired consciousness at onset
• Partial seizures evolving into secondary generalised seizures
0 Generalised seizures (convulsive or non-convulsive)
• Absence seizures
• typical
• atypical
• Myoclonic seizures
• Clonic seizures
• Tonic seizures
• Tonic-clonic seizures
• Atonic seizures
• Unclassified seizures
Table 1: Simplified version of the International classification of epileptic 
seizures (Brodie and Schachter, 2001).
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Myoclonic seizures are more prevalent among infants and children. This type of 
generalised seizure is characterised by brief jerks usually in the arms that last 1 -5  
seconds (Gram, 1990). Occasionally, myoclonic seizures affect the legs, causing 
falls. As with all generalised episodes, myoclonic seizures often occur within the 
first few hours after arising from sleep (Brodie and Schachter, 2001).
1.1.1 Treatment o f epilepsy
Most patients with recurrent epileptic seizures require treatment. Exceptions are 
those patients with provoked seizures and those whose episodes are separated by 
years (Brodie and Dichter, 1996). The treatment of epilepsy involves drug 
therapy, or a surgical approach may be taken if an underlying structural lesion is 
identified and can be readily removed (Barker et al, 2000).
Although epilepsy has been a recognised disorder for approximately 4000 years, it 
was not until the 19th century that the first effective antiepileptic therapy was 
introduced (Patsalos and Sander, 1994). The anticonvulsant actions of bromide, 
which was introduced in 1857 were associated with severe side-effects, most 
notably sedation (Patsalos and Sander, 1994). Screening of other sedative 
compounds resulted in the discovery of phenobarbital (PB) which was first used 
as treatment for epilepsy in 1912. The search for less sedative compounds resulted 
in the introduction of phenytoin (PHT; Merritt and Putnam, 1938b). The 
subsequent discovery of carbamazepine (CBZ; 1967), primidone, (PRIM; 1952),
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ethosuximide (ESM; 1958) and numerous benzodiazepines (BZDs), including 
diazepam, clobazam and clonazepam (Harden, 1994; Rang et al, 1995), were 
largely due to serendipitous drug discoveries and extensive drug screening 
programmes (Brodie and Dichter, 1996). The anticonvulsant properties of sodium 
valproate (VPA) were discovered in 1963 when the compound was being used as 
a solvent for other agents. The drug was approved for use against epilepsy in 
Europe in 1974 (Brodie and Dichter, 1997).
In the last ten years there has been a huge increase in the number of antiepileptic 
drugs (AEDs) available to treat epilepsy with vigabatrin (VGB), lamotrigine 
(LTG), felbamate (FBM), gabapentin, (GBP), oxcarbazepine (OXC), topiramate 
(TPM), zonisamide (ZNS), tiagabine (TGB) and levetiracetam (LEV) being 
licensed in at least one country in the 1990’s.
The decision about treatment with AEDs should be made following extensive
discussion with the patient with the benefits and side-effects of drug treatment
made clear. Many patients will have to take medication for the rest of their lives,
therefore it is important that a drug suited to the patient’s lifestyle and seizure
type is selected (Brodie and Dichter, 1997). Approximately 30% of patients with
epilepsy are refractory to treatment with a single AED (Kwan and Brodie, 2000).
Before long-term treatment with more than one drug is undertaken, all reasonable
options for monotherapy should be exhausted (Brodie and Dichter, 1996). Studies
have shown that if a patient does not respond to two first-line AEDs as
monotherapy, it is unlikely that their condition will be controlled on any
monotherapy regime (Brodie and Schachter, 2001). Only a relatively small
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subgroup of patients will benefit from a combination of two AEDs, often at the 
expense of an increased burden in terms of side effects. In some cases, 
polytherapy may even result in a paradoxical increase in seizure frequency as a 
manifestation of toxicity (Perucca et al, 1998). There is, however, increasing 
evidence of the beneficial effects of some AED combinations (Stephen et al, 
1998). Many clinicians will combine AEDs that have different mechanisms of 
action for patients with more than one seizure type, and drugs with similar 
mechanisms when there is a single type of seizure that proves unresponsive to 
monotherapy (Brodie and French, 2000).
1.2 Neurochemistry of epilepsy
1.2.1 Neurotransmission
One of the fundamental features of the nervous system is its ability to generate 
and conduct electrical impulses. These can take the form of generator potentials, 
synaptic potentials and action potentials - the latter being defined as a single 
electrical impulse passing down an axon (Barker et al, 2000). Nerve cells usually 
have a potential difference across their resting membrane, with the inside being 
negatively charged with respect to the outside. This potential originates from the 
fact that Na+ ions exist mainly outside the cell, and K+ ions mainly inside, but 
permeability to the latter is about 10-times greater than to Na+ (Stone, 1995).
A small increase in Na+ permeability or decrease in K+ permeability will lead to a 
fall of membrane potential known as a depolarisation. Once this depolarisation 
reaches the threshold stimulus intensity, voltage-activated Na+ channels in the 
neuronal membrane open, which allows Na+ ions to flow down their
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electrochemical gradient. The rapid influx of Na+ ions cannot be compensated by 
K+ efflux and causes a robust depolarisation. This depolarisation is responsible for 
the upstroke of the neuronal action potential (Barker et al, 2000).
This is an all or nothing phenomenon. Once the threshold stimulus intensity is 
reached, an action potential will be generated. The threshold is defined as the 
value at which the net inward current (largely determined by Na+ ions) is just 
greater than the net outward current (largely carried by K+ ions), and is typically 
around -55 mV (Rang et al, 1995).
The falling phase of the action potential then follows as the Na+ channels become 
inactivated (section 1.2.2). This inactivation is also voltage dependent, in that it 
occurs in response to the initial depolarising stimulus, but has slower kinetics than 
the activation process and consequently occurs later (Barker et al, 2000).
During this falling phase a voltage-dependent K+ current becomes important as its 
activation by depolarisation of the membrane has even slower kinetics than 
sodium channel inactivation. This voltage activated K+ channel current leads to a 
brief period of membrane hyperpolarisation before it deactivates and the 
membrane potential is returned to the resting state (Rang et al, 1995).
Immediately after the spike of the action potential there is a refractory period 
when the neuron is either inexcitable or only activated to submaximal levels by 
suprathreshold stimuli. The refractory period has two important implications for
action potential generation and conduction. First, action potentials can only be
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conducted in one direction, away from the site of generation, and secondly, they 
can generated only up to certain limited frequencies (Barker et al, 2000).
When an action potential reaches the synaptic terminal it triggers the influx of 
Ca2+ across the cell membrane, from the extracellular fluid into the cytoplasm.
This influx of Ca2+ causes the neurotransmitter containing vesicles to migrate 
towards the presynaptic membrane, where they fuse and then release their 
contents into the synaptic cleft between the presynaptic and postsynaptic cells. 
Each vesicle may contain several thousand molecules of transmitter and several 
hundred vesicles are often released with each action potential. Even in the absence 
of stimulation, single vesicles occasionally collide with the presynaptic membrane 
and release their contents. This basal release of neurotransmitter is important in 
the mechanism of action of some AEDs (Stone, 1995).
1.2.2 Ion channels
Voltage-gated ion channels control the flow of cations across surface and internal 
cell membranes (Barchi, 1998). Of these, the Na+ channel is arguably the most 
important. As discussed above, voltage-dependent Na+ channels are responsible 
for the upstroke of neuronal action potentials, and ultimately control the 
excitability of the nervous system (Porter and Rogawski, 1992). The neuronal Na+ 
channel is a multi-subunit structure that forms a Na+ selective, voltage-gated pore 
through the plasma membrane. The protein structure undergoes conformational 
alteration in response to changes in membrane potential, regulating conductance 
through the intrinsic pore (Ragsdale and Avoli, 1998).
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In order to detect a change in membrane potential the receptor protein must 
possess a charged structure within the hydrophobic portion of the membrane. The 
highly conserved and highly charged 4th transmembrane region of each receptor 
subunit is now widely accepted as forming the voltage sensors (Anger et al,
2000).
At normal membrane potentials, most Na+ channels exist in a closed, resting 
state. Upon depolarisation, the channel activates, facilitating ion influx.
Thereafter, the Na+ channel enters an inactivated state from which it is not 
readily re-activated. Repolarisation of the neuronal membrane rapidly 
converts the channel back to the resting state, from which it can respond to 
subsequent depolarisations (Catterall, 1992; Ragsdale and Avoli, 1998). The 
ability of neuronal Na+ channels to progress through these various functional 
states within a few milliseconds is an essential characteristic for sustaining 
normal brain function and is also implicated in the production of epileptic 
discharges. The complexity of Na+ channels provides enormous scope for 
genetic mutations leading to pathophysiological changes in channel function 
and several forms of generalised epilepsy have been linked to Na+ channel 
mutations (Wallace et al, 1998; Anger et al, 2001). The neuronal Na+ channel 
represents one of the most important targets for AED action (Upton, 1994; 
Macdonald and Kelly, 1995; Meldrum, 1996; White, 1999).
Voltage-dependent Ca2+ channels share key structural elements and sequence
homology with their Na+ channel counterparts (Barchi, 1998). These channels
can be broadly classified into low or high threshold, according to the
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membrane potential at which they are activated (Hofmann et al, 1994). The 
low-threshold T-type Ca2+ channel is expressed predominantly in 
thalamocortical relay neurones, where it is believed to be instrumental in the 
generation of generalised absence seizures (Coulter et al, 1989a). High- 
threshold Ca2+ channels are sub-classified by their pharmacological properties 
into L-, N-, P-, Q-, and R-types (Hofmann et al, 1994; Catterall, 1995; 
Dolphin, 1995). These channels are distributed throughout the nervous system 
on dendrites, cell bodies, and nerve terminals. The N-, P-, and Q-type 
channels, in particular, have been implicated in the control of neurotransmitter 
release at the synapse (Stefani et al, 1997). Several AEDs have been reported 
to block voltage-sensitive Ca2+ channels in a subtype-specific manner, an 
effect that may contribute to their antiepileptic actions (Stefani et al, 1997).
Neuronal K+ channels are large protein complexes which form tetrameric 
structures. The association of 4 subunits in the neuronal membrane is required 
for the formation of a K+-sensitive pore and, therefore, channel function 
(Pongs, 1999). At a neuronal level, K+ channels are intimately involved in 
excitability. They are responsible for the action potential downstroke or, more 
specifically, repolarisation of the plasma membrane following Na+ channel 
activation (Pongs, 1999). Direct activation of voltage-dependent K+ channels 
hyperpolarises the neuronal membrane and limits action potential firing 
(Porter and Rogawski, 1992). Accordingly, K+ channel activators have 
anticonvulsant effects in some experimental seizure models (Gandolfo et al, 
1989; Rostock et al, 1996), whereas K+ channel blockers potentiate seizures
(Yamaguchi and Rogawski, 1992). Potentiation of voltage-sensitive K+
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channel currents may prove to be an important target for future AED 
development (Rundfeldt and Netzer, 2000).
1.2.3 Neurotrcmsmitters
Normal CNS function is maintained by a balance between excitatory and 
inhibitory neurotransmission. Disruption of this balance may result in the 
generation of abnormal electrical activity (Schwartzkroin, 1993). There are 
countless neurotransmitter systems that contribute to the balance of excitability of 
the brain.
GABA is the major inhibitory neurotransmitter in the central nervous system 
(CNS). It exerts an inhibitory action in all forebrain structures, and it may play a 
role in certain neurological conditions, including epilepsy (Olsen and Avoli, 1997). 
Following its identification in brain (Awapara et al, 1950; Roberts and Frankel, 
1950; Udenfriend, 1950), it was discovered that direct application of GABA to 
the canine motor cortex could arrest a local epileptic discharge (Hayashi and 
Nagai, 1956; Hayashi, 1959). Around the same time it was shown that certain 
convulsant hydrazides inhibited glutamic acid decarboxylase (GAD), the enzyme 
responsible for the synthesis of GABA in the brain (Killam and Bain, 1957).
GABA is synthesised entirely from glutamate. The reaction is catalysed by GAD 
with pyridoxal phosphate acting as a cofactor (Meldrum, 1975). GAD, a soluble 
or cytoplasmic enzyme is found exclusively in GABAergic neurones. Antibodies 
to this enzyme can be used as a marker for GABAergic neurones in the CNS 
(Snead, 1983).
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GABA acts on at least 3 types of receptor, GABAa, GABAb and GABAc. 
GABAa receptors, which are mainly post-synaptic, form a ligand-gated ion 
channel. Activation of this receptor subtype leads to an increase in Cf 
permeability and thus hyperpolarisation. These receptors are activated by GABA 
and muscimol and antagonised by bicuculline and picrotoxin. GABAb receptors 
are located both pre- and post-synaptically and exert an inhibition of adenylate 
cyclase via g-protein activation as their transduction mechanism. The net result of 
GAB Ab receptor activation can be a cAMP-mediated increase in K+ conductance 
or a decrease in Ca2+ conductance, both of which cause hyperpolarisation of the 
neuronal membrane. GABA and baclofen are agonists at this receptor subtype, 
while phaclofen and 2-hydroxy-saclofen are antagonists. (Stone, 1995). The 
GABAc receptor subtype is pharmacologically distinct from GABAa and GABAb. 
Located predominantly in the vertebrate retina, GABAc receptors form a 
transmitter-gated Cf channel consisting of a single protein subunit. These 
receptors are not blocked or modified by bicuclline or baclofen, respectively. 
Instead, GABAc receptors are selectively activated by c/s-4-aminocrotonic acid 
and (lS,2R)-2-(aminomethyl)-l-carboxycyclopropane, which are analogues of 
GABA. Another GABA analogue, (l,2,5,6-tetrahydropyridine-4- 
yl)methylphosphinic acid, acts as an antagonist at this receptor subtype (Chebib 
and Johnston, 1999).
Following release and receptor activation, GABA is removed from the synaptic
cleft into nerve terminals and astrocytes by high affinity uptake carriers. Four
subtypes have been identified by molecular cloning and designated GABA-
transporter (GAT) -1, GAT-2, GAT-3, and betaine GAT (BGT)-l (Borden et al,
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1994). Following uptake, GABA is successively metabolised by two mitchondrial 
enzymes, GABA-transaminase (GABA-T) and succinic acid semialdehyde 
dehydrogenase (SSADH). GABA-T catalyses the metabolism of GABA to 
succinic acid semialdehyde and glutamate with a-KG serving as a cofactor. 
SSADH completes the metabolism to the inactive compound succinic acid in the 
presence of nicotinamide-adenine dinucleotide (NAD) and water (Meldrum,
1975).
Considerable evidence suggests that impaired GABA function can cause seizures. 
Altered GABAergic synaptic functions, especially those linked with GABAa 
receptors, may contribute to inherited or acquired epilepsies. Whether caused by a 
GABAergic mechanism or not, many patients may have their seizures controlled 
by drugs acting on the GABA system (Olsen and Avoli, 1997).
Glutamate is a key substance in the brain. It is involved in metabolism, pathology 
and neurotransmission and is also an essential source of energy (Kvamme, 1998). 
Glutamate is the main excitatory neurotransmitter in the mammalian brain and is 
released at a large proportion of synapses in the CNS. Its concentration in the 
brain is higher than any other amino acid (Greenamyre and Porter, 1994). The 
epileptogenic properties of glutamate, when applied directly to brain tissue or 
when administered systemically, are well documented (Bradford and Dodd, 1975; 
Stone and Javid, 1983).
There are a number of ways in which glutamate can be synthesised although
glutamine and glucose-derived a-KG are considered to be the main precursors of
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metabolic and neurotransmitter glutamate both in vitro and in vivo (Kvamme,
1998).
As with all excitatory neurotransmitters, release of glutamate via Ca2+-dependent 
exocytosis causes depolarisation of the post-synaptic neurone (Rang et al, 1995). 
Glutamate receptors can be divided into two categories, ionotropic and 
metabotropic. NMD A, a-amino-3-hydroxy-5-methyl-isoxazole propionic acid 
(AMP A) and kainate are the recognised types of ionotropic glutamate receptor.
All three receptor subtypes form ion channels with NMDA receptors being 
permeable to Na+ and Ca2+, AMPA receptors permeable to Na+, K+ and Ca2+ and 
kainate receptors permeable to Na+ and Ca2+. The permeability of each channel to 
individual ions is dependent of the subunit composition of the receptor with the 
exception of the NMDA receptor which is always permeable to Ca2+ (Dingledine 
et al, 1999). Under normal circumstances, neurotransmitter glutamate excites cells 
via an action on the kainate and AMPA receptors (Stone, 1995).
The NMDA receptor belongs to the ion channel linked superfamily. Accordingly, 
the receptor components each have 4 membrane-spanning sequences of which six 
distinct subunits have been identified - NMDA1, NMDA2A-D and the recently 
discovered NMD A3 A subunit. It is believed that NMDA receptors are made up of 
tetrameric and heteromeric subunit assemblies which have different physiological 
and pharmacological properties (Danysz and Parsons, 1998). Differences include 
CNS distribution, gating properties and magnesium sensitivity (Sucher et al, 1996; 
Parsons et al, 1998).
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As seen in Figure 1, NMDA receptors have several attachment sites for agents 
that can modulate, or may indeed be required for, receptor activity. The ion 
channel the receptor forms is partially blocked by Mg2+ ions under normal 
physiological conditions. When the neurones are subjected to prolonged periods 
of depolarisation the Mg2+ block is reduced. Convulsions, which involve the 
excessive firing of neurones will recruit NMDA receptors. Their involvement 
helps to maintain and prolong the seizure event (Stone, 1995). The recruitment of 
NMDA receptors during periods of prolonged depolarisation has made the 
receptor an important target for AED action.
There is an abundance of evidence suggesting an important role for glutamate in 
epilepsy. As discussed above, glutamate itself has been shown to cause seizures 
when administered systemically (Bradford and Dodd, 1975). An increase in 
glutamate receptor density has also been reported in children suffering from 
generalised seizures (Represa et al, 1989). Finally, elevated plasma levels of 
glutamate have been found in patients with primary generalised or focal epilepsy 
(Janjua et al, 1982).
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Figure 1: The NMDA receptor for glutamate. Receptor activation is
facilitated by glycine and polyamine binding sites. The receptor 
can be blocked by zinc or by blockade of the channel by Mg2+, 
phencyclidine (PCP) or dizocilpine (Stone, 1995).
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As discussed above, there are countless neurotransmitter systems in the 
mammalian brain, each of which may contribute to intrinsic excitability. In 
addition to GABA and glutamate, the involvement of monoamines in the 
initiation or maintenance of epileptic phenomena has been extensively studied. 
Spontaneous and experimentally induced deficiencies in norepinephrine (NE), 
dopamine (DA) and/or 5-HT have been implicated in the onset and 
perpetuation of many seizure disorders (Racine and Coscina, 1979; Applegate 
et al, 1986; Zis et al, 1992; Bentue-Ferrer et al, 1994; Okada et al, 1997a; 
Applegate and Tecot, 1998). Conversely, many experimental procedures 
designed to increase monoaminergic activity have proven antiepileptic 
properties (Barry et al, 1989; Browning et al, 1989; Bengzon et al, 1992; 
Pelletier and Corcoran, 1993; Loscher and Hoenack, 1995; Dailey et al,
1997).
Electrophysiological studies have indicated that catecholamine and 
indoleamine systems can exert inhibitory neuronal control and modulate the 
release of other neurotransmitters (Jobe et al, 1972). Monoamines may, 
therefore, contribute to the regulation of neuronal excitability and hence 
seizure susceptibility (Kresch et al, 1989). The role of monoamines in epilepsy 
will be discussed in greater detail in chapter 8.
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1.3 Animal models
In recent years, animal models involving induction of seizures by chemical or 
electrical stimuli have played an increasingly important role in epilepsy 
research. Although valuable in the screening of new AEDs, the majority of 
animal models serve only as tools for demonstrating single seizures than as 
true models of epilepsy (Loscher & Schmidt 1988). Despite the diversity of 
the clinical syndromes that they attempt to mirror, all models have significant 
limitations. Nevertheless, a great number of animal models remain in continual 
use for the investigation of epilepsy and the identification of novel AEDs and 
are likely to remain in use until they are superseded by more clinically relevant 
experimental paradigms.
1.3.1 In vitro models
Cell cultures of neurones and glial cells are now extensively employed in epilepsy 
research (Crain, 1972) and indeed many of the mechanisms of action of AEDs 
have been identified using cultured cells (Macdonald and Kelly, 1993). Primary 
cultures of such cells can be used for neurochemical (Gallo et al, 1982), 
neurophysiological (White et al, 1992), and neuropharmacological (Carboni and 
Wojcik, 1988) investigations. Such studies may incorporate whole cell recordings 
(McLean and Macdonald, 1986a; 1986b) or patch clamp techniques (Twyman et 
al, 1992).
The advantages of using primary cultured cells include a lack of interference of
neighbouring cells, the ability to apply known concentrations of drug to the cell
membrane, and ease of direct physiological recording. Disadvantages of such
47
preparations include a lack of correlation with whole animal studies and possible 
inter-assay heterogeneity (Stone, 1989).
The rodent hippocampal slice preparation has been utilised by investigators 
extensively since the early 1970’s (Fisher, 1989). This in vitro preparation 
was initially used to investigate cerebral metabolism but was later adapted for 
physiological studies (Yamamoto and Mcllwain, 1966). The isolation of the 
hippocampus has proved to be especially productive in terms of understanding 
the epilepsies. Hippocampal slices have the advantages of mechanical stability, 
absence of the blood-brain barrier for applied drugs, and absence of 
anaesthetics. Disadvantages include partial mechanical injury and hypoxia of 
the tissue. Despite this, hippocampal slices can exhibit an impressive range of 
neuronal behaviours, including synaptic plasticity and epileptiform bursting 
(Andersen et al, 1971; Schwartzkroin and Prince, 1978).
1.3.2 Acute seizure models
Acute models, which use either electrical or chemical stimulation to
precipitate seizure activity, have been in widespread use for a number of
years. The maximal electroshock (MES) test is arguably the best-studied and
most useful seizure model available (Fisher, 1989). The fact that electrical
stimulation of the brain results in seizure generation has been recognised for
over a century (Fritsch and Hitzig, 1870; Albertoni, 1882). Quantification of
these observations into a reliable laboratory technique facilitated the use of the
MES test in anticonvulsant drug screening for the first time (Spiegel, 1937).
In 1938, Merritt and Putnam described the identification of PHT following the
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use of the MES test to evaluate the anticonvulsant properties of various 
phenyl derivatives. The test itself relies on administration of a supramaximal 
electrical stimulus, via ear-clip or corneal electrodes, to elicit tonic extension 
of the hind-limbs of both mice and rats. Anticonvulsant drug efficacy is 
determined by the ability of a drug to reduce the incidence of this ‘all or 
nothing’ event when compared to saline treated controls. The MES test may 
be a useful indicator for drugs with a likely clinical efficacy against generalised 
tonic-clonic seizures. One of the major drawbacks of this model is that it 
occasionally yields false negative results as a function of its supramaximal 
nature (Loscher and Schmidt, 1988).
Pentylenetetrazol (PTZ) is the most commonly employed chemoconvulsant in
the laboratory evaluation of AED action (Loscher and Schmidt, 1988). The
PTZ test involves the subcutaneous administration of a species-dependent
dose of the convulsant (70 - 100 mg/kg) to induce sustained myoclonic
seizures, generalised clonic seizures with loss of the righting reflex and, at
higher doses, generalised tonic seizures within 3 -5  minutes (Fisher, 1989).
This test is sometimes referred to as the CD97 PTZ test, as it employs a
convulsant dose (CD) sufficient to induce seizures in 97% of naive animals.
The incidence of or latency to, individual seizure states is recorded and
compared in drug evalution studies (Loscher et al, 1991a). The PTZ test has
been proposed as an indicator for efficacy against absence seizures in man
(Eadie, 1985). While this suggestion holds true for the efficacy of
ethosuximide (ESM; Swinyard and Woodhead, 1989) and the inactivity of
PHT (Krall et al, 1978) in this model, the rather loose correlation with the
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clinical syndrome has been repeatedly questioned. Current opinion would now 
suggest that the PTZ seizure model has no direct parallel with the clinical 
disease (Loscher and Schmidt, 1988).
Gamma-hydroxybutyrate (GHB) is a naturally occurring metabolite of GAB A 
found in the brain of several mammalian species, including man (Snead,
1996). When administered to a variety of animals, GHB can produce a 
response which is indistinguishable from a generalised absence seizure (Snead,
1988). The GHB treated animal shows an arrest of activity with a staring 
appearance, occasional myoclonic jerks, and, in the monkey, automatisms and 
pupillary dilatation. Behavioural characteristics and electroencephalogram 
(EEG) readings vary depending on the species. In rodents, a 4-6/second spike 
and wave pattern can be expected (Snead, 1978). It is not known how GHB 
produces an absence-like seizure, although it is believed that the underlying 
mechanism may involve a GHB-GABAergic interaction (Fisher 1989).
There are several compounds that have been proposed to exert their
convulsant effects by antagonism of the GABAa receptor complex (Loscher
and Schmidt, 1988). Those most commonly used include bicuculline and
picrotoxin. Although these two agents differ in their precise mechanisms of
convulsant action, with bicuculline competitively antagonising GAB A binding
and picrotoxin irreversibly interacting with the Cf ionophore of the GAB Aa
receptor complex (Barolet et al, 1985), they tend to have similar sensitivities
to AED action (Fisher, 1989). The seizures produced by these compounds are
similar to those produced by PTZ and so do not offer any significant
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advantages in this respect (Loscher and Schmidt, 1988). As with the PTZ 
model, the motor manifestations caused by systemic bicuculline and picrotoxin 
have no direct clinical counterpart (Loscher and Schmidt, 1988).
Strychnine is a chemoconvulsant compound which precipitates tonic extensor 
spasms following systemic administration (Fisher, 1989). An irreversible 
antagonism of glycine binding is reported to contribute to its convulsant 
action (Curtis et al, 1971). Glycine is an important inhibitory neurotransmitter 
in the brainstem and spinal cord and is also a co-agonist at the NMDA 
receptor via an action on a strychnine-insensitive site. In addition, strychnine 
interacts with the GABAa receptor (Braestrup and Nielsen, 1980). Like 
bicuculline and picrotoxin, this model is reported to have no clinical 
counterpart and furthermore, the tonic seizures produced by strychnine are 
not fully inhibited by doses of AEDs that are active in other chemoconvulsant 
models (Fisher, 1989).
The glutamate receptor agonists, NMDA and kainate are also employed in the
production of experimental seizures in animals. Systemic kainic acid
administration results in the acute production of seizures which may be
manifested for several hours or days (Fisher, 1989). It is predominantly used
as a model of partial seizures arising in the hippocampus. At higher doses,
kainate has been employed as a model for the limbic cell damage which can
occur following clinical status epilepticus (Sloviter, 1987). Systemic
administration of NMDA to mice precipitates a chain of events characterised
by initial behavioural abnormalities, followed by clonic and then tonic
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seizures, and eventually death within 60 minutes (Fisher, 1989; Palmer et al, 
1993). All aspects of the NMDA response have been employed for 
comparative drug evaluations. Like strychnine-induced seizures, NMDA 
responses are relatively resistant to conventional AED treatment. While the 
kainic acid model has a degree of relevance to a clinical epilepsy syndrome, no 
such correlation has been described for NMDA (Loscher and Schmidt, 1988). 
Similarly, following intravenous injection with the NMDA receptor agonist, 
NMDLA, mice develop convulsions within a few minutes followed by 
mortality. Investigations assessing the efficacy of drugs again both the 
convulsions and the mortality may be conducted (Czuczwar et al, 1986).
1.3.3 Chronic seizure models
The kindling phenomenon was developed on the basis tha t4epilepsy induces 
epilepsy ’ (Frey and Janz, 1985) and exploits the observation that repeated 
electrical stimuli to various parts of the brain results in increased local 
excitability (Fisher, 1989). The amygdala is reported to be the area of the 
brain most responsive to the kindling process, although other regions, 
including the hippocampus, are commonly used (Loscher and Schmidt, 1988). 
The process of kindling an animal is time-consuming, taking up to three 
weeks in most cases. Bi-polar electrodes are inserted into the brain area of 
interest and screw electrodes placed in the skull to record the EEG 
(Morimoto et al, 1997; Amano et al, 1998).
Following recovery, the kindling stimulus is applied on a once daily basis.
After a few days, this initially sub-convulsive current begins to induce
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progressively more complex and prolonged afterdischarges and modest 
seizure manifestations (Goddard, 1983).
Continued daily stimulation results in the generation of kindled seizures which 
progressively evolve through the classes as described by Racine (1972).
Stage 0- after discharge without motor manifestations 
Stage 1- facial twitching
Stage 2- head nodding with simultaneous mastication 
Stage 3- forelimb clonic convulsion 
Stage 4- rearing on hind legs
Stage 5- full blown generalised convulsion with falling 
Table 2: Racine scale of seizure severity (1972).
An animal is described as being “fully kindled” when the stimulus produces 
stage 5 seizures on five consecutive days (Morimoto et al, 1997; Paschoa et 
al, 1997; Amano et al, 1998). Once the enhanced sensitivity to the stimulus 
has developed, the animal retains the same high responsiveness to the low 
intensity stimulation for the rest of its life (Ferencz et al, 1997).
The various stages of the kindled seizure can be compared to the human
disorder. The behaviour observed in stages 1 and 2 mimics that found in
human complex partial seizures which most often originate from foci within
the limbic system. Stage 3 seizures are said to mimic simple partial seizures
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while the later two stages (4 & 5) represent secondary generalised motor 
seizures (McNamara, 1984).
One of the benefits of this model is its variety of end-points. The efficacy of 
drugs can be evaluated on the electrical discharges, the development of the 
kindled response (epileptogensis) and on the fully kindled (Fisher, 1989).
The genetically epilepsy-prone rat (GEPR) possesses an inborn 
hypersensitivity to a variety of seizure-inducing stimuli. The GEPR was 
developed from the Sprague-Dawley strain of which some 15-30% of the 
population exhibits spontaneous spike-wave discharges (Loscher and 
Schmidt, 1988). The incidence of these seizures was found to be markedly 
increased when pairs of these rats were used for breeding, therefore 
demonstrating the genetic nature of the phenomenon (Jobe and Laird, 1987). 
Although these rats were originally selected for their sensitivity to sound- 
induced seizures, they are also more prone to exhibit convulsions in response 
to hyperthermia, electroshock, PTZ and bicuculline. The GEPR has increased 
5-HT and acetylcholine levels in the thalamus and striatum. It is, however, 
impossible to determine whether these alterations are responsible for the 
increased seizure susceptibility or merely a consequence of it. Audiogenic 
seizures similar to those in the GEPR may be produced in normal rats by 
infusing with NMDA into the inferior colliculus (Jobe and Laird, 1987).
The DBA/2 strain of mouse is another genetic model of reflex epilepsy. These
animals exhibit severe audiogenic (sound-induced) seizures between the ages of 2
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and 4 weeks (Seyfried and Glaser, 1985). At 8 weeks of age this audiogenic 
susceptibility is replaced by an increased sensitivity to seizures induced by MES or 
administration of excitatory amino acids (Engstrom and Woodbury, 1988). It is 
believed that the audiogenic seizure susceptibility is caused by a monoamine 
imbalance in the inferior colliculus area of the brain (Fisher, 1989). Seizure 
severity is again measured on the Racine (1972) scale. The majority of AEDs in 
clinical use are active in this model and while this may restrict its use in the search 
for novel therapies for drug-resistant epilepsy, it is unlikely that any potential 
anticonvulsant compound would fail in this model (Loscher and Schmidt, 1988).
The tottering mouse (tg/tg strain) suffers from spontaneous myoclonus and 
frequent partial and absence seizures from approximately 4 weeks of age 
(Kaplan et al, 1979; Noebels and Sidman, 1979). This strain has been 
especially useful for the investigation of neurotransmitters in epilepsy (Fisher,
1989). Tottering mice possess increased numbers of noradrenergic terminals 
and elevated levels of NE in the hippocampus, cerebellum and locus coeruleus 
(Levitt and Noebels, 1981). Lesions of noradrenergic terminals by the 
selective neurotoxin 6-hydroxydopamine (6-OHDA) have been shown to 
protect these animals against seizures (Noebels, 1984).
55
1.4 Antiepileptic drugs
As discussed in section 1.1.3, the majority of patients with recurrent epileptic 
seizures require treatment (Brodie and Dichter, 1996). These drugs afford 
symptomatic relief from seizures in up to 70% of the epileptic population (Kwan 
and Brodie, 2000). The following section describes the cellular mechanisms of 
action of both established and new AEDs. The majority of these effects have been 
determined by in vitro investigations in isolated cells and tissue preparations.
1.4.1 Established antiepileptic drugs 
CARBAMAZEPINE
CBZ was first synthesised in 1953 in an attempt to produce a new antipsychotic 
drug (Brodie and Dichter, 1997). Following successful clinical studies, CBZ was 
introduced as a treatment for partial and generalised tonic-clonic seizures in 1967 
(Editorial, 1989a).
CBZ is effective in a variety of seizure models including the MES seizure test in 
mice. It acts by preventing the repetitive firing of action potentials in depolarised 
neurones through a voltage- and use-dependent blockade of Na+ channels 
(Dichter, 1993). This proposed mechanism of action has been confirmed by 
investigations in cultured mouse central neurones (McLean and Macdonald, 
1986b), batrachototoxin-induced 22Na+ flux measurements in rat brain 
synaptosomes and channel binding studies (Willow and Catterall, 1982). CBZ 
reduces the rate of recovery of Na+ channels from the inactive state, thus 
preventing neuronal firing. The voltage-dependent nature of the block produced
by CBZ means that it is removed by hyperpolarisation. Voltage-clamp studies
56
have shown that CBZ exerts a frequency-dependent block resulting in the 
maintenance of normal brain neurotransmission (Macdonald and Kelly, 1995). 
Clinically, the use of CBZ is complicated by the fact that it is a hepatic enzyme 
inducer, accelerating the breakdown of a number of other lipid soluble drugs 
(Brodie, 1992). CBZ also induces its own metabolism resulting in the need for 
careful monitoring following administration (Macphee et al, 1987).
PHENYTOIN
PHT was first synthesised in 1908 (Blitz, 1908), but pharmacological studies were 
not reported until 30 years later. Preliminary screening for a hypnotic action was 
conducted by Parke-Davis Laboratories (Gruhzit, 1939). However, Merritt and 
Putnam (1938a) reported efficacy of PHT against MES in cats and an 
anticonvulsant action in man (Merritt and Putnam, 1938b).
PHT is effective against partial and tonic-clonic seizures (Brodie and Dichter,
1996). Like CBZ, PHT appears to act via a voltage- and use-dependent block of
Na+ channels (Yaari et al, 1977; Selzer, 1978). Experimental evidence suggests
that PHT binds to the fast inactivated state of the channel and reduces the
frequency of sustained repetitive firing of action potentials without affecting their
amplitude or duration (McLean and Macdonald, 1983). PHT reduces the rate of
recovery of Na+ channels from their inactivated state more efficiently than CBZ
but requires a longer period of high frequency firing to exert a frequency-
dependent block (Macdonald and Kelly, 1995). Evidence suggests that PHT may
preferentially bind to different subtypes of Na+ channels (Song et al, 1996). It has
also been reported to block high voltage-activated Ca2+ channels (Schumacher et
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al, 1998), attenuate post-ictal glutamate release (Rowley et al, 1995) and, 
paradoxically, reduce K+ currents (Nobile and Vercellino, 1997). PHT is a hepatic 
enzyme inducer and is capable of accelerating the metabolism of a range of lipid 
soluble drugs including CBZ, VPA and ESM.
PHENOBARBITAL
The discovery of the antiepileptic properties of PB was a classic example of 
serendipity. Initially prescribed as a hypnotic, Alfred Hauptmann, a German 
physician, discovered the anticonvulsant properties of the drug in 1912. PB is 
used world wide and clinical trials have confirmed that it is as effective as CBZ 
and PHT in reducing partial and generalised tonic-clonic seizures (Mattson et al, 
1985). The anticonvulsant effects of PB are believed to be mediated through 
potentiation of the actions of GABA by binding to a specific site on the GAB Aa 
receptor Cl' channel complex (Brodie and Dichter, 1997). At the cellular level, PB 
increases post-synaptic potentials by increasing the mean Cl" channel opening time 
and hence the duration of GABA-induced inhibitory post-synaptic bursts 
(Twyman et al, 1989). PB is a well-known hepatic enzyme inducer and can 
accelerate the metabolism of a long list of lipid-soluble drugs, including other 
AEDs (Patsalos and Duncan, 1993).
SODIUM VALPROATE
Sodium valproate (VPA) was discovered when it was used as a solvent for other 
compounds being screened for anticonvulsant effects (Meunier et al, 1963). VPA 
is effective over a wide range of seizure types and has been particularly valuable 
for the treatment of the idiopathic generalised epilepsies (Editorial, 1988).
The precise mechanisms by which VPA exerts its anticonvulsant effects remain to 
be confirmed. It has been shown to inhibit the sustained repetitive firing of mouse 
neurones in cell culture, an action associated with blockade of voltage-dependent 
Na+ channels (McLean and Macdonald, 1986a). VPA may also have an inhibitory 
action on T-type Ca2+ channels, similar to that of ESM (see below). Such an 
action would explain the efficacy of the drug against generalised absence seizures 
(Kelly et al, 1990). There is also evidence to suggest that VPA elevates whole 
brain GABA levels and potentiates GAB A responses, possibly via an action on 
the enzymes responsible for the synthesis and degradation of GABA (Loscher,
1999). VPA is an inhibitor of several hepatic metabolic processes and may 
decrease the metabolism of other AEDs such as PHT, CBZ and PB (Brodie and 
Dichter, 1996).
PRIMIDONE
Primidone (PRM) is a prodrug which is biotransformed in vivo to PB and another 
active metabolite, phenylethylmalonamide (PEMA; Brodie and Dichter, 1997). 
PEMA has a similar spectrum of anticonvulsant efficacy to PB with efficacy 
against both MES and PTZ seizures, but is 16-30 times less potent (Leal et al, 
1979; Bourgeois et al, 1983). In contrast, PRM itself is nearly as potent as PB 
against MES seizures but has little activity in the PTZ test, suggesting that these 
drugs have different actions on Na+ channels (Bourgeois et al, 1983). The clinical 
efficacy of PRM is similar to that of PB although it is less well tolerated (Mattson 
et al, 1985). There is little to recommend this drug over PB for patients in whom 
treatment with a barbiturate is contemplated (Brodie and Dichter, 1996).
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ETHO SUXIMLDE
ESM, which was first introduced in 1958, is used for the treatment of 
uncomplicated generalised absence seizures (Brodie and Dichter, 1996). It was 
discovered during a search for less toxic alternatives to trimethadione (Brodie and 
Dichter, 1997). ESM acts by reducing low threshold, voltage-dependent T-type 
Ca2+ conductance in thalamic neurones (Coulter et al, 1989b). ESM alone does 
not influence hepatic metabolism although its concentrations are altered by 
enzyme inducers such as PHT and CBZ and by enzyme inhibitors such as (Pisani 
et al, 1990).
BENZODIAZEPINES
Benzodiazepines (BZDs), such as clobazam, diazepam and clonazepam, are used 
in the treatment of for absence, tonic-clonic, myoclonic and atonic seizures 
(Fisher and Blum, 1995). Like PB, BZDs act on the GABAa receptor Cl" channel 
complex. They increase the frequency of channel opening, thereby potentiating 
the effects of GABA (Rang et al, 1995). The use of BZDs is complicated by their 
sedative effect and tolerance following prolonged administration (Brodie and 
Dichter, 1996). Diazepam and lorazepam can be used for the acute treatment of 
status epilepticus (Treiman et al, 1998).
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1.4.2 New antiepileptic drugs 
LAMOTRIGINE
Lamotrigine (LTG) is a novel AED that was developed as a result of an erroneous 
link between anticonvulsant and antifolate properties (Reynolds et al, 1966). The 
drug has a broad spectrum of activity and is effective against partial, absence, 
myoclonic and tonic-clonic seizures (Leach and Brodie, 1995).
LTG inhibits the sustained repetitive firing of Na+-dependent action potentials in 
mouse neuroblasts, suggesting an action on Na+ channels (Cheung et al, 1992). It 
has been suggested that LTG may selectively target Na+ channels on neurones 
that synthesise glutamate and aspartate (Leach et al, 1986). LTG has also been 
shown to reduce whole cell Ca2+ currents in rat amygdalar neurones, possibly via 
an action on the N- and P-type channels that have been implicated in 
neurotransmitter release (Stefani et al, 1996, 1997; Wang et al, 1996). Like PHT, 
it is ineffective in the PTZ-induced seizure model, suggesting a similar mechanism 
of action (Rogawski and Porter, 1990). LTG is susceptible to the actions of 
enzyme-inducing and enzyme inhibiting drugs (Brodie and Schachter, 2001).
VIGABATRIN
Vigabatrin (VGB) was the first AED to be developed on the basis of a targeted
mechanism of action. It is an irreversible inhibitor of the enzyme responsible for
GABA degradation, GABA-T (Dichter and Brodie, 1996). Inhibition of this
enzyme increases the amount of GABA in the brain (Petroff et al, 1995). VGB is
used for the treatment of partial seizures in adults and is the drug of choice in
children with infantile spasms (Chiron et al, 1991; Dulac et al, 1991). VGB has
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demonstrated efficacy in a variety of seizure models including those induced by 
picrotoxin (Bemasconi et al, 1988) and amygdaloid kindling (Loscher et al,
1989). It is also effective in genetic models of reflex epilepsy (Schechter et al, 
1977). VGB elevates GABA levels in plasma, cerebrospinal fluid and in the brains 
of experimental animals (Bohlen et al, 1979) as well as in the plasma and 
cerebrospinal fluid of man (Ben-Menachem et al, 1989). There is evidence to 
suggest that, in addition to its action on GABA-T, VGB may block the uptake of 
GABA into glial cells (Leach et al, 1996b).
In recent years, it has become apparent that long-term VGB treatment is 
associated with persistent visual field problems (Eke et al, 1997; Wilson et al, 
1997; Harding et al, 1998). Recent studies (Sills et al, 2001) suggest that 
following acute administration in rats, VGB accumulates in the retina. It is unclear 
whether the VGB accumulation or the associated increase in GABA levels is 
responsible for visual field problems. VGB does not interfere with hepatic 
enzymes but does produce a reduction of PHT levels of around 20% by an 
unknown mechanism (Brodie and Schachter, 2001).
TOPIRAMATE
Topiramate (TPM) was licensed in the UK for use as add-on therapy in refractory
epilepsy in 1995. It is effective against partial-onset and generalised seizures in
man (Brodie and French, 2000; Stephen et al, 2000). TPM possesses multiple
mechanisms of action, including inhibition of Na+ and Ca2+ currents, blockade of
AMPA/kainate subtypes of glutamate receptor and facilitation of GABA effects at
the GABAa receptor. TPM also inhibits carbonic anhydrase although this modest
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effect is unlikely to contribute to its anticonvulsant efficacy (Shank et al, 1994). In 
animal models, TPM is effective against seizures induced by MES (Shank et al,
1994) and amygdaloid kindling (Wauquier and Zhou, 1996) and also in genetic 
models of epilepsy (Nakamura et al, 1994). TPM has been found to be ineffective 
against chemically-induced seizures (Shank et al, 2000).
TPM does not appear to alter the metabolism of other drugs. It is a target for 
hepatic enzyme inducing agents such as PHT and CBZ (Bourgeois, 1996) with 
TPM plasma concentrations reduced by 48% and 40% (Sachdeo et al, 1996), 
respectively following co-administration.
TIAGABINE
TGB is a product of rational drug design which acts specifically on the GAT-1 
GABA uptake transporter. By blocking its action, the post-release actions of 
GABA are prolonged (Krogsgaard-Larsen et al, 1987). TGB is effective for the 
treatment of partial seizures with or without secondary generalisation (Leach and 
Brodie, 1998).
In animal models, TGB is effective against audiogenic seizures in DBA/2 mice, 
the development (Dalby and Nielsen, 1997) and motor manifestations of 
amygdaloid kindled seizures (Pierce et al, 1991) and against the tonic-clonic 
components of PTZ-induced seizures. TGB is ineffective against MES-induced 
seizures in rodents (Nielsen et al, 1991). No other mechanisms of action have 
been proposed for TGB, and it does not affect Na+ or Ca2+ channels (Schachter,
1998).
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TGB is rapidly and extensively metabolised by the cytochrome P450 isoenzyme 
CYP3 A. Due to its short half-life (5-9 hours), TGB is particularly susceptible to 
the actions of hepatic enzyme inducers such as CBZ and PHT (Brodie and 
Schachter, 2001).
GABAPENTIN
Gabapentin (GBP) is a structural analogue of GABA which can cross the
blood/brain barrier via an amino acid transport system (Leach et al, 1997c). The
drug was licensed in the UK in 1993 as adjunctive therapy for the treatment of
refractory partial seizures, with or without generalisation (Wilson and Brodie,
1996). GBP is effective in a variety of animal seizure models, including the MES
test (Rogawski and Porter, 1990). The precise mechanism of action of GBP
remains unclear. Studies have shown that it does not directly interact with GABA
receptors (Taylor et al, 1998) or transporters (Su et al, 1995; Macdonald and
Greenfield, 1997) although there is some evidence to suggest that it may increase
the synthesis (Taylor et al, 1992) and non-vesicular release of GABA (Gotz et al,
1993). In addition, GBP has been shown to increase GABA turnover in isolated
areas of the brain (Loscher et al, 1991b). The results of these experiments have
been validated by the work of Taylor and colleagues (1998) who reported an
increase in the activity of GAD, the enzyme responsible for the conversion of
glutamate to GABA, following GBP administration. GBP has also been reported
to reduce the sustained repetitive firing of neurones in a similar manner to PHT
(Wamil and McLean, 1994) and has been found to bind with high affinity to a
Ca2+ channel subunit in the brain (Gee et al, 1996). The implication of this finding
remains to be fully investigated, but the lack of effect of GBP on whole cell Ca2+
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currents in human dentate granule cells acutely isolated from patients with 
temporal lobe epilepsy (Schumacher et al, 1998) questions the pharmacological 
relevance of this finding. GBP is not metabolised, and does not induce or inhibit 
hepatic enzymes. Drug interactions are, therefore, not an issue with this agent 
(Brodie and Schachter, 2001).
OXCARBAZEPINE
Oxcarbazepine (OXC) is the 10-keto analogue of CBZ (White, 1999). It is 
essentially a pro-drug and is rapidly and completely reduced in the liver to its 
active metabolite, the monohydroxy derivative (Editorial, 1989b). OXC and CBZ 
have a similar profile and degree of efficacy against partial and generalised tonic- 
clonic seizures (Dam et al, 1989; Friis et al, 1993). Like CBZ, OXC is not 
effective against absence seizures or myoclonic jerks (Dichter and Brodie, 1996). 
OXC appears to exert its effects by blockade of voltage-dependent Na+ channels 
in a similar manner to CBZ and PHT (McLean et al, 1994). It has also been 
shown to reduce presynaptic glutamate release possibly via an action on Ca2+ 
currents (Calabresi et al, 1995; Stefani et al, 1995, 1997). Unlike any other 
licensed AED, OXC may also increase K+ channel conductance (McLean et al,
1994).
LE VETIRACET AM
LEV is an ethyl analogue of the no-otropic agent piracetam and is the most
recently licensed AED (Genton and Van Vleymen, 2000). Results of clinical trials
suggest that LEV is effective against partial seizures with or without secondary
generalisation (Bialer et al, 1999), although extensive clinical use of the drug is
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required to determine its full spectrum of clinical activity (Kwan et al, 2001). LEV 
would appear to have a unique mode of action which, at this time, is unclear. 
Preclinical investigations have demonstrated that LEV does not interact with Na+, 
Ca2+ or K+ channels or with GABA and glutamate neurotransmitter systems 
(Noyer et al, 1995; Sills et al, 1997). However, LEV has been found to reduce 
GABA turnover in the striatum of the rat by increasing GAB A-T activity and 
reducing GAD activity (Loscher et al, 1996).
In acute animal seizure models, such as MES and PTZ induced seizures, LEV is 
ineffective at doses of up to 540 mg/kg (i.p.). However, this lack of 
anticonvulsant activity against acute seizures is contrasted by the protection 
afforded in amygdala and comeally kindled animals, DBA/2 mice and other 
genetic models of epilepsy (Loscher et al, 1996). The metabolism of LEV is 
independent of the cytochrome P450 system and so there are no pharmacokinetic 
interactions with other drugs (Patsalos, 2000)
FELBAMATE
Felbamate (FBM) was licensed in the USA for use as monotherapy and adjunctive
therapy in refractory partial onset seizures in adults and children in July 1993.
FBM has multiple mechanisms of action. It potentiates GABA responses at the
G A B A a  receptor complex, blocks Na+- and dihydropyridine-sensitive Ca2+-
channels and interacts with the strychnine-insensitive glycine modulatory site on
the NMDA receptor (McCabe et al, 1993; Rho et al, 1994; White et al, 1995).
FBM has been shown to be effective in a variety of animal seizure models
including PTZ, NMDA and MES induced seizures in mice (Swinyard et al, 1986).
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Over 100,000 patents received FBM in the first year following its launch. Shortly 
after, however, cases of aplastic anaemia and hepatotoxicity emerged and the use 
of the drug has been limited to patients with severe intractable epilepsy (Leppik 
and Wolff, 1995; Wilson and Brodie, 1996; Pellock and Brodie, 1997).
1.5 Remacemide
There is now convincing neurochemical and neurophysiological evidence to 
suggest that increased excitatory neurotransmission is involved in epilepsy 
(Meldrum, 1991; Loscher et al, 1993; Scheyer, 1998). As described in section 
1.4, many of the currently available drugs act by increasing the effects of 
GABA, either by elevating GABA concentrations or by modifying its 
postsynaptic action (Rogawski and Porter, 1990). The other major group of 
drugs are those which block voltage-gated Na+ channels. These drugs are 
classed as those which decrease excitatory transmission (Macdonald and 
Kelly, 1994).
It is known that glutamatergic synapses play a critical role in all epileptic 
phenomena and enhanced activation of post-synaptic glutamate receptors is 
proconvulsant (Chapman, 1998). Consequently, antagonists of NMDA 
receptors are powerful anticonvulsants in many animal models of epilepsy 
(Tauboll and Gjerstad, 1998). Early attempts to pharmacologically modulate 
glutamatergic transmission resulted in anticonvulsant compounds such as 
dizocilpine (MK801) and phencyclidine. Preclinical testing of these agents 
generally showed efficacy but also demonstrated severe side effects including
neuropathological changes (vacuolisation of neuronal cytoplasm in the 
neocortex) and significant behavioural malfunctions (McNamara et al, 1988; 
Olney, 1989; Willetts et al, 1990). A clinical application of pure glutamate 
antagonists has not yet been established (Chapman, 1998).
1.5.1 Background and pharmacology
Remacemide hydrochloride (RMD; (±) 2-amino-N-(l-methyl-1,2- 
diphenylethyl)-acetamide monohydrochloride) emerged from a drug screening 
programme conducted by Fisons’ laboratories (now AstraZeneca) in 
conjunction with the National Institutes of Health AED development 
programme (Palmer et al, 1993). It resulted from a strategy to create 
compounds with a similar three-dimensional structure to phenytoin (Rogawski 
and Porter, 1990). RMD is a racemic mixture of two enantiomers that do not 
have clinically meaningful stereoselective pharmacological properties 
(Schachter and Tarsy, 2000). The drug undergoes desglycination to form 
desglycinyl-remacemide (DGR; formerly known as AR-R12495; figure 2).
The hydrolase enzymes responsible for this conversion exist in almost all 
peripheral tissues (Heyn et al, 1994b), although the majority of the conversion 
is said to take place at the blood/brain barrier, resulting in an accumulation of 
DGR in the brain (Heyn et al, 1994a).
Conversion of RMD to DGR results in the production of glycine, an inhibitory
neurotransmitter and co-agonist at the NMDA receptor (Stone, 1995). A
number of other RMD metabolites have been identified in man, rodents and
dogs including ARR-14464 and ARR-14330. These metabolites are also
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active although the concentrations required for a pharmacological action are 
never likely to be reached following RMD administration (Palmer et al, 1992).
A unique dual mechanism of action has been proposed for RMD and DGR 
(Schachter and Tarsy, 2000). Both compounds inhibit the sustained repetitive 
firing of cultured spinal cord neurones (Wamil et al, 1996) and reduce [3H]- 
batrachotoxin binding (Palmer et al, 1992), actions associated with a blockade 
of voltage-gated Na+ channels. DGR was shown to be the more potent of the 
two compounds with an IC50 of 1 .2 pM compared to an IC50 of 7.9 pM 
calculated for the parent drug (Wamil et al, 1996).
Figure 2: The biotransformation of remacemide to desglycinyl-remacemide
H2N
Remacemide Desglycinyl-remacemide
In addition to the proposed action on Na+ channels, investigations have shown
that both RMD and DGR inhibit the binding of [3H]MK801 (Palmer et al,
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1992), a channel blocking ligand at NMDA receptors (Huettner and Bean, 
1988). As with the action on Na+ channels, DGR appears to be the more 
active moiety at the NMDA receptor with an IC50 for the displacement of 
MK801 of 0.48 pM compared to 6 8  pM for RMD. There does appear, 
however, to be slight differences in the mechanism of block exerted by the 
two compounds (Subramaniam et al, 1996). The block produced by DGR was 
found to be strongly use- and voltage-dependent and could be occluded by 
Mg2+ (figure 1), indicating that it occurs by an open channel mechanism. More 
recent evidence also suggests an open channel block with DGR (Ahmed et al,
1999). Although RMD is also said to displace MK801, the block exerted was 
found to be only partially voltage-dependent, suggesting that at least a portion 
of its action occurs via an non-channel blocking mechanism. Previous studies 
have reported that RMD has slight affinity for both the glutamate and glycine 
binding sites on the NMDA receptor (Garske et al, 1991), whereas DGR 
displacement of [3H]MK801 has been shown to be unaffected by glutamate or 
glycine (Ray et al, 1992). Despite RMD having a much higher IC50 than DGR 
in this model, the block exerted by RMD was found to be much more rapidly 
produced and prolonged under periods of depolarisation. Therefore, in vivo, 
the contribution of the parent drug to overall NMDA receptor blockade 
cannot be discounted (Subramaniam et al, 1996).
The neurochemical effects of DGR have also been investigated (Leach et al,
1997d). Repeated dosing of DGR to mice was found to increase the activity
of GABA-T, the enzyme responsible for the breakdown of GABA to succinic
semialdehyde (SSA) and glutamate. In addition, DGR was also found to
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decrease the activity of GAD, the enzyme responsible for the synthesis of 
GABA from glutamate. Despite these apparent proconvulsant actions, DGR 
was seen to slightly reduce brain glutamate concentrations although the 
results obtained were not statistically significant (Leach et al, 1997d).
1.5.1 Preclinical evaluation
RMD and DGR have been tested in many animal models and a number of 
reviews have been published (Muir and Palmer, 1991; Clark et al, 1995; 
Davies, 1997; Schachter and Tarsy, 2000).
Both RMD and DGR have been found to be effective against MES-induced 
seizures in mice and rats with ED5o values of 21.5 and 17.1 mg/kg (i.p.) in 
mice, respectively (Palmer et al, 1992). Following administration of the 
approximate ED98, RMD continued to protect against MES seizures in 20% 
of animals after 4 hours. DGR offered 40 - 50% protection after 4 hours 
(Palmer et al, 1992). The MES-seizure test is said to be indicative of a likely 
clinical efficacy against generalised tonic-clonic seizures (Fisher, 1989).
Both RMD and DGR prevent against the convulsions produced by NMDLA 
with ED5o values of 57.4 and 32.4 mg/kg, respectively. Protection against 
NMDLA-induced mortality was also afforded by both compounds, with ED50 
values of 22.4 and 17.1 mg/kg respectively (Palmer et al, 1992).
Studies in the kindling model of epilepsy have found that RMD offers only
8 % protection from established seizures in rats at 400 mg/kg. CBZ was seen
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to protect 40% of animals at 200 mg/kg. RMD was previously found to be 
ineffective against the development of kindled seizures (Garske et al, 1991). 
DGR, however, was found to reduce seizure development (Palmer et al,
1992).
RMD is ineffective against seizures induced by PTZ, bicuculline, picrotoxin 
and strychnine (Garske et al, 1991). However, efficacy is observed for both 
compounds against seizures induced by kainate and 4-AP (Cramer et al, 1994) 
and against audiogenic seizures in the DBA/2 mouse model (Clark et al,
1995). In addition, both RMD and DGR have shown efficacy in the WAG/Rij 
strain of rat, a genetic model of absence epilepsy. This finding is unexpected 
as, traditionally, sodium channel blockers such as CBZ and PHT are without 
effect in this model (Van Luitelaar and Coenen, 1995).
In vitro investigations have found that RMD and DGR are almost equipotent 
in their limitation of sustained repetitive firing in CA1 cultured neurones from 
rats (Norris and King, 1997a). This is in contrast to the different profiles 
observed in cultured rat spinal cord neurones (Wamil et al, 1996). The reason 
for this difference is unclear but could reflect species variation, differential 
neuronal susceptibility, variations in recording conditions and drug exposure 
times (Norris and King, 1997b). In the rat hippocampal slice model, RMD 
was found to have no significant effects on evoked responses, recurrent 
inhibition, induction of long-term potentiation, penicillin-induced discharges 
or veratridine (VTD)-induced depolarisations (Garske et al, 1991). In
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contrast, DGR was seen to decrease the amplitude and rate of rise of action 
potentials in the hippocampal slice (Norris and King, 1997b).
Consistent with its proposed mechanism of action, DGR has been found to 
significantly reduce spontaneous depolarisations and associated afterpotentials 
in cortical wedges prepared from DBA/2 mice subjected to Mg2+-free 
conditions. NMDA- but not AMPA-induced depolarisations were also 
reduced in this model (Hu and Davies, 1995). DGR has also been shown to 
significantly reduce both VTD- and K+-induced release of glutamate and 
aspartate from cortical slices prepared from mice (Srinivasan et al, 1995). The 
inhibition of K+-stimulated glutamate release required much higher 
concentrations of DGR than those required to decrease VTD-induced 
glutamate release (Srinivasan et al, 1995). This finding is consistent with 
suggestions that DGR is a relatively weak NMDA antagonist and therefore 
inhibits the entry of Ca2+ into neurones (Muir and Palmer, 1991; Clark et al,
1995).
Neuronal impairment investigations have found that RMD is less toxic than 
DGR (Palmer et al, 1992). This is perhaps to be expected due to the greater 
efficacy of DGR at the NMDA receptor.
1.5.2 Clinical findings
RMD and DGR are weak bases with good water and lipid solubility (Clark et 
al, 1995). When taken orally, RMD is quickly and extensively absorbed from
the gastrointestinal (GI) tract with approximately 74% of the drug bound to
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plasma proteins in man. Due to its physicochemical properties, RMD is 
subjected to extensive metabolism. First pass metabolism, although high in 
rodents (>85%), is relatively low in humans (-10%; Clark et al, 1995). In 
man, RMD is said to reach peak serum concentrations within 1 -2  hours of 
administration (Patsalos and Sander, 1994) with DGR levels reaching maximal 
2-3 hours following dosing (Stables et al, 1995). DGR has a longer half-life 
than RMD, reportedly 12-24 hours compared to 3 - 4 hours respectively, 
(Stables et al, 1995). Steady-state concentrations of RMD and DGR are 
reached within 24 hours and 3 -4  days following initiation of treatment, 
respectively (Clark et al, 1995).
In healthy volunteers, doses of up to 300 mg RMD are well tolerated. Above 
this dose, lightheadedness, headache, fatigue, and GI upset can be observed 
with increasing frequency (Muir and Palmer, 1991; Brodie et al, in prep.). 
Similar side effects have recently been reported in children following RMD 
treatment (Besag et al, 2001).
In an early double-blind, placebo-controlled crossover study of 28 patients 
with refractory epilepsy, RMD reduced seizure frequency by 33% with 4/28 
of the patients being seizure-free during the RMD treatment section 
(Crawford et al, 1992). In another early monotherapy study, RMD (600 
mg/day) was administered to patients undergoing acute withdrawal of their 
AEDs during evaluation for possible epilepsy surgery. Results indicated that 
seven of the nine patients suffered fewer partial seizures in the 24 following
RMD treatment compared to the preceding 24 hours (Alarcon et al, 1992).
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Two major trials assessing the efficacy (Richens et al, 2000) and safety 
(Chadwick et al, 2000) of RMD as add-on therapy in refractory epilepsy 
patients have been conducted in the UK. Richens and colleagues reported a 
significant reduction in seizure frequency during treatment with 600 mg/day 
RMD when compared with placebo. Analysis of the individual seizure types in 
the study showed no statistical differences. No patients were found to be 
seizure-free during the placebo arm of the treatment, however, 13% of 
patients were seizure-free during treatment with RMD (Richens et al, 2000). 
Of the 28 patients in the study, 24 were taking CBZ as one of their 
concomitant AEDs.
Only one major, international, multicentre trial of RMD monotherapy has 
been conducted. The SEReNE (Sequential Evaluation of RMD in Newly 
diagnosed Epilepsy) trial compared 600 mg/day RMD with 600 mg/day CBZ 
in newly diagnosed epilepsy patients (Brodie et al, in prep). A total of 570 
patients were randomised to receive RMD (288) or CBZ (282). Patient 
demographics were well matched in terms of sex, age and race. The results 
suggest that CBZ was significantly superior at increasing the time to first, 
second, third and fourth seizures following randomisation of treatment 
(Brodie et al, in prep).
Pharmacokinetic interactions are important factors to consider when co­
administering AEDs (Patsalos, 1998). As a result, the effects of co­
administration of various AEDs on the pharmacokinetics of RMD have been
investigated (Leach et al, 1996a; Leach et al, 1997a; Leach et al, 1997b;
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Mawer et al, 1999). RMD itself undergoes cytochrome P450 (CYP450) 
dependent oxidation and induces the activity of various CYP450 isoforms in 
rats and mice (Palmer et al, 1992; Riley et al, 1995). The main isoforms 
believed to be affected are those which are also inducible by PB 
administration, namely those from the CYP2B and 3 A families (Palmer et al,
1993). There appears to be no evidence of autoinduction (Leach et al, 1996a; 
Leach et al, 1997b). The addition of RMD to already established CBZ therapy 
results in a 22% increase in CBZ concentrations although levels of CBZ-10,
11 epoxide are unaffected (Leach et al, 1996a). In the same study, 
concentrations of RMD and DGR were reduced to 60 and 30% of control, 
indicating that DGR is more susceptible to the hepatic enzyme inducing 
properties of CBZ. A similar study found that co-administration of CBZ and 
RMD resulted in the need for CBZ dose withdrawal in 63% of patients 
(Mawer et al, 1999). Results with PHT co-administration were similar to 
those observed with CBZ (Leach et al, 1997b). Once again, RMD treatment 
was shown to increase the circulating concentrations of the co-administered 
drug. PHT is almost exclusively metabolised by the CYP2C9 and 2C19 
isoforms (Levy et al, 1995). It is therefore possible that RMD or DGR inhibits 
the activity of one or both of these isoforms. PHT caused a decrease in 
circulating RMD and DGR levels. As with CBZ treatment, DGR appeared to 
be more susceptible to the enzyme inducing properties of PHT (Leach et al, 
1997b). Co-administration with the hepatic enzyme inhibitor VP A has no 
affect on the pharmacokinetics of RMD, DGR or indeed VP A itself (Leach et 
al, 1997a).
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In addition to the known effects against seizures, RMD exhibits 
neuroprotective properties in cerebral ischaemia (Bannan et al, 1994; Dyker 
and Lees, 1999; Halonen et al, 1999; Pisani et al, 2001). Investigations have 
also indicated that RMD treatment may be beneficial in patients suffering from 
either Parkinson’s or Huntington’s disease (Clarke and Feigin, 1999; Kieburtz 
et al, 1999; Alexi et al, 2000; Shoulson et al, 2000; Clarke et al, 2001;
Schwid, 2001). It also appears to have efficacy as an analgesic, (Asghar et al,
2000).
In summary, clinical trials have found that RMD, when administered as add­
on therapy is effective in reducing seizure frequency in patients who have 
been unsuccessfully treated with other AEDs (Richens et al, 2000). 
Monotherapy trials have demonstrated that CBZ is superior to RMD when 
comparing time to first, second, third and fourth seizures following 
randomisation (Brodie et al, in prep). CBZ and PHT, two known inducers of 
hepatic enzymes cause a decrease in the circulating concentrations of RMD 
and DGR (Leach et al, 1996a; Leach et al, 1997b). It appears from these 
studies that DGR is significantly more susceptible to the effects of this 
induction. RMD itself inhibits the metabolism of PHT and CBZ although 
cases of toxicity were predictable, rare and reversible following dosage 
reduction (Leach et al, 1997b; Mawer et al, 1999).
77
1.6 General aims
The aim of this project was to investigate the preclinical pharmacology of 
RMD and DGR. Particular emphasis was placed on the relative contribution 
of each moiety to the antiepileptic actions of the parent compound and the 
relative importance of individual mechanisms of action. In the development of 
RMD, it was assumed that additional inhibitory effects at the NMDA receptor 
might confer advantages for the drug over standard sodium channel blocking 
AEDs. This premise was subsequently challenged by clinical trial data, which 
emerged during the conduct of these studies, suggesting that RMD 
monotherapy was inferior to that with CBZ. In light of these observations, the 
preclinical pharmacological investigations described herein assumed greater 
significance. An attempt to formulate a hypothesis to explain why RMD, a 
drug with a promising preclinical profile and recognised clinical efficacy as 
add-on treatment, performed so poorly as monotherapy was subsequently 
undertaken.
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Chapter 2
Materials and recurrent methods
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2.1 MATERIALS
2.1.1 Chemicals and reagents
Adenosine diphosphate (ADP; sodium salt), 4-aminopyridine (4-AP), p- 
nicotinamide dinucleotide (p-NAD), p-NADH (reduced form; disodium salt), 
bovine serum albumin (BSA), calcium chloride (CaCl2), DMI hydrochloride 
(10,11 -dihydro-N-methyl-5H-dibenz[b,f]azepine-5-propanamine), dimethyl 
sulfoxide (DMSO), 7-ethoxycoumarin, EDTA (ethylenediaminetetra-acetic acid; 
free acid), EGTA (ethylene glycol-bis[p-aminoethyl ester]-N, N, N’, N’-tetra- 
acetic acid), Ficoll, glycerol, gramicidin D, D-glucose, L-glutamic acid 
(monosodium salt), glycofurol, HEPES (N-[2-hydroxyethyl]piperazine-N’-[2- 
ethanesulfonic acid]), 5-hydroxytryptamine (serotonin), a-ketoglutarate (a-KG), 
magnesium sulphate (MgSC>4), NE, NMD A, pargyline (N-methyl-N- 
propargylbenzylamine), nomifensine (NMF; l,2,3,4-tetrahydro-2-methyl-4- 
phenyl- 8-isoquinolinamine), pluronic F-127, potassium chloride (KC1), potassium 
EDTA (di-potassium salt), potassium phosphate (K2HP04; monobasic), rotenone, 
SBFI-AM, sodium bicarbonate (NaHC03), sodium chloride (NaCl), sodium 
dithionite (Na2S20 4), TES (N-tris[hydroxymethyl]methyl-2-aminoethanesulfonic 
acid), tetracaine, tris HC1, and veratridine (VTD), were all obtained from Sigma 
Chemical Company (Poole, UK).
Acetonitrile, ammonium chloride (NFLC1), chloroform, methanol, potassium 
dihydrogen orthophosphate (KHP04), potassium orthophosphate (KP04), sodium 
hydroxide (NaOH) and sucrose were bought from Fisher Scientific 
(Loughborough, UK). Hydrochloric acid (HC1), magesium chloride (MgCl2),
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perchloric acid (HCIO4) were purchased from Merck (UK). Ascorbic acid, 
trichloro-acetic acid (TCA) and Triton X-100 (iso-octylphenoxypoly- 
ethoxyethanol) were obtained from BDH (Poole, UK). Tetrodotoxin (TTX) was 
purchased from Tocris (UK). Dopamine (3-hydroxytyramine hydrochloride) was 
bought from Fluka Chemicals (UK). Ecoscint A scintillation fluid was purchased 
from National Diagnostics (Hull, UK). Coomassie Brilliant Blue G-250 protein 
dye was obtained from BIORAD (Hertfordshire, UK).
2.1.2 Radioisotopes
Dopamine (dihydroxyphenylethylamine hydrochloride, 3,4 -[ring-2, 5-6-3H]), NE 
(norepinephrine hydrochloride, DL-[7-3H(N)]), and 5-HT (hydroxytryptamine, 
creatinine sulfate, 5-[l,2-3H(N)]) radioisotopes were purchased from New 
England Nuclear (Stevenage, UK).
2.1.3 Pharmaceuticals
RMD ((±)-2~amino-N-(l-methyl-1,2-diphenylethyl) acetamide hydrochloride), 
DGR ((±)-1 -methyl-1,2-diphenylethylamine-monohydrochloride), AR-R15896 
((+)-a-phenyl-2-pyridine-ethanamine dihydrochloride) and the internal standard 
(2-(methyl-amino)-A-[ 1 -phenyl-1 -(phenylmethyl)propyl]-acetamide 
hydrochloride) for the HPLC assay were obtained from AstraZeneca, R&D 
Chamwood (Loughborough, UK). CBZ (5H-dibenz(b, f) azepine-5- 
carboxamide), PB (5 ethyl-5-phenyl-2, 4, 6-trioxohexahydropyrimidine) and PHT 
(5, 5-diphenyl-2, 4-imidazolidinedione) were purchased from Sigma Chemical
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Company (Poole, UK). LTG (6-(2, 3-dichlorophenyl)-1, 2, 4-triazine-3, 5- 
diamine) was obtained from GlaxoWelcome R&D (Stevenage, UK).
2.1.4 Equipment
Centrifugation: Blood samples were centrifuged on a Wifiig haemicrofuge. All 
other samples were centrifuged in a Heraeus Sepatec 15R Biofuge (<1,000 x 
g) or in a Sorvall OTD-50 ultracentrifiige (> 1,000 x g).
Cytochrome P450 analysis: The enzyme content of samples was determined 
using a Cecil CE 594 Double Beam Spectrophotometer. Analysis of 7- 
hydroxycoumarin activity was measured using a Perkin Elmer LS-5 
Luminescence Spectrometer.
Hippocampal slice studies: Recordings were made using a Neurolog system. 
Results were integrated on a Hitachi VC-6023 digital storage oscilloscope and 
displayed on a Reba Instruments PAR 1000 chart recorder.
Homogenisation: Whole brain samples were homogenised using a Polytron PT 
1200 CL homogeniser. Cortex and liver samples were homogenised using a 
motorised teflon pestle and glass mortar.
HPLC Experiments: The chromatography equipment consisted of a Gilson 
231 sample injector and Gilson 401 dilutor, a Shimadzu SPD-6A UV 
spectrophotometric detector (218 nm), a Shimadzu LC-10AT liquid
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chromatograph and a Shimadzu C-R6A chromatopac recorder. The HPLC 
column was a Sphereclone C6 (100 x 4.6 mm; 3 pm) which was used at room 
temperature. Solid-phase extraction columns were benzenesulfonic acid 
columns with pore size A54 (100 mg; 1 ml columns).
Maximal electroshock: An Ugo Basile 7800 ECT unit was employed.
Monoamine uptake experiments: A Brandel harvester was employed for rapid 
filtration purposes. Liquid scintillation counting was carried out on a Canberra 
Packard TriCarb 2100TR liquid scintillation counter.
Protein assay and measurements of glutamate dehydrogenase activity:
Analysis was performed using a Dynex MRX version 2.01 microplate reader. 
Results were integrated on a Viglen Contender ATX P5/166 MMX computer 
using Revelation (version 3.2) software.
Sodium uptake measurements: Analysis was performed using a Perkin Elmer 
LS-5 luminescence spectrometer.
2.2 Recurrent methods
2.2.1 Animal use
All the animals used in this project were purchased from Harlan Olac, Bicester, 
UK. Animals were housed in the Central Research Facility at the University of 
Glasgow where they were exposed to a controlled temperature and humidity
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environment. All animals had access to food and water ad libitum and were 
subject to a 12 hour light/dark cycle.
2.2.2 Determination o f protein concentration
The BIORAD method is a sensitive test of protein concentration which is 
particularly useful when samples contain low amounts of protein. The method 
utilises the colour change of a dye (Coomassie Brilliant Blue G-250) in response 
to protein. Standards were prepared, in duplicate, covering the range of 0.5 - 2 
pg/ml using BSA. Unknown samples, again analysed in duplicate, were diluted 
into this range. BIORAD protein assay dye (100 pi) was added to standards and 
unknown samples. Following vortex-mixing, 200 pi of each standard and sample 
was transferred to a 96-well plate and read at 595 nm on the microplate reader. 
The results were corrected for dilution, averaged, and expressed in mg/ml.
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Chapter 3
Pharmacokinetics of remacemide and desglycinyl- 
remacemide in brain tissue and serum
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3.1 Introduction
Preclinical studies of AEDs often fail to consider the brain concentrations at 
which the candidate therapies exert their pharmacological effects (Santangeli et al,
2000). It is important to know the pharmacokinetics of compounds so that future 
dosing schedules can be developed without risk of toxicity. In addition, 
pharmacokinetic interactions, which are common with AED administration 
(Patsalos, 1998), can also involve active metabolites (Leach et al, 1996a) and so 
baseline levels of these compounds have to be known.
As discussed in section 1.5, the actions of RMD can be largely attributed to DGR, 
an active metabolite. Following acute RMD administration in man, DGR is 
present in much lower concentrations in plasma compared to the parent 
compound (Clark et al, 1995). These findings are consistent with reports that the 
majority of the conversion of RMD to DGR occurs at the blood/brain barrier, 
resulting in an accumulation of DGR in the brain (Heyn et al, 1994a).
3.2 Aims
The aim of the following experiments was to construct pharmacokinetic profiles 
of RMD and DGR in serum and brain tissue. An insight as to the extent of RMD 
conversion to the reportedly more active DGR would have applications for 
further concentration-effect studies and AED interaction investigations.
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3.3 Methods
The following high-performance liquid chromatography (HPLC) assay was 
adapted from the previously published human plasma methodology (Flynn and 
O’Brien, 1992; Wilson et al, 1992).
3.3.1 Standards and solutions
Aqueous stock solutions of RMD (0.5 mg/ml), DGR (0.5 mg/ml) and internal 
standard (0.2 mg/ml) were prepared, aliquoted and stored at -70°C until 
required. Two monobasic potassium phosphate buffers (0.5 M and 0.05 M) 
were prepared weekly with the pH adjusted to 2.5 and 3.3, respectively. 
Mobile phase (29:71 acetonitrile / 0.05 M potassium phosphate buffer) and 
working standard solutions of RMD (50 pg/ml) and DGR (50 pg/ml) were 
prepared daily as required. Prior to use, the mobile phase was passed through 
an aqueous filter (pore size 0.45 pm; Millipore, France) and degassed with 
helium. The flow rate of the mobile phase was 1 ml/min.
3.3.2 Preparation o f tissue
For serum samples, truncal blood samples obtained from mice were
centrifuged for one minute. Following collection, serum and brain samples
were immediately placed in liquid nitrogen. The assay technique was validated
with the use of naive mouse brains (adult male ICR mice; 25-30 g)
homogenised at high speed for 15 seconds in 15 volumes (v/w) of 1%
perchloric acid. Blank homogenates were spiked with known concentrations
of RMD and DGR. Internal standard (50 pi of 0.2 mg/ml stock) was then
added to each sample. Homogenates were vortex mixed and then centrifuged
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at 800 x g for 15 minutes at 4°C. One ml of the supernatant from each sample 
was then transferred into a tube containing 1.5 ml of 0.5 M potassium 
phosphate buffer and, thereafter, samples were gently mixed prior to 
extraction. Unknown brain samples were treated in the same manner, 
although no drug was added to the homogenate. It was at this point that 
serum samples entered the sample preparation method. In cases where less 
than 1 ml of serum was obtained, the volume was adjusted to 1 ml with 0.5 M 
potassium phosphate buffer and samples extracted without further 
intervention.
3.3.3 Solid-phase extraction
Solid phase extraction columns were conditioned immediately prior to use by 
lml methanol, 1ml elution fluid (60:40 acetonitrile / 0.05 M sodium 
bicarbonate) and 2 ml 0.05 M potassium phosphate buffer. Individual samples 
were added and washed with 1 ml 0.05 M potassium phosphate buffer. The 
columns were then rinsed with 1.5 ml methanol, 2 ml distilled water and 
allowed to dry. The analytes of interest were subsequently eluted from the 
columns into Pyrex borosilicate glass culture tubes (10 x 75 mm) with 3 x 
0.25 ml elution fluid with the columns being allowed to dry between each 
application. Finally, the culture tubes were vortex mixed, samples transferred 
into glass autosampler vial inserts, and 75 pi injected into the chromatography 
system.
Limits of detection and quantification were determined by analysing samples
of brain homogenate that had been spiked to a known concentration (0.5 -
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100 ng/ml) with the minimum concentrations giving visible and measurable 
peaks noted.
3.4 Experimental protocol
Time study: Adult, male ICR mice were randomised into 15 groups of 6 animals. 
Each group was administered a single, acute injection of 40 mg/kg RMD (i.p.) 
and sacrificed at a different time point (5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 
180, 210, 240, 360 or 480 minutes) following injection, with brain and truncal 
blood samples obtained.
Concentration study: Adult, male ICR mice were randomised into 6 groups of 5 
animals. One animal from each group was administered a single dose of RMD (5, 
10, 20, 40 or 80 mg/kg; i.p.) and were again sacrificed at a variety of time points 
(15, 30, 60, 120, 240 or 480 minutes). Brain and truncal blood samples were 
obtained. This protocol was repeated on 6 occasions.
RMD and DGR concentrations in serum and brain were measured according to 
the methods described in section 3.3.
3.5 Data analysis and statistics
Statistical analysis was performed using MINITAB for Windows version 10.1 
on a Viglen P2 400 microcomputer. Results are expressed as the mean of 
absolute concentrations (pg/ml, serum; pg/g, brain) ± the standard error of 
the mean (SEM).
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3.6 Results
RMD was detectable in serum 5 minutes after intraperitoneal administration (40 
mg/kg). Serum RMD concentrations appeared to peak at 15 minutes post-dosing 
(28.1 pg/ml; ± 2.3) with no drug detected after 90 minutes (figure 3).
DGR was not detected in serum until 10 minutes after i.p. administration of the 
parent compound (figure 3). Serum concentrations of DGR appeared to be 
maximal at 60 minutes post-dosing (13.3 pg/ml; ±1.3) with no drug detected 
after 240 minutes.
Brain sample analysis suggested that RMD and DGR concentrations reached 
maximal levels at 20 minutes (10.3 pg/g; ± 0.2) and 60 minutes (17.9 pg/ml; ± 
0.9) post-dosing, respectively (figure 4). RMD was not detectable in brain tissue 
240 minutes following dosing. DGR was still measurable at 8 hours post-dosing.
RMD levels in serum decreased from 15 minutes following dosing (5 - 80 
mg/kg RMD; figure 5). RMD was only detected in serum at 4 hours following 
80 mg/kg administration. DGR levels in serum appeared to peak at 60 minutes 
post-dosing, independent of the dose of RMD administered (figure 6). Only 
following 40 and 80 mg/kg of RMD could DGR be measured more than 8 
hours after administration. Half-lives of 62 and 250 minutes in serum were 
calculated for RMD and DGR, respectively, following an 80 mg/kg dose of 
RMD.
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Figure 3: Pharmacokinetic profiles of remacemide and desglycinyl- 
remacemide in mouse serum 0-360 minutes after a single 
intraperitoneal injection of 40 mg/kg remacemide. Results (n = 6) 
are expressed as the mean of absolute serum concentrations 
(|j,g/ml) with error bars denoting the standard error of the mean.
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Figure 4: Pharmacokinetic profiles of remacemide and desglycinyl- 
remacemide in mouse brain 0-360 minutes after a single 
intraperitoneal injection of 40 mg/kg remacemide. Results (n = 6) 
are expressed as the mean of absolute brain concentrations 
(|ig/g) with error bars denoting the standard error of the mean.
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Figure 5: Pharmacokinetic profile of remacemide in mouse serum 
following a single intraperitoneal injection (5 - 80 mg/kg). 
Results (n = 6) are expressed as the mean of absolute serum 
concentrations (|a.g/ml). Error bars have been omitted for 
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In brain, RMD concentrations reached maximal at 30 minutes post-dosing, 
irrespective of the dose of RMD administered (figure 7). RMD was only 
detected in brain tissue after 4 hours following 80 mg/kg administration.
With the exception of the 10 mg/kg RMD group, DGR levels in the brain 
were maximal at 60 minutes post-dosing (figure 8). DGR levels following 40 
and 80 mg/kg RMD were detectable 8 hours following administration.
3.7 Discussion
Previously published literature has shown that DGR is more active than RMD 
in a variety in vitro models (Clark et al, 1995; Davies, 1997). The above 
studies were conducted to determine to what degree RMD is converted to 
DGR in mice following acute administration of RMD. The results obtained 
would be useful for further concentration effect studies and would give an 
indication of the concentrations of RMD and DGR to use for further in vitro 
experiments.
Results from serum measurements of RMD and DGR suggest that conversion 
of RMD to DGR occurs in the peripheral tissues. The results also suggest that 
RMD is rapidly and extensively converted to DGR in the brain following 
acute administration to mice. The pharmacokinetics of DGR outlast those of 
the parent compound both in serum and brain.
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In man, RMD reaches peak serum concentrations within 1 -2  hours following 
oral administration (Patsalos and Sander, 1994). DGR is said to reach 
maximal concentrations at 2 - 3 hours (Stables et al, 1995). Clinical studies 
have also found that CSF concentrations of DGR are much higher than those 
of RMD (Lindstrom et al, 1996). Our measurements of RMD and DGR 
concentrations in the brain concur with these findings. The terminal half-lives 
of RMD and DGR in man are reported to be approximately 3.8 and 12.9 
hours, respectively (Palmer et al, 1993). Following multiple dosing, a greater 
degree of accumulation is observed with DGR than RMD, as would be 
expected from its half-life. In the investigations above, half-lives of 62 and 
250 minutes were calculated for RMD and DGR, respectively, following an 
80 mg/kg dose of RMD. Terminal half-lives of RMD and DGR in the rat are 
reported to be 42 and 150 minutes (Clark et al, 1995).
Results from the above study indicate that, when maximal, RMD levels in the 
brain were found to be 7.45% of those measured in the serum with DGR 
concentrations in the brain 25.6% of those in the serum. There are a number 
of reasons why the ratios of RMD to DGR may differ between brain and 
peripheral circulation. As previously discussed, the blood/brain barrier is said 
to be an important site for the conversion of RMD to DGR (Heyn et al, 
1994a). It is possible that the conversion at this site results in the apparent 
accumulation of DGR in the brain. Alternatively DGR may simply pass into 
the brain via passive difiusion more easily than RMD by virtue of its smaller 
molecular size. If the actions of RMD and DGR differ in any way, as has been
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previously suggested, it is possible that the ratio of RMD to DGR may be 
critical to the actions of the drug.
In conclusion the kinetics of DGR appear to outlast those of the parent 
compound both in serum and brain with a significantly greater half-life 
calculated. This is in agreement with previous studies (Clark et al, 1995). The 
findings presented in this chapter have consequences for later concentration- 
effect studies and AED interaction investigations.
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Chapter 4
The effects of hepatic enzyme induction on the pharmacokinetics 
and pharmacodynamics of remacemide
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4.1 Introduction
A drug interaction can be described as the modification of the effect of one drug 
by prior or concomitant administration of another (Patsalos, 1998). Drug 
interactions can be divided into two categories, pharmacokinetic and 
pharmacodynamic (Rang et al, 1995).
Pharmacokinetic interactions are those which can affect the way that drugs are 
absorbed, distributed, metabolised or excreted (Neal, 1992). The key mechanism 
of interaction of the AEDs relates to inhibition or induction of drug metabolism. 
The mono-oxygenases, known collectively as cytochrome P450, are by far the 
most important drug-metabolising enzymes.
Four of the established AEDs (CBZ, PHT, PB and PRIM) and three new AEDs 
(FBM, TPM and OXC) are recognised inducers of the cytochrome P450 system. 
Most pharmacokinetic drug interactions have been discovered as a result of an 
unexpected change in the clinical status of a patient upon addition to, or 
withdrawal from, existing medication (Brodie, 1992). The interaction potential of 
a drug can substantially affect its clinical use. Consequently, interaction studies 
are now an integral part of phase I and II development for all new AEDs 
(Patsalos, 1998).
Cytochrome P450 is the generic term for the superfamily of haem-containing
mono-oxygenases that are responsible for the oxidative biotransformation of a
wide range of chemically and biologically related exogenous and endogenous
substrates (Porter and Coon, 1991). Located primarily in the endoplasmic
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reticulum of the liver, the cytochrome P450 enzymes are the most powerful 
oxidising agents in vivo (Park et al, 1995). The general equation for P450- 
dependent oxidation is:
RH + NADPH + 0 2 + H+ => ROH + NADP+ + H20
The insertion of oxygen into the substrate (R) makes the compound more 
reactive, a process sometimes termed fimctionalisation (Gibson & Skett,
1986), and thereby more susceptible to further metabolism. There are many 
different cytochrome P450 subtypes, or isoenzymes, and more than 30 of 
these can be expressed in a particular tissue at any one time (Nebert et al, 
1981). The capacity of the cytochrome P450 system can be altered by enzyme 
induction or inhibition. This can be selective or non-selective and provides a 
source of inter- and intra-individual variation in both rates and routes of drug 
metabolism (Park and Kitteringham, 1990).
Enzyme induction by drugs and other xenobiotic chemicals was initially 
discovered by virtue of the profound effects that induction can have on 
pharmacological responses. Thus its phenomenon was reported before the 
discovery and naming of the cytochrome P450 superfamily (Okey, 1990). 
Cytochrome P450 was first identified by Omura and Sato (1964). They 
named the pigment P450 because it exhibited a spectral peak at 450nm when 
the cytochrome was reduced and bound to carbon monoxide. Their spectral 
characterisation also provided the first means of quantitating the P450 content 
of tissue fractions.
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A number of assays employing various model substrates have been developed 
as measurements of basal and PB-inducible mono-oxygenase activities 
(Greenlee and Poland, 1978). Sensitive fluorometric assays have been 
reported for the O-deethylation of 7-ethoxycoumarin (Ullrich and Weber, 
1972; Jacobson et al, 1974) and 7-ethoxyresorufin (Burke and Mayer, 1974), 
and the O-demethylation of harmine (Burke and Upshall, 1976). The O- 
deethylation of 7-ethoxycoumarin to the highly fluorescent product, 7- 
hydroxycoumarin, is a particularly sensitive indicator of mono-oxygenase 
activity, with the apparent potential to serve as a screening assay for a wide 
range of inducers (Greenlee and Poland, 1978).
PB, chronically administered to rats, gradually decreases its own sedative 
effect by enhancing barbiturate metabolism and clearance (Remmer, 1962; 
Remmer and Merker, 1963). After induction with PB, the concentration of 
total P450 in rat liver microsomes, measured spectrally, typically increases 2- 
to 3-fold and is elevated in proportion to the increase in enzyme catalytic 
activity (Conney, 1967). Repeated injections of 80 mg/kg PB have been used 
to induce the hepatic enzymes of mice in a number of studies (Honkakoski 
and Lang, 1989; Kim et al, 1990; Corcos, 1992; Noguchi et al, 1994; Panesar 
et al, 1996; Charpentier et al, 1997; Carlile et al, 1999).
4.2 Aims
A pharmacokinetic study was conducted to assess the effects of hepatic
enzyme induction with CBZ and PB on the pharmacokinetics of RMD and
DGR. A further pharmacodynamic study investigated the effects of hepatic
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enzyme induction on the efficacy of RMD against MES-induced seizures 
following acute administration in mice.
4.3 Methods
4.3.1 Induction o f cytochrome P450
The cytochrome P450 hepatic enzyme system of male ICR mice was induced 
by administration of 100 mg/kg CBZ or 80 mg/kg PB (i.p.) once daily for 4 
days.
4.3.2 Maximal electroshock-seizure test
This test was performed in accordance with the method described by Loscher 
and Schmidt (1988). Constant current electroshock stimuli were delivered to 
mice via auricular electrodes from an ECT unit. Stimuli consisted of 0.2 
seconds of rectangular positive pulses (pulse width = 0.4 ms) at a frequency 
of 60 Hz. The stimulation current used to induce tonic hind-limb extension 
(THE) was 50 mA.
4.3.3 Remacemide anddesglycinyl-remacemidepharmacokinetics
RMD and DGR concentrations were determined in brain tissue by the method 
described in section 3.3.
4.3.4 Measurement o f cytochrome P450 content
The cytochrome P450 content of liver microsomes was determined by a
modification of the method of Omura and Sato (1964). Microsomes were
prepared from livers that had been perfused in situ with ice-cold saline. The
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excised liver was homogenised with a motorised teflon pestle in 3 ml ice-cold 
0.25 M sucrose. The homogenates were then centrifuged at 10,000 x g for 20 
minutes at 4°C. The supernatant produced was centrifuged at 105,000 x g for 
one hour at 4°C.
The resulting pellets were resuspended in 3 ml 0.01 M Tris-HCl buffer which 
contained 151 mM KC1, 1 mM EDTA and 20% glycerol (pH 7.6). The 
prepared microsomes were then stored at -80°C until required.
On the day of the assay, the samples were removed from the freezer and 
allowed to defrost completely. Following centrifugation at 105,000 x g for 
one hour at 4°C, the pellets were resuspended in 0.1 M KH2PO4 (pH 7) to a 
protein concentration of 2 mg/ml as determined by the BIORAD method 
(section 2 .2 .2 ).
The resuspended microsomes were split between two cuvettes, each with 1
cm path lengths. Carbon monoxide (CO) was bubbled through one of the cells
(designated the test cell). An excess of sodium dithionite was then added to
both cuvettes and CO bubbled through the test cell once again. The test cell
was then scanned against the reference cell (no CO) on a double beam
spectrophotometer. The cytochrome P450 content of the microsomes was
determined from the CO-induced difference spectrum of dithionite-reduced
microsomes produced between 400 - 500 nm at 20°C. The extinction
coefficient s = 91 nm was used to account for the difference in cytochrome
extinction between 450 and 490 nm. The figure indicating the peak difference
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in absorbance observed between the test cell and control cell between 450 and 
490 nm was therefore multiplied by 91 to obtain an accurate result.
4.3.5 Measurement o f cytochrome P450 activity 
The cytochrome P450 activity of liver microsomes was determined by 
measuring the 7-ethoxycoumarin O-deethylase activity of the preparation by 
the method described by Greenlee and Poland (1978). The O-deethylation of 
7-ethoxycoumarin to the highly fluorescent product, 7-hydroxycoumarin, is a 
particularly sensitive indicator of mono-oxygenase activity.
Microsomes were prepared from livers perfused in situ with ice-cold saline. 
The excised livers were homogenised with a motorised teflon pestle in 3 ml 
0.15 M KC1. The homogenate was centrifuged at 10,000 x g for 20 minutes at 
4°C. The resulting supernatant was diluted with 0.15 M KC1 to give a final 
protein concentration of 1 mg/ml as determined by the BIORAD method 
(section 2.2.2). At this stage the microsomes could be stored at -80° C until 
required.
Each sample was divided into three 100 pi aliquots and was measured in 
duplicate plus a blank. Test and blank samples were added to a buffer 
containing final concentrations of 0.5 pM NADH, 0.5 pM NADPH, 5.0 pM 
MgCl2, 5 pM BSA and 65 pM KH2P 04 buffer (pH 7.2) to give a total volume 
of 1 ml. The reaction was initiated by the addition of 50 pi of the substrate 
(7-ethoxycoumarin; 0.5 pM final concentration). In the blank samples, 125 pi
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15% (w/v) TCA was added prior to the addition of the substrate to prevent 
any reaction. All samples were then incubated at 37°C. After 10 minutes, 125 
pi TCA (15%) and 2 ml chloroform were added, in sequence, to the test 
samples. Chloroform (2 ml) only was added to the blank samples. The product 
was extracted into the chloroform by shaking the tubes vigorously for 10 
minutes. The chloroform extract was seen to separate into two phases. A 1 ml 
portion of the organic (lower) phase was removed and added to 1.5 ml 50% 
(v/v) 0.01 N NaOH/1 M NaCl. The sample was then vortex mixed. The 
alkaline phase of this solution (upper layer) was then removed and diluted 1:1 
with 1 M NaCl. The concentration of 7-hydroxycoumarin in the samples was 
determined fluorometrically with excitation at 368 nm and emission at 456 
nm.
The quantity of 7-hydroxycoumarin formed was calculated by comparing the 
net fluorescent units observed (sample minus blank) in the final extract with a 
standard solution of 7-hydroxycoumarin, after correcting for the dilution 
factors in the two extractions. Activity was corrected for percentage recovery 
of product and is expressed as the quantity of product formed (nmol/mg/min).
4.4 Experimental protocol
Pharmacokinetic study: Adult male ICR mice were randomised into three
groups (n = 30) and administered either saline, 100 mg/kg CBZ or 80 mg/kg
PB by intraperitoneal (i.p.) injection. Treatment continued once daily for 4
days. On day 5, 24 hours after the last chronic treatment, animals were given
a single injection of RMD (40 mg/kg; i.p.). Six animals from each group were
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sacrificed at 30, 60, 120, 240 and 360 minutes following RMD administration. 
Their brains were removed and analysed for RMD and DGR concentrations 
by the method described in section 3.3. Livers were also removed following 
perfusion in situ with ice cold saline and were analysed for cytochrome P450 
content (section 4.3.3) and cytochrome P450 activity (section 4.3.4).
Pharmacodynamic study: Adult male ICR mice were randomised into two 
groups (n = 48) and administered either saline or 80 mg/kg PB i.p. once daily 
for 4 days. On day 5, 24 hours after the last chronic treatment, eight animals 
from each group were given a single injection of 0, 0.3, 1,3, 10 or 30 mg/kg 
RMD (i.p.). One hour later, animals were subjected to the MES seizure test 
with the incidence of THE recorded. Following the seizure test, animals were 
sacrificed and had their brains removed. RMD and DGR concentrations in 
brain samples were analysed by the HPLC method described in section 3.3.
4.5 Data analysis and statistics
Statistical analysis was performed using MINITAB for Windows version 10.1
on a Viglen P2 400 microcomputer. Results for both cytochrome P450
content and activity are given in absolute values (nmol/mg and nmol/mg/min,
[± SEM] respectively). Statistical differences from control ip < 0.05) were
determined by one-way analysis of variance with a Dunnett correction for
multiple comparisons. MES results were expressed as the percentage of
animals per group exhibiting THE. ED50values were calculated by simple
regression analysis of the data. ED5o values are defined as the dose of RMD
required to protect 50% of the animals in any particular group from THE.
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Area under the curve analysis was performed using the Fig P scientific 
processor package.
4.6 Results
Pharmacokinetic study: Repeated administration of PB caused a decrease in 
the brain concentrations of RMD (figure 9) and DGR (figure 10). CBZ 
significantly decreased the concentrations of DGR only (figure 10). The 
results from saline and PB-treated animals are compared in figure 11. Area 
under the curve analysis demonstrated that DGR was significantly (p < 0.05) 
more susceptible than RMD to hepatic enzyme induction by PB (figure 12). 
Cytochrome P450 content analysis demonstrated that PB-treated animals had 
66% more cytochrome P450 when compared to the saline treated controls 
(figure 13 A). Enzyme activity was also increased in the PB-treated animals 
with an increase of 516% when compared to the control group (figure 13B). 
Data for animals treated with CBZ is unavailable due to contamination of the 
assay.
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Figure 9: Pharmacokinetic profile o f remacemide (40 mg/kg) in mouse 
brain 24 hours after chronic treatment with either saline, 
carbamazepine (CBZ; 100 mg/kg) or phenobarbital (PB; 80 
mg/kg) once daily for 4 days. Results (n = 6) are expressed as the 
mean o f absolute brain concentrations (pg/g). Error bars have 
been omitted for ease o f comprehension.
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Figure 10: Pharmacokinetic profile o f desglycinyl-remacemide in mouse 
brain after a single intraperitoneal injection o f  remacemide (40 
mg/kg) administered 24 hours after chronic treatment with either 
saline, carbamazepine (CBZ; 100 mg/kg) or phenobarbital (PB; 
80 mg/kg) once daily for 4 days. Results (n = 6) are expressed as 
the mean o f  absolute brain concentrations (pg/g). Error bars 
have been omitted for ease o f comprehension.
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Figure 11: Pharmacokinetic profiles o f remacemide (RMD) and desglycinyl- 
remacemide (DGR) in brain tissue o f  animals following a single 
injection o f remacemide (40 mg/kg). Animals had been 
previously treated for 4 days with either saline or phenobarbital 
(PB; 80 mg/kg). Results (n = 5) are expressed in absolute 
brain concentrations (pg/g). Error bars have been omitted for ease 
o f comprehension.
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Figure 12A: Area under the curve analysis for brain concentrations of 
remacemide and desglycinyl-remacemide following a single 
intraperitoneal injection of remacemide (40 mg/kg) in mice 
chronically treated with saline (controls) or carbamazepine 
(induced). Results (n= 30) are expressed as the mean percentage 
of control (saline-treated) and error bars denote the standard error 
of the mean.
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Figure 12B: Area under the curve analysis for brain concentrations of 
remacemide and desglycinyl-remacemide following a single 
intraperitoneal injection of remacemide (40 mg/kg) in mice 
chronically treated with saline (controls) or phenobarbital 
(induced). Results (n= 30) are expressed as the mean percentage 
of control (saline-treated) and error bars denote the standard error 
of the mean. Statistical differences (*p<  0.05) between 
remacemide and desglycinyl-remacemide levels in induced animals 
was determined by performing a Student’s t-test.
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Figure 13: (A) Cytochrome P450 (CYP450) content of liver microsomes 
prepared from mice chronically treated with saline or 
phenobarbital (PB; 80 mg/kg) once daily for 4 days. The mean 
enzyme content of the microsomes (n = 30) is expressed in 
nmol/mg. Error bars denote the standard error of the mean. 
Statistical significance (*/? < 0.05) from control was determined 
by a Student’s t-test. (B) Cytochrome P450 (CYP450) activity of 
liver microsomes prepared from mice chronically treated with 
saline or phenobarbital (PB; 80 mg/kg) once daily for 4 days. 
Mean enzyme activity of the microsomes (n = 30) is expressed in 
nmol/mg/min. Error bars denote the standard error of the mean. 
Statistical differences from control were determined by a 
Student’s t-test.
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Pharmacodynamic study: Animals treated for 4 days with 80 mg/kg PB prior to 
RMD (figure 14) exhibited lower brain concentrations of RMD and DGR than 
animals that were previously treated with saline (figure 15). When expressed as a 
percentage of non-induced control results, DGR concentrations were found to be 
significantly ip < 0.05) lower than RMD concentrations following administration 
of 10 and 30 mg/kg RMD (figure 16). An ED5o value of 2.1 mg/kg RMD in the 
MES test was calculated for control animals. In PB treated animals the ED5o value 
was calculated 41 mg/kg (figure 17).
4.7 Discussion
Results from clinical trials (Chadwick et al, 2000; Richens et al, 2000) suggest 
that RMD is effective in reducing seizure frequency when administered as 
adjunctive therapy. There is also the suggestion that DGR is more susceptible 
to the effects of hepatic enzyme induction than the parent compound (Leach 
et al, 1996a; Leach et al, 1997b; Chadwick et al, 2000; Richens et al, 2000).
The above study was designed to investigate the effects of hepatic enzyme 
induction on the relationship between RMD and DGR and also on efficacy 
against MES-induced seizures in mice.
Combination therapy is common in patients with active epilepsy and in 
patients with multiple seizure types. Due to the chronic nature of epilepsy and 
its treatment, the possibility of AED interactions is high. Pharmacokinetic 
interactions may affect the absorption, distribution, metabolism, or excretion 
of a drug. The effects of enzyme induction and
116
Br
ain
 
co
nc
en
tra
tio
n 
(u
g/
g)
□ remacemide 
■ desglycinyl-remacemide
0 0.3 1 3 10 30
RMD dose (mg/kg;i.p.)
Figure 14: Pharmacokinetic profiles of remacemide (RMD) and desglycinyl- 
remacemide in mouse brain one hour following a single 
intraperitoneal injection of RMD (0 - 30 mg/kg). All animals 
were previously treated with saline (0.3 ml) once daily for 4 days. 
Results (n = 8) are expressed as the mean of the absolute brain 
concentrations (pg/g) with error bars representing the standard 
error of the mean.
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Figure 15: Pharmacokinetic profiles of remacemide (RMD) and desglycinyl- 
remacemide in mouse brain one hour following a single 
intraperitoneal injection of RMD (0 - 30 mg/kg). All animals 
were previously treated with phenobarbital (80 mg/kg) once daily 
for 4 days. Results (n = 8) are expressed as the mean of the 
absolute brain concentrations (pg/g) with error bars representing 
the standard error of the mean.
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Figure 16: Brain concentrations of remacemide and desglycinyl-
remacemide following a single intraperitoneal injection of 
remacemide. Animals had been previously treated with 
phenobarbital (80 mg/kg) for 4 days. Results (n = 8) are 
expressed as a percentage of control (saline treated) 
concentrations. Statistical significance (*/? < 0.05) between 
remacemide and desglycinyl-remacemide results was determined 
by a Student’s t-test.
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Figure 17: Effects of hepatic enzyme induction, caused by four days
pretreatment with 80 mg/kg phenobarbital, on the efficacy of 
remacemide against maximal electroshock (MES)-induced 
seizures. Animals were subjected to the MES seizure test one 
hour following intraperitoneal administration of remacemide (0 - 
30 mg/kg). Results (n = 8) are expressed as a percentage of 
animals exhibiting tonic hind-limb extension.
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inhibition are the most common cause of pharmacokinetic problems (Brodie, 
1992). The clinical result of hepatic enzyme induction is increased metabolism 
of the target drug, with a reduction in circulating concentrations which can 
result in attenuation of its pharmacological effect (Brodie, 1992).
In the above study, chronic administration of CBZ (100 mg/kg; i.p) and PB 
(80 mg/kg; i.p) once daily for 4 days was found to decrease brain 
concentrations of DGR with the effects of PB being more pronounced. CBZ 
was seen to have no significant effects of the pharmacokinetics of RMD. 
CYP450 content of liver microsomes prepared from PB-treated animals were 
shown to be significantly greater than those from saline-treated control 
animals. Similarly, a significant increase in CYP450 activity was observed in 
PB-treated animals when compared to controls. The effects of hepatic enzyme 
induction by PB on the brain concentrations of RMD and DGR were shown 
to be dependent on the dose of RMD administered. DGR was found to be 
significantly more susceptible to the effects of hepatic enzyme induction when 
results were expressed as a percentage of control. Chronic PB treatment 
caused the ED50 value for RMD in the MES seizure test to increase from 2.1 
mg/kg for non-induced controls to 41 mg/kg RMD (i.p.) in PB-treated 
animals.
Previous clinical pharmacokinetic studies have found that RMD inhibits the
metabolism of CBZ, and CBZ itself induces metabolism of RMD and DGR
(Leach et al, 1996a). This mutual interaction was not significant enough to
warrant an alteration of either treatment regimen. Closer analysis of the data
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shows that DGR was more susceptible to the effects of hepatic enzyme 
induction than the parent compound. Another study (Mawer et al, 1999) 
reported that reduction of CBZ dosage was required when administered with 
RMD in order to avoid toxicity although this study employed greater doses of 
RMD and a longer treatment schedule to that mentioned above (Leach et al, 
1996a). PHT, a well known inducer of CYP450 (Brodie, 1992) decreases the 
terminal half-lives of both RMD and DGR following co-administration with 
RMD (Leach et al, 1997b). RMD was also shown to cause a slight inhibition 
of PHT metabolism via an action on the CYP2C9 isoform. This study also 
reported that DGR was more susceptible to the effects of this induction than 
RMD (Leach et al, 1997b). VP A, a well known hepatic enzyme inhibitor 
(McKee and Brodie, 1994), was shown to have no effects on the kinetics of 
RMD or DGR following single or multiple dosing with RMD (Leach et al, 
1997a).
Our results demonstrate that PB induces the metabolism of RMD and DGR to
a greater degree than CBZ. The reasons for this are unclear. CBZ induces its
own metabolism (Macphee et al, 1987) so it is possible that the circulating
levels of CBZ were not sufficient to produce the same degree of induction as
PB. PB also induces its own metabolism but not to the same extent as CBZ
(Remmer, 1962; Remmer and Merker, 1963). The known variability of the
extent of CBZ induction is perhaps also involved (Macphee et al, 1987).
Alternatively, CBZ may not induce the appropriate isoforms of CYP450
required to alter RMD and DGR metabolism. PB is known to induce multiple
forms of cytochrome P450 in rat liver, including CYP2A1, 2B1, 2B2, 2C6,
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2C7, 2C11, 3A1, and 3A2 (Gonzalez, 1989; Waxman and Azaroff, 1992). 
Some of the induction responses are substantial with increases approximately 
50- to 100-fold (2B1/2B2), whereas others are much smaller (2- to 4-fold 
with 2A1/2C6).
As discussed above, RMD and CBZ have a mutual interaction in terms of 
metabolism (Leach et al, 1996a). RMD inhibits CBZ metabolism by 
decreasing the activity of the CYP3 A4 isoform. Clinically, CBZ, a known 
inducer of CYP3A4, increases the metabolism of RMD and DGR (Leach et 
al, 1996a), suggesting that both the drug and the parent compound are 
metabolised to some degree by this isoform. In the above study, CBZ only 
significantly decreased the concentrations of DGR suggesting that it is more 
susceptible to CYP3 A4 metabolism than RMD. There is evidence to suggest 
that RMD and DGR are also metabolised by other isoforms of CYP450. As 
described above, PB induces a variety of CYP450 isoforms to various degrees 
but has no significant effect on CYP3A4 (Gonzalez, 1989; Waxman and 
Azaroff, 1992). The results described above indicate that PB does 
significantly induce the metabolism of both RMD and DGR. It is therefore 
possible that the 2B1 and 2B2 CYP450 isoforms, the principal isoforms 
induced by PB, are largely responsible for the metabolism of both RMD and 
DGR.
The increased metabolism of DGR compared to RMD reported here and in
previous clinical investigations (Leach et al, 1996a; Leach et al, 1997b;
Chadwick et al, 2000; Richens et al, 2000) suggests that either additional
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isoforms of CYP450 may contribute to its clearance or that the compound, 
being of smaller molecular size, is simply more susceptible to drug 
metabolism. Alternatively, RMD, under induced conditions, may be converted 
more readily to one of its other inactive metabolites. The oxidation of RMD 
to the phenol metabolite AR-R14330 is catalysed by the 3A4 and 2D6 
(AstraZeneca, unpublished results). Although neither of these isoforms are 
significantly induced by PB, an increase in the formation of this metabolite 
would explain the observations regarding CBZ and PHT co-administration 
(Leach et al, 1996a; Leach et al, 1997b; Mawer et al, 1999). The PB-induced 
increase in other isoforms of CYP450 may cause RMD to be converted to 
other metabolites rather than DGR, resulting in lower concentrations of the 
desglycinyl derivative.
P450 induction requires de novo protein (enzyme) synthesis. It is not merely 
an increase in activation of latent enzyme that is observed (Conney, 1967). 
Increased catalytic activity of P450-mediated mono-oxygenases is primarily 
the consequence of increased levels ofP450 apoproteins. In turn, specific 
P450 protein contents are elevated, mainly as a result of increased gene 
transcription (Adesnik et al, 1981; Adesnik and Atchison, 1985; Whitlock, 
1986; Nebert and Gonzalez, 1987). The results presented above demonstrate 
a disproportional increase in enzyme activity when compared to enzyme 
content. It is possible that sensitivity of the enzyme content assay is the reason 
for this observation. Another possibility is that the observed PB-induced 
change in whole CYP450 content is mainly due to an increase in CYP2B, the
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isoform primarily responsible for the metabolism of 7-ethoxycoumarin to 7- 
hydroxycoumarin (Greenlee and Poland, 1978).
Efficacy in the MES model is described as an indicator of activity against 
primary and secondary generalised tonic-clonic seizures (Fisher, 1989). The 
ED50 levels calculated from non-induced animals in this study are significantly 
lower than those previously reported (Stagnitto et al, 1990; Garske et al, 
1991; Palmer et al, 1991; Palmer et al, 1992; Clark et al, 1995; Davies, 1997). 
There are a number of possible reasons for this observation, including 
variation in pre-treatment times. Investigations that have performed the MES 
test 30 minutes following injection have significantly higher ED50 values than 
the above study in which animals were tested after one hour (Stagnitto et al, 
1990; Palmer et al, 1992). DGR has been shown to be significantly more 
potent than RMD in the MES test and therefore it is possible that the lower 
levels of DGR at 30 minutes post-dosing account for the higher ED50 values 
in these studies. Variation in the type of electrodes used may also contribute 
to differing results. The majority of previous studies have used comeal 
electrodes, whereas auricular electrodes were employed in the above study 
(Stagnitto et al, 1990; Palmer et al, 1992).
The observed decrease in the efficacy of RMD against MES-induced seizures
following PB treatment may be due to various factors. The most plausible
explanation is the decrease in circulating drug concentrations. However, it is
also possible that the increase in DGR metabolism when compared to RMD
and the subsequent change in ratio may contribute to the lack of
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pharmacological effect given that DGR is the more effective of the two 
compounds in the MES model (Clark et al, 1995; Davies, 1997).
With hindsight, an additional study investigating the effects of hepatic enzyme 
induction on the efficacy of DGR alone would have afforded a greater degree 
of understanding of the above results. Circulating plasma levels of RMD and 
DGR and a more detailed analysis of the specific isoforms of CYP450 that 
were induced by PB would also have been useful.
In conclusion, the above study demonstrates that administration of PB (80 
mg/kg; i.p.) for 4 days, results in a significant increase in both the content and 
activity of cytochrome P450 enzymes in the livers of mice. This increase in 
hepatic enzyme activity was shown to significantly decrease the brain 
concentrations of RMD and DGR. The efficacy of RMD against MES- 
induced seizures when compared to saline-treated control animals was also 
decreased in induced animals. The increased susceptibility of DGR to enzyme 
induction and a subsequent change in the ratio of RMD to DGR in the brain is 
suggested to contribute to the observed decrease in pharmacological effect, 
although further investigations are required.
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Chapter 5
Effects of remacemide and desglycinyl-remacemide on zero 
Mg^/4-AP-induced epileptiform activity in the rat hippocampal
slice
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5.1 Introduction
Many sources indicate that the hippocampus and associated structures are 
critical for complex partial seizures originating in the mesial temporal lobe in 
humans (de Lanerolle et al, 1989; Lothman et al, 1991; Stringer and Lothman, 
1992). Electrophysiological recordings from the hippocampus of epileptic 
patients either in situ or following resective surgery exhibit marked 
epileptiform activity (Babb et al, 1987). Many features common to human 
epilepsy and experimental models of epilepsy have been shown to be 
hippocampal in origin, for example, mossy fibre sprouting and dentritic 
changes (Ross, 1998).
Despite being an in vitro model, the hippocampal slice retains all of its distinct 
neuronal pathways which can be selectively activated (Skrede and Westgaard, 
1971). The afferent pathways into the hippocampus as well as the intrinsic 
connections and outputs are all glutamatergic with both ionotropic (NMDA, 
AMPA and kainic acid) and metabotropic subclasses of receptor present 
(Collingridge et al, 1982). Under normal physiological conditions, 
transmission within the hippocampus is carried by AMPA and kainic acid 
receptors with NMDA receptors only recruited during periods of prolonged 
depolarisation or when Mg2+ is removed from the surrounding medium 
(Collingridge et al, 1983).
The hippocampal slice model has a number of advantages over in vivo
electrophysiological models. Ionic environments can be tightly controlled
which permits easy manipulation, drugs can be applied without the restrictions
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of the blood/brain barrier and systemic metabolism, and distinct intact 
pathways can be visualised and selectively activated (Skrede and Westgaard, 
1971). Manipulation can be achieved by either changing the perfusion medium 
or by the direct application of compounds to the slice. Epileptiform activity is 
generated by raising the basal level of excitation by the use of excitatory 
compounds or procedures, compounds which reduce inhibition or by altering 
the ionic content of the perfusing medium (Voskul and Albus, 1985; Watts 
and Jefferies, 1993; Morris et al, 1996).
The extracellular concentration of K+ is raised during seizures induced in vivo 
in cats (Moody et al, 1974; Fisher et al, 1976) and in vitro in hippocampal 
slices (Yaari et al, 1986). Interictal activity in the CA3 region of the 
hippocampus occurs when slices are bathed in a high K+ medium (~ 12 mM; 
Rutecki et al, 1985; Korn et al, 1987; Traynelis and Dingledine, 1988). This 
activity propagates to the CA1 region where intense seizure-like activity 
results (Traynelis and Dingledine, 1988; Leschinger et al, 1993). Increased 
extracellular K+ reduces K+ efflux as a result of a modified concentration 
gradient (Dietzel et al, 1980). It is suggested that seizures develop when the 
CA1 region can no longer clear the excess K+ from the interstitial space 
before the next interictal burst (Dichter et al, 1972; Traynelis and Dingledine, 
1988).
Reduced levels of Mg2+ have been associated with the symptoms of clinical
epilepsy (Durlach, 1967). Slice preparations of various CNS tissues generate
epileptiform activity when perfused with a medium devoid of added Mg2+
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(Mody et al, 1987; Stanton et al, 1987; Gean and Shinnick-Gallagher, 1988; 
El-Beheiry and Puil, 1990). The absence of Mg2+ removes the voltage- 
dependent Mg2+ block from the NMDA subtype of glutamate receptor, again 
facilitating enhanced excitatory neurotransmission (Traub et al, 1995). Mg2+ 
and Ca2+, as divalent cations, are involved in membrane charge screening 
which acts to stabilise membrane currents. The removal of Mg2+, therefore, 
reduces membrane screening and facilitates the production of inward ionic 
currents and action potentials (Frankenhaeuser and Hodgkin, 1957; 
McLaughlin et al, 1971). Similarly, low or zero Ca2+ can also be used to cause 
epileptiform activity in hippocampal slices (Jefferies and Haas, 1982;
Konnerth et al, 1986).
4-aminopyridine (4-AP) is known to induce epileptiform activity in vivo 
(Szenet and Pongracz, 1979) and in vitro (Chesnut and Swann, 1988; Watts 
and Jefferies, 1993; Arvanov et al, 1995; Traub et al, 1995). The principal 
action of 4-AP is the blockade of neuronal K+ currents (Storm, 1988) 
although an enhanced release of neurotransmitters can also be stimulated 
(Thesleff, 1980). This release is thought to be secondary to the elongation of 
action potential duration allowing a greater influx of Ca2+ into the presynaptic 
neurone (Molgo et al, 1977; Flores-Herandez et al, 1994).
Other methods of inducing epileptiform activity in the hippocampal slice
include perfusion of GABA receptor antagonists, such as picrotoxin (Lee and
Halbitz, 1989) and bicuculline (Herron et al, 1985), and other convulsive
agents such as kainic acid (Westbrook and Lothman, 1983), tetanus toxin,
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(Whittington and Jefferies, 1994), penicillin (Wong and Prince, 1979), PTZ 
(Mirski et al, 1994) and pilocarpine (Nagao et al, 1996).
5.2 Aims
An in vitro conversion study was conducted to determine whether RMD is 
metabolised to DGR in hippocampal slices. Subsequent investigations were 
designed to compare and contrast the effects of RMD and DGR on the 
generalised epileptiform activity produced by omission of Mg2+ and the addition 
of 4-AP to the bathing medium of rat hippocampal slices. CBZ, a prototypic 
sodium channel blocking anticonvulsant, and ARR-15896, a putative NMD A 
receptor blocker were employed for comparative purposes.
5.3 Methods
5.3.1 Preparation o f tissue
Hippocampal slices were prepared from adult, male Wistar rats (200 - 250 g) 
according the the method of Ross and co-workers (1998). Animals were 
anaesthetised with 1.3 g/kg urethane and sacrificed by cervical dislocation.
After decapitation the brain was carefully removed and placed in oxygenated, 
ice-cold ACSF (NaCl 115 mM, CaCl2 2.5 mM, KC1, 2 mM, NaHC03 25 mM, 
MgSC>4 1.2 mM, D-glucose 10 mM). The cerebellum and pons/medulla were 
removed and the two cerebral hemispheres separated using a scalpel blade.
The hippocampi were dissected from each hemisphere using microspatulas.
Transverse hippocampal slices (450 pm) were prepared using a McHwain
tissue chopper. The slices were kept in an interface chamber containing
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ACSF, gassed with 95% 0 2 / 5% C02 and allowed to recover for at least one 
hour prior to experimentation. Following the recovery period, individual slices 
were transferred to a 1 ml submersion chamber which was continually 
perfused with ACSF at a rate of 3-4 ml/minute. The temperature of the 
chamber was held at 34°C.
5.3.2 Measurement o f remacemide and desglycinyl-remacemide
RMD and DGR concentrations in hippocampal slices and in ACSF from the in 
vitro conversion study were determined by the method described in section 
3.3.
5.3.3 Stimulation and recording
A bipolar stimulation electrode was placed in the CA1 region of the 
hippocampal slice (figure 18) to allow orthodromic stimulation of the mossy 
fibres. The response to this stimulation (0.2 Hz) was recorded via a glass 
capillary electrode, filled with 0.9% NaCl, whose tip was positioned in the 
pyramidal cell layer of the CA1 region (figure 18). The brief period of 
stimulation confirmed slice viability and correct positioning of the electrode 
indicated by the ability to record a population spike in the CA1 stratum 
pyramidals.
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Figure 18: Diagram of a hippocampal slice. (A) - Stimulating electrode CA1; 
(B) - Recording electrode in CA1; (C) -  Dentate gyrus.
(D) -  Schaffer collaterals
5.3.4 Generation o f epileptiform activity
For initiation of epileptiform bursting, stimulation was stopped and the slices 
perfused with a modified ACSF (mACSF) which contained no Mg2+ and 50 
pM 4-AP (zero Mg2+/4-AP). Bursts were observed on a digital storage 
oscilloscope and recorded on a chart recorder. Burst frequency was 
determined by counting the number of spikes displayed on the chart recorder 
per minute. Experiments were performed when the burst frequency was 
constant and greater than 20 bursts per minute.
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5.3.5 Drug preparation
RMD, DGR, CBZ and ARR-15896 (all 0-100 pM) were dissolved in 
mACSF. CBZ was first dissolved in 2 ml glycofurol before being diluted with 
mACSF to give a final concentration of 2% glycofurol. Pilot studies indicated 
that 2% glycofurol had no effect on epileptiform activity.
5.4 Experimental protocols
5.4.1 In vitro conversion study
Concentration study- Slices were randomised into 7 groups (n = 5) with individual 
slices placed in the wells of 96 well plates with 250 pi of oxygenated ACSF 
containing 0, 62.5, 125, 250, 500, 750 or 1000 pM RMD. An additional well 
contained 1000 pM RMD with no tissue present. Plates were incubated for 10 
minutes at 37°C after which time the ACSF and tissue were removed from each 
well and stored at -20°C until required for analysis of RMD and DGR 
concentrations.
Time study: Slices were randomised into 8 groups (n = 5) and placed individually 
in the wells of a 96 well plate. All slices were incubated with 250 pi oxygenated 
ACSF containing 500 pM RMD at 37°C for 1, 2, 5, 7.5, 10, 15, 20 or 30 minutes. 
Following incubation, tissue and ACSF were removed from each well and stored 
at -20°C until required for analysis of RMD and DGR concentrations.
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7.4.2 Electrophysiological studies
The effects of RMD, DGR, CBZ and ARR-15896 (all 0-100 pM) were 
investigated in one hippocampal slice preparation from each of five different 
rats and individual slices were employed for the study of one drug alone. All 
drugs were perfused for 25 minutes and slices washed with mACSF alone for 
35 minutes between drug concentrations.
5.5 Data analysis and statistics
Statistical analysis was performed using MINITAB for Windows version 10.1 
on a Viglen P2 400 microcomputer. In vitro conversion study results are 
expressed as the mean of absolute values (pM) ± the standard error of the 
mean (SEM). In the electrophysiological studies, the effects of individual drug 
concentrations were expressed as the percentage of control frequency and 
group results expressed as mean percentage (± SEM). Control frequency was 
determined as the mean burst frequency for the 5 minute period immediately 
preceding drug perfusion. Drug effects were assessed by recording the mean 
burst frequency in the final 5 minutes of perfusion. Statistical differences from 
control were determined by Student’s paired t-test with Bonferroni correction 
for multiple comparisons.
5.6 Results
5 .6.1 In vitro conversion study
Concentration study: DGR was detected in ACSF samples when the incubated 
concentration of RMD was greater than 250 pM (figure 19). The concentration of
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DGR measured when the maximum RMD concentration was incubated (1000 
jj.M) was found to be 1 pM (± 0.05). No DGR was measured in the tissue 
samples.
Time study: DGR was measured in all ACSF samples (figure 20) where 500 pM 
RMD was present. Again no DGR was found in the tissue samples. The 
concentration of RMD in the tissue samples was shown to increase with time 
(figure 21).
5.6.2 Electrophysiological studies
Mean burst frequency in the slices used for experimentation was found to be 
37 bursts per minute (± 18). RMD was without effect on zero Mg2+ / 4-AP 
induced epileptiform burst firing at all concentrations (0.1 - lOOpM) 
investigated (figure 22). In contrast, DGR, CBZ and ARR-15896 (0.1 - 
lOOpM) significantly (p < 0.05) reduced mean burst frequency (± S.E.M.) to 
42.5% (± 4.4; figure 23), 19.5% (± 12.2; figure 24) and 35.9% (± 3.5; figure 
25) of control, respectively.
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Figure 19: Bathing medium concentrations of remacemide ( □ ) and 
desglycinyl-remacemide (•) following the incubation of rat 
hippocampal slices with remacemide (0 - 1000 pM) for 10 
minutes at 37°C. Results (n = 5) are expressed as the mean 
absolute drug level (pM) with the error bars denoting the 
standard error of the mean.
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Figure 20: Bathing medium concentrations of remacemide ( □ ) and 
desglycinyl-remacemide (•) following the incubation of rat 
hippocampal slices with 500 jjM  remacemide for 0 - 30 
minutes at 37°C. Results (n = 5) are expressed the mean 
absolute drug level (pM) with the error bars denoting the 
standard error of the mean.
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Figure 22: The effects of remacemide (0 -100 pM) on zero Mg2+/4-AP 
induced epileptiform bursting in the rat hippocampal slice 
following a 25 minute perfusion. Results (n = 5) are expressed as 
the mean percentage of control bursting. Error bars denote the 
standard error of the mean.
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Figure 23: The effects of desglycinyl-remacemide (0 - 100 p,M) on 
zero Mg2+/4-AP induced epileptiform bursting in the rat 
hippocampal slice following a 25 minute perfusion. Results (n =
5) are expressed as the mean percentage of control bursting. Error 
bars denote the standard error of the mean. Statistical differences 
(* p  < 0.05) from control were determined by Student’s 
paired t-test with Bonferroni correction for multiple 
comparisons.
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Figure 24: The effects of carbamazepine (0 -100 pM) on zero Mg2+/4-AP 
induced epileptiform bursting in the rat hippocampal slice 
following a 25 minute perfusion. Results (n = 5) are expressed as 
the mean percentage of control bursting. Error bars denote the 
standard error of the mean. Statistical differences (*/? < 0.05) 
from control were determined by Student’s paired t-test 
with Bonferroni correction for multiple comparisons.
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Figure 25: The effects of ARR-15896 (0- 100 jiM) on zero Mg2+/4-AP 
induced epileptiform bursting in the rat hippocampal slice 
following a 25 minute perfusion. Results (n = 5) are expressed as 
the mean percentage of control bursting. Error bars denote the 
standard error of the mean. Statistical differences (* p  < 0.05) 
from control were determined by Student’s paired t-test with 
Bonferroni correction for multiple comparisons.
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5.7 Discussion
The above investigations were designed to investigate the conversion of RMD to 
DGR in vitro and compare and contrast the effects of both compounds on the 
generalised epileptiform activity produced by omission of Mg2+ and the addition 
4-AP to the bathing medium of rat hippocampal slices. CBZ and ARR 15896 
were employed for comparative purposes.
The hippocampal slice is a useful in vitro tool for the investigation of AED 
action (Yonekawa et al, 1995). Perfusion with 4-AP alone is generally 
sufficient to induce epileptiform burst firing in this model, as is removal of 
Mg2+ from the bathing medium (Mody et al, 1987; Chesnut and Swann, 1988; 
Watts and Jefferies, 1993; Traub et al, 1994; Arvanov et al, 1995; Traub et al, 
1995). However, in this case a dual stimulus was chosen to provoke the 
robust, frequent and reproducible discharges required for pharmacological 
study. The primary induction of burst firing in the zero Mg2+/ 4-AP model is a 
consequence of multiple cellular mechanisms.
Three mechanisms have been proposed to underlie burst generation caused by
the omission of Mg2+ from the perfusate. As previously described, divalent
cations, such as Mg2+ and Ca2+, are involved in the process of stabilising
membrane currents. The removal of Mg2+ facilitates the production of inward
ionic currents and therefore action potentials (Frankenhaeuser and Hodgkin,
1957; McLaughlin et al, 1971). In addition, Mg2+ and Ca2+ are mutual
antagonists, with Mg2+ blocking Ca2+ entry into pre- and post-synaptic
membranes (Katz and Miledi, 1969; Czeh and Somjen, 1989). By removing
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Mg2+, neurotransmitter release is facilitated, causing enhanced excitability of 
the postsynaptic neurone (Mody et al, 1987). Finally, the absence of Mg2+ 
removes the voltage-dependent Mg2+ block from the NMDA subtype of 
glutamate receptor, again facilitating enhanced excitatory neurotransmission 
(Traub et al, 1995). Blockade of voltage-gated K+ channels by 4-AP further 
increases the hyperexcitability by preventing repolarisation of the neuronal 
membrane (Traub et al, 1994). The resultant epileptiform burst firing is, 
however, a manifestation of generalised hyperexcitability involving non- 
synaptic events and non-specific synaptic and neuronal activation (Kohling et 
al, 2001). Accordingly, drugs with a variety of mechanisms of action are 
effective in this model (Yonekawa et al, 1995).
The results from the conversion study indicate that small amounts of DGR are
measurable in the bathing medium of hippocampal slices following incubation
with 250 pM RMD and above. The concentration of DGR increased with the
incubated RMD concentration. DGR concentrations following incubation with
500 pM RMD were time-independent suggesting that the presence of DGR in
the samples is due to contamination of the parent drug and not conversion of
RMD to DGR although small levels of conversion by hydrolase enzymes in
the hippocampal slice cannot be discounted. The concentrations of DGR
detected, even at the highest concentration of RMD incubated, are not
thought to be of a sufficient concentration to influence any results observed in
the hippocampal slice model. This is in contrast to the low concentrations of
DGR required to block NMDA currents (Subramaniam et al, 1996) and for
MK801 displacement (Palmer et al, 1992). However, the model utilised in this
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study is an extremely general model of excitation and therefore higher 
concentrations of any compound will be required to exert an effect on the 
various mechanisms of excitation. From the results shown in figure 23, it is 
also clear that 1 pM DGR has no effect in this model.
Electrophysiological studies revealed that DGR, CBZ and ARR-15896 all 
decrease zero Mg2+/ 4-AP induced epileptiform activity in a concentration 
dependent manner. RMD was found to have no effect in this model at any of 
the concentrations studied.
CBZ and ARR-15896 reduced zero Mg2+/ 4-AP induced epileptiform activity 
in the rat hippocampal slice in a concentration-dependent manner, suggesting 
that blockade of voltage-gated Na+ channels and the NMDA receptor are 
effective mechanisms for the prevention of burst firing in this model. This 
finding is substantiated by the efficacy of DGR. In contrast, RMD was 
without effect on zero Mg2+/ 4-AP induced epileptiform burst firing. To 
confirm that the RMD findings were due to lack of efficacy and not slice 
insensitivity, tetracaine (100 pM) was perfused at the conclusion of each 
RMD study. In all cases, spiking was rapidly and completely abolished (data 
not shown). The contrasting effects of RMD and DGR in this study may be 
related to the relative potencies of the two compounds at the voltage-gated 
Na+ channel and the NMDA receptor.
This proposal has implications for investigations of the anticonvulsant efficacy
of RMD in animals and man. RMD and DGR have a common anticonvulsant
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profile in experimental animals characterised by efficacy against seizures 
induced by maximal electroshock and the systemic administration of NMDA, 
4-AP and kainate (Garske et al, 1991; Palmer et al, 1993; Cramer et al, 1994). 
The E D 5o values in these models are similar (Palmer et al, 1997), giving the 
impression that RMD and DGR are roughly equi-potent. However, one must 
consider the rapid conversion of RMD to DGR in both animals and man 
before making such comparisons. One hour after systemic administration of 
the parent compound, the metabolite accounts for more than 50% of 
circulating drug concentrations in experimental animals (Section 3.6). In 
human studies, under steady state conditions, DGR represents approximately 
30% of the total drug load (Schacher and Tarsy, 2000). These findings, 
together with the recognised separation in potency and longer half-life of the 
metabolite (Schachter and Tarsy, 2000), suggest that, following systemic 
administration of the parent compound, DGR is the principal pharmacological 
moiety and NMDA receptor blockade the primary mechanism of action.
Although in general terms RMD and DGR have a common pharmacological
profile, the desglycinyl derivative is reported to be more potent, at both
voltage-gated Na+ channels and the NMDA receptor (Subramaniam et al,
1996; Wamil et al, 1996). In cultured mouse spinal cord neurones, RMD and
DGR prevent sustained repetitive firing, a marker for Na+ channel activity,
with IC50 values of 7.9 pM and 3.3 pM, respectively (Wamil et al, 1996).
Displacement of [3H]-batrachotoxin binding to neuronal Na+ channels has also
been reported, with IC50 values of 15.6 pM for RMD and 7.9 pM for DGR
(Palmer et al, 1992). At the NMDA receptor, RMD and DGR displace [3H]-
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MK801 binding with half maximal inhibitory concentrations of 68 pM and 
0.48 pM, respectively (Palmer et al, 1992). In addition, NMDA currents are 
reduced by 50% at concentrations of 75 pM RMD and 0.7 pM DGR 
(Subramaniam et al, 1996). These studies reveal an important two-fold 
separation in potency at the Na+ channel and up to a 100-fold difference at the 
NMDA receptor which may explain the contrasting effects of RMD and DGR 
on zero Mg2+ / 4-AP induced epileptiform activity.
However, previous investigations conducted in vitro have indicated that there 
may be possible differences in the NMDA receptor blocking actions of RMD 
and DGR (Subramaniam et al, 1996). The NMDA receptor block produced 
by DGR was shown to be strongly use- and voltage-dependent and could be 
occluded by Mg2+, indicating an open channel block mechanism. In contrast, 
the partial voltage dependence of RMD suggests that at least a portion of its 
action on NMDA receptors occurs via a non-channel blocking/allosteric 
mechanism (Subramaniam et al, 1996). Previous evaluation of RMD in the 
hippocampal slice demonstrated that it has no effects on evoked CA1 
discharges, recurrent inhibition, induction of long term potentiation, penicillin- 
induced discharges or the latency of depolarisation produced by VTD (Palmer 
et al, 1991).
Previously reports of CBZ effects in the hippocampal slice model are
conflicting. CBZ has been reported to significantly decrease 4-AP induced
bursting in the hippocampus of both young and old rats at concentrations
similar to those used in the above study (Fueta and Avoli, 1992). The drug
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was also found to have efficacy in both the low calcium and low Mg2+ models 
(Dost and Rundfeldt, 2000). In contrast, it has also been reported that CBZ 
has no effect on burst frequency in the 4-AP model at a concentration of 51 
pM. A decrease in burst amplitude however, was observed (Yonekawa et al,
1995).
As with all models, the hippocampal slice preparation has its disadvantages. 
As discussed in section 1.3.1, the trauma of dissection may alter the 
metabolism of the slice or cause partial mechanical injury and hypoxia of the 
tissue. In addition, ionic environments do not exactly mimic normal 
extracellular conditions in vivo and variability between different areas in the 
one region of the slice, perhaps caused by damage, may affect responses (Bak 
et al, 1980; Grinvald and Segal, 1984; Reid et al, 1988). Although the 
hippocampus can be considered a two-dimensional structure, longitudinal and 
contralateral pathways do exist. These pathways are severed during the 
preparation process thus altering both excitatory and inhibitory inputs.
Despite this, the hippocampal slice preparation is widely regarded as an 
important in vitro preparation (Fisher, 1989) and can exhibit an impressive 
range of neuronal behaviours. This model can help differentiate drugs with 
similar in vivo spectrums of anticonvulsant activity (Yonekawa et al, 1995).
In conclusion, it would appear that small levels of DGR are detectable in
ACSF samples following hippocampal slice incubation with RMD. It is
suggested that this is a result of contamination of the RMD supply. The
concentrations of DGR measured, even at the highest concentrations of
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RMD, were not sufficient to affect further studies. RMD was without effect 
on zero Mg2+ / 4-AP induced epileptiform burst firing in the rat hippocampal 
slice. In contrast, DGR, CBZ and ARR-15896 all significantly reduced 
epileptiform activity. These results suggest that blockade of voltage-gated Na+ 
channels and the NMDA receptor protect against paroxysmal discharges in 
this model. The relatively low potency of RMD at these pharmacological 
targets may explain its lack of efficacy in this regard. In addition, the different 
mechanism of NMDA receptor blockade produced by RMD and DGR may 
have contributed to the results. These findings, together with those of 
pharmacokinetic investigations (Schachter and Tarsy, 2000), suggest that the 
anticonvulsant effects of RMD in both animals and man may be mediated by 
its desglycinyl metabolite.
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Chapter 6
Effects of remacemide and desglycinyl-remacemide on sodium 
influx in rat brain synaptosomes
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6.1 Introduction
Blockade of voltage-gated sodium channels is a recognised mechanism of 
action of several commonly used AEDs, including CBZ, PHT and LTG 
(Rogawski and Porter, 1990; White, 1999). A plethora of electrophysiological 
investigations suggest that these agents produce a characteristic voltage- and 
use-dependent blockade of sodium channels, reducing high frequency 
neuronal firing with little or no effect on the amplitude or duration of single 
action potentials (Schwartz and Grigat, 1989; Ragsdale et al, 1991; Lang et 
al, 1993; Kuo and Bean, 1994; Kuo et al, 1997). Binding studies (Willow and 
Catterall, 1982) and numerous neurochemical investigations (Willow et al,
1984; Leach et al, 1986a; Waldmeier et al, 1995; Deffois et al, 1996; 
Lingamaneni and Hemmings, 1999) substantiate these observations.
The sodium channel effects of RMD and DGR are considerably less 
characterised. There is evidence to support inhibition of sustained repetitive 
firing of sodium-dependent action potentials (Wamil et al, 1996; Norris and 
King, 1997b) and an interaction with [3H]-batrachotoxin binding (Palmer et 
al, 1992). However, specific neurochemical investigations of sodium channel 
blockade with RMD and DGR are limited (Srinivasan et al, 1995) and the 
results potentially confounding (Davies, 1997).
6.2 Aims
The following study was designed to characterise the sodium channel blocking
properties of RMD and DGR using a simple neurochemical technique in rat brain
synaptosomes. CBZ, ARR-15896, LTG and PHT were included for comparative
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purposes. ARR-15896 is a neuroprotective compound with structural similarities 
to RMD and DGR (Palmer et al, 1999). It is an NMDA receptor ion channel 
antagonist with a pharmacological profile similar to that of MK801 (Greene et al,
1996).
6.3 Methods
The following methodology was adapted from the methods of Urenjak and 
coworkers (1991) and Deri and Adam-Vizi (1993).
6.3.1 Preparation o f synaptosomes
The cortex of an adult, male Wistar rat (200-250 g) was homogenised with a 
motorised teflon pestle in 15 ml ice-cold homogenisation buffer (0.32 M 
sucrose, 5 mMNa-2-([2-hydroxy-l,l-bis-(hydroxymethyl)ethyl]- 
amino)ethanesulphonate, 0.5 mM EDTA, 16 pM BSA; pH 7.4). The 
homogenate was then centrifuged at 1,000 x g for 10 minutes at 4°C.
Thereafter, the resulting supernatant was centrifuged at 28,000 x g for 20 
minutes at 4°C to produce a crude mitochondrial/synaptosomal pellet.
Following resuspension in 4 ml homogenisation buffer, the pellet was layered 
on a discontinuous Ficoll gradient (2.5 ml 12% Ficoll, 1.5 ml 9% Ficoll, 2.5 
ml 6% Ficoll, 2 ml homogenate). This gradient was then centrifuged at 90,000 
x g for 60 minutes at 4°C.
The two synaptosomal layers found within the 9% Ficoll region were removed
and diluted to 18 ml with homogenisation buffer (minus EDTA). This
suspension was then centrifuged for 20 minutes at 20,000 x g at 4°C. The
153
resulting pellet was resuspended in 9.96 ml standard incubation medium 
(3mM KC1, 2mM MgCl2, 25mM HEPES, lOmM glucose and 140 mM 
sucrose; pH 7.4) and placed on ice.
6.3.2 Sodium-sensitive dye uptake
Before being added to the synaptosomes, 20 pi 2mM SBFI-AM was mixed 
with 20 pi 2% pluronic F-127. Previous studies have shown that the presence 
of the detergent facilitates the influx of the dye into the synaptosomes. The 40 
pi solution of dye and detergent was added to 9.96 ml of synaptosomal 
suspension and continually shaken in an enclosed incubator for 70 minutes at 
37°C. During this time the dye was taken up by the synaptosomes and 
hydrolysed to SBFI. The influx of the dye was monitored by removing a 2 ml 
aliquot of the suspension and observing the increase in fluorescence at an 
excitation of 340 nm and an emission of 510 nm on a Perkin Elmer LS-5 
Luminescence Spectrometer.
To account for the possible leakage of dye from the synaptosomes, a ratio 
was taken between the excitation at 340 nm, the Na+-dependent intensity and 
at 380 nm, the Na+-independent intensity as suggested by Harootunian and 
coworkers (1989) and Borin and Siffert (1990).
Following incubation, the synaptosomal suspension was centrifuged at 12,000
x g for 10 minutes at 4°C. In order to remove any dye that was not taken up,
the synaptosomes were then resuspended in standard incubation medium and
a further spin of 5 minutes at 12,000 x g was performed at 4°C. Thereafter,
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the pellet was again resuspended in standard incubation medium to a protein 
concentration of 6 mg/ml as determined by the BIORAD method (section 
2.2.2) and stored on ice.
6.3.3 Construction o f standard curve
In order to relate fluorescence to internal sodium concentration, a standard 
curve was prepared. This was carried out in the presence of gramicidin D, an 
ionophore which makes plasma membranes permeable to monovalent cations 
(Pressman et al, 1967; Podleski and Changeux, 1969, Keen and White, 1971). 
In the presence of gramicidin D (2 pM), it was assumed that Na+ 
concentrations between the external medium and synaptosome cytoplasm 
were in equilibrium. Synaptosomes were prepared in a sodium free 
environment, as described above. The samples were then exposed to known 
concentrations of sodium (12 - 200 mM) in the presence of gramicidin D for 5 
minutes (at 37°C) after which time the 340/380 nm fluorescence intensity ratio 
(at an emission of 510 nm) was noted. A standard curve was constructed by 
plotting the 340/380 nm ratios as a function of Na+ concentration (figure 26).
6.3.4 Determination o f resting sodium
To determine drug effects on the resting internal sodium concentration of the
synaptosomes, 100 pi of the synaptosomes was added to 1.85 ml standard
incubation medium containing the appropriate concentration of drug and
supplemented with 140 mM NaCl and 2 mM CaCkfat 37°C). The 340/380
fluorescence intensity ratio was noted at 0 and 5 minutes. The internal sodium
concentration at 5 minutes was deemed to be the resting concentration for
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that preparation and also served as the control level for the veratridine 
(VTD)- stimulated influx investigations.
6.3.5 Veratridine-induced sodium influx
VTD is known to open voltage-dependent Na+ channels, which in turn causes 
a Na+influx and, consequently, depolarisation (Blaustein and Goldring, 1975). 
Once the resting Na+ concentration for the preparation was established (see 
above), 50 pi 8 mM VTD was added to the cell giving a final concentration of 
200 pM (final volume 2 ml). Following a 5 minute incubation at 37°C, the 
340/380 fluorescence intensity ratio was noted.
6.3.6 Assay validation
To ensure that the methodology was specific for measuring changes in 
internal sodium concentrations, the assay was validated by using the sodium 
channel blocker, tetrodotoxin (TTX). Synaptosomes were prepared and 
loaded with dye as described above. The effects of TTX (0-10 pM) on resting 
sodium concentrations and veratridine-stimulated Na+ influx were then 
investigated.
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Figure 26: Relationship between absolute sodium concentration (mM; in 
parentheses) and 340/380nm fluorescence ratio in rat cortical 
synaptosomes in the presence of the sodium ionophore 
gramicidin D (n = 5). Linearity (r2 = 0.9979) was determined by 
simple regression analysis.
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6.4 Experimental protocol
The effects of RMD, DGR, CBZ, ARR-15896, PHT (all 0 - 1000 pM) and LTG 
(0 -100 pM) were investigated in this model. Each drug concentration was tested 
on 5 occasions.
6.5 Data analysis and statistics
Results for VTD-stimulated sodium uptake are expressed as a percentage of 
control ± SEM. Resting sodium concentrations are given in absolute values 
(mM; ± SEM). Linear regression analysis was employed in the determination 
of IC50 values. Results were compared to control by one-way analysis of 
variance with Dunnett correction for multiple comparisons.
6.6 Results
TTX decreased VTD-stimulated sodium uptake to 6.9% (± 6.2) of control at 
10 pM (figure 27).
RMD (figure 28A) and DGR (figure 29A) significantly (p < 0.05) reduced 
VTD-stimulated sodium influx (± SEM) to 30.6% (± 4.7) and 13.2% (± 6.2) 
of control at 1000 pM, with ICsovalues of 160.6 pM and 85.1 pM, 
respectively. CBZ (figure 30A), ARR15896 (figure 31 A), LTG (figure 32A) 
and PHT (figure 3 3 A) reduced VTD-stimulated sodium influx (± SEM) to 
20.1% (± 2.2), 47.4% (± 13.1), 27.9% (± 10.0) and 79.8% (± 6.6) of control, 
respectively at the maximum concentrations studied. IC50 values for CBZ and 
LTG were 325.9 pM and 23.0 pM, respectively.
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Figure 27: Effect of tetrodotoxin (0 -10  pM) on veratridine-induced sodium 
influx in rat cortical synaptosomes. Results (n = 5) are expressed 
as the mean percentage of the maximal response to veratridine. 
Error bars denote the standard error of the mean.
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Figure 28: (A) Effect of remacemide (0 - 1000 pM) on veratridine-induced 
I sodium influx in rat cortical synaptosomes. Results (n = 5) are
j
I
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I Figure 29: (A) Effect of desglycinyl-remacemide (0 - 1000 pM) on
ii
j veratridine-induced sodium influx in rat cortical synaptosomes.
if
I Results (n = 5) are expressed as the mean percentage of the
I
| maximal response to veratridine. Error bars denote the standard
i
| error of the mean. (B) Effect of desglycinyl-remacemide (0 -
1000 pM) on resting internal sodium concentration in rat cortical
!
| synaptosomes. Results (n = 5) are expressed as absolute sodium
concentrations (mM). Statistical significance (p < 0.05) in (A) 
and (B) was determined by one-way analysis of variance with 
Dunnett correction for multiple comparisons.
Although ARR-15896 reduced VTD-stimulated sodium influx to less than 
50% of control, the data was not conducive to calculating IC50 levels.
The mean (± S.E.M.) resting sodium concentration of the synaptosomes was
22.5 mM (± 2.0; n = 25). DGR (1 and 10 pM) significantly ip < 0.05) 
increased the resting sodium concentration (figure 29B). In contrast, a 
significant ip <0.05) decrease in resting sodium levels was observed with 
1000 pM DGR and also with 1000 pM CBZ (figure 30B). RMD (figure 
28B), ARR15896 (figure 3 IB), LTG (figure 32B) and PHT (figure 33B) had 
no effect. TTX had no effect on resting sodium levels (data not shown).
6.7 Discussion
As discussed in previous sections, considerable electrophysiological and 
neurochemical evidence suggests that blockade of voltage-gated sodium 
channels is a common and important mechanism of AED action (Rogawski 
and Porter, 1990; White, 1999).
This investigation was designed to confirm and characterise the sodium 
channel effects of RMD and DGR using a simple neurochemical assay in rat 
brain synaptosomes.
Assay validation with the prototypic sodium channel blocker TTX confirmed
the specificity of the technique and its suitability for the study of voltage-
gated sodium channels and their pharmacological amelioration. Subsequent
studies with RMD and DGR suggested that both agents blocked voltage-
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Figure 30: (A) Effect of carbamazepine (0 - 1000 pM) on veratridine-
induced sodium influx in rat cortical synaptosomes. Results (n = 
5) are expressed as the mean percentage of the maximal response 
to veratridine. Error bars denote the standard error of the mean. 
(B) Effect of carbamazepine (0 - 1000 jiM) on resting internal 
sodium concentration in rat cortical synaptosomes. Results (n =
5) are expressed as absolute sodium concentrations (mM). 
Statistical significance (*p< 0.05) in (A) and (B) was determined 
by one-way analysis of variance with Dunnett correction for 
multiple comparisons.
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Figure 31: (A) Effect of ARR-15896 (0 - 1000 pM) on veratridine-induced 
sodium influx in rat cortical synaptosomes. Results (n = 5) are 
expressed as the mean percentage of the maximal response to 
veratridine. Error bars denote the standard error of the mean. 
Statistical significance (*p<  0.05) was determined by one-way 
analysis of variance with Dunnett correction for multiple 
comparisons. (B) Effect of ARR-15896 (0 - 1000 pM) on resting 
internal sodium concentration in rat cortical synaptosomes. 
Results (n = 5) are expressed as absolute sodium concentrations 
(mM).
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Figure 32: (A) Effect of lamotrigine (0-100 pM) on veratridine-induced 
sodium influx in rat cortical synaptosomes. Results (n = 5) are 
expressed as the mean percentage of the maximal response to 
veratridine. Error bars denote the standard error of the mean. 
(B) Effect of lamotrigine (0-100 pM) on resting internal 
sodium concentration in rat cortical synaptosomes. Results (n: 
5) are expressed as absolute sodium concentrations (mM). 
Statistical significance (*p<  0.05) in (A) and (B) was 
determined by one-way analysis of variance with Dunnett 
correction for multiple comparisons.
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Figure 33: (A) Effect of phenytoin (0 - 1000 pM) on veratridine-induced 
sodium influx in rat cortical synaptosomes. Results (n = 5) are 
expressed as the mean percentage of the maximal response to 
veratridine. Error bars denote the standard error of the mean.
(B) Effect of phenytoin (0 - 1000 pM) on resting internal sodium 
concentration in rat cortical synaptosomes. Results (n = 5) are 
expressed as absolute sodium concentrations (mM).
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gated sodium channels in a concentration dependent manner, confirming 
previous electrophysiological findings in this regard. The reference 
compounds, CBZ, ARR-15896, PHT and LTG, similarly reduced VTD- 
stimulated sodium influx, in accordance with their reported mechanisms of 
action. ARR-15896 was included due to its action on the NMDA subtype of 
glutamate receptor. In terms of relative potency, however, a wide variability 
was observed. LTG was the most potent agent (ICso= 23 pM), followed by 
DGR (IC50= 85 pM), RMD (IC50= 161 pM), CBZ (IC50= 326 pM) and PHT 
which, even at supra-therapeutic concentrations, reduced sodium influx by 
only 20%, compared to control. An IC50 value for ARR-15896 could not be 
calculated.
Previous studies suggest that both RMD and DGR displace [3H]- 
batrachotoxin binding to voltage-gated sodium channels with IC50 values of
15.6 pM and 7.9 pM, respectively (Palmer et al, 1992). In cultured mouse 
spinal cord neurones, RMD and DGR reduce sustained repetitive firing, an 
electrophysiological marker for voltage-gated sodium channel activity, with 
IC50 values of 7.9 pM and 1.2 pM, respectively (Wamil et al, 1996). A similar 
study, recording sustained repetitive firing of CA1 neurones in the intact 
hippocampal slice preparation reported half maximal inhibitory concentrations 
of 66 pM and 60 pM for RMD and DGR, respectively (Norris and King, 
1997a). Finally, a neurochemical investigation, employing VTD-induced 
glutamate and aspartate release as surrogate markers of sodium channel 
activity, reported an IC50 of 12.5 pM for DGR (Srinivasan et al, 1995).
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Although these findings largely support the two-fold separation in potency 
between RMD and DGR in the current investigation, when IC50 values are 
compared, questions of pharmacological sensitivity arise.
However, similarly disparate results are reported from a surfeit of studies with 
other sodium channel blocking AEDs. CBZ reduces sustained repetitive firing 
in cultured mouse central neurones with an IC50 of 4 pM (McLean and 
Macdonald, 1986b) and prevents batrachotoxin-induced 22Na+ flux into rat 
brain synaptosomes at 22 pM (Willow et al, 1984). In addition, it displaces 
[3H]-batrachotoxin binding with an IC50 of 131 pM (Willow and Catterall, 
1982) and prevents VTD-induced glutamate release from rat brain 
synaptosomes at 200 pM (Lingamaneni and Hemmings, 1999). A similar 
range of potencies have been reported from multiple and diverse studies with 
PHT (4 - 200 pM; Willow and Catterall, 1982; Willow et al, 1984; Willow et 
al, 1985; Lang et al, 1993; Deffois et al, 1996; Lingamaneni and Hemmings, 
1999). ARR-15896 has no reported effects on sodium channels and was 
included so that the effects of NMDA receptor blockade could be assessed in 
this model. Given the high concentrations at which they occurred, it is thought 
that the effects observed with ARR-15896 in this study were down to 
synaptosomal toxicity and not a pharmacological effect.
In order to understand wide variations in potency when comparing the 
findings of pharmacological studies of sodium channel blockade, it is 
important to consider methodological influences and to appreciate that
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sodium channels are considerably more sensitive to AED-mediated 
amelioration under depolarising conditions (Rogawski and Porter, 1990). This 
reflects the significantly greater affinity of these agents for the inactivated 
state of the channel and is fundamental in their ability to reduce high 
frequency neuronal firing with little or no effect on the amplitude or duration 
of single action potentials (Kuo, 1998). As such, electrophysiological 
investigations of the voltage- and use-dependent blockade of sodium channels 
by AEDs are consistently more sensitive than neurochemical studies which are 
usually conducted under physiological conditions and accordingly restricted to 
reporting tonic inhibitory effects of AEDs on sodium channel function. 
Moreover, the response to any given compound is generally greater in studies 
employing acutely isolated or cultured neurones than brain slices. Similarly, 
receptor binding studies often reveal impressive drug potencies while those 
employing surrogate markers of sodium channel activity, such as 
neurotransmitter release, are less sensitive. These variabilities in 
pharmacological response may reflect differences in drug penetration, non­
specific binding and, in the case of brain slice preparations, glial cell 
interaction.
The results of this study, and countless previous investigations, suggest that, 
at therapeutic concentrations, the sodium channel effects of AEDs are 
restricted to a characteristic voltage- and use-dependent blockade which 
reflects affinity for the inactivated state of the channel and underlies the ability 
of these drugs to prevent high frequency neuronal burst firing. Tonic
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inhibition of sodium channels, with the potential to influence action potential 
generation, is only observed at supra-therapeutic concentrations.
There is no evidence to suggest that AEDs influence sodium homeostasis at 
resting membrane potential. In this study, however, DGR (1 and 10 pM) 
significantly increased resting sodium concentration. A contrasting decrease 
was observed with both DGR and CBZ at 1000 pM, although this finding can 
be discounted on the basis of drug toxicity. The effect of DGR on resting 
internal sodium concentration is unlikely to be related to voltage-gated 
sodium channel blockade, given the wide separation in effective 
concentrations. It is possible that DGR has a weak pharmacological action on 
one of the many transport systems, such as Na+/K+ ATP-ase and the Na7tT 
antiport, which maintain the sodium ion gradient across the cell membrane. 
This hypothesis requires further detailed investigation before appropriate 
conclusions can be made.
In conclusion, the novel anticonvulsant compound RMD, and its active
metabolite DGR, reduce voltage-gated sodium channel activity in a
concentration-related manner. Previous electrophysiological investigations
have reported voltage- and use-dependent blockade of sodium channels with
these agents (Wamil et al, 1996; Norris and King, 1997a). This neurochemical
study supports these findings and suggests that tonic inhibition of sodium
channel function is only observed at supra-therapeutic concentrations. Given
the relative potencies and steady state concentrations of both agents following
RMD administration in man, it is likely that the desglycinyl metabolite is the
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principal pharmacological moiety and NMDA receptor blockade the primary 
mechanism of action (Davies, 1997). Nevertheless, inhibition of voltage-gated 
sodium channels by RMD undoubtedly contributes to its anticonvulsant effect.
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Chapter 7
Effects of remacemide and desglycinyl-remacemide on 
glutamate dehydrogenase activity in rat brain
mitochondria
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7.1 Introduction
Glutamate dehydrogenase (GDH) is one of the enzymes involved in glutamate 
homeostasis. It is responsible for the conversion of glutamate to a-KG by 
oxidative deamination and also for the conversion of a-KG to glutamate by 
reductive animation (figure 34; Kuo et al, 1994). a-KG, which is derived from 
glucose in both neurones and astrocytes, is a cofactor in the conversion of GABA 
to glutamate and succinic semialdehyde and an important precursor for metabolic 
and neurotransmitter glutamate (Shank and Aprison, 1981).
The activity of GDH in brain homogenates is relatively high compared to other 
enzyme systems (Salganicoff and De Robertis, 1965; Cooper et al, 1985), which 
indicates that the enzyme is capable of rapid catalytic turnover. However, several 
studies in cultured astrocytes (Yudkoff et al, 1986; Farinelli and Nicklas, 1992), 
neuronal fragments (Erecinska and Nelson, 1990; Yudkoff et al, 1991), and whole 
brain in vivo (Cooper et al, 1979), have shown that the reductive amination of a- 
KG and oxidative deamination of glutamate are slow processes. This suggests that 
the activity of GDH may be under the control of an inhibitory factor or factors. 
The rapid increase in extracellular glutamate concentrations that are measured 
following ischaemic episodes suggests that these factors may be destroyed when 
the integrity of the nervous tissue is lost (Kuo et al, 1994).
Increased levels of GDH have been measured in seizure foci (Sherwin and Gelder, 
1986) indicating a possible involvement of the enzyme in seizure processes.
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Previous neurochemical studies (Leach et al, 1997d) have demonstrated that DGR 
exerts an effect on the GAD and GABA-T enzymes that are involved in 
GABA/glutamate homeostasis following chronic administration. The following 
study was designed to investigate the effects of RMD and DGR on the activity of 
GDH for both the reductive amination of a-KG and the oxidative deamination of 
glutamate.
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Figure 34: A simplified diagram demonstrating the various routes of 
glutamate and GABA formation (Goldlust et al, 1995). 
Abbreviations: GAD, glutamate decarboxylase. Gln-S, glutamine 
synthetase; SSA, succinic acid semialdehyde; SSADH, succinic 
acid semialdehyde dehydrogenase; a-KG, a-ketoglutarate.
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7.2 Aims
The following experiments were conducted to investigate the effects of RMD and 
DGR on the actions of GDH in isolated rat brain mitochondria. CBZ and ARR- 
15896 were employed for comparative purposes.
7.3 Methods
The following method was adapted from the published methodologies of Kaur 
and Kanungo (1970) and Erecinska and Nelson (1990).
7.3.1 Preparation o f tissue
Mitochondria were prepared from adult, male Wistar rats (200-250 g).
Animals were sacrificed by cervical dislocation with the forebrain immediately 
removed and placed in an ice-cold isolation medium consisting of 0.32 M 
sucrose, 1 mM K+ EDTA and 10 mM Tris HC1 (pH 7.4). The tissue was then 
chopped into small pieces using a scalpel blade. Blood and other debris were 
removed by adding 10 ml of isolation medium and decanting the supernatant 
following a 3 minute spin at 1,000 x g at 4°C. This process was carried out 
twice prior to the tissue being homogenised with a motorised teflon pestle in 
30 ml of isolation medium.
The homogenate was centrifuged at 1,300 x g for 3 minutes at 4°C. The
resulting supernatant was centrifuged at 17,000 x g for 10 minutes at 4°C to
produce a crude mitchondrial/synaptosomal pellet. The pellet was
resuspended in 2 ml isolation medium and diluted to 15 ml with a 12%
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Ficoll/sucrose medium (12% (w/w) Ficoll, 0.32 M sucrose, 50 pM K+ EDTA; 
pH 7.4). This suspension was given 5 hand held turns with a teflon pestle. The 
suspension was divided into three centrifuge tubes with 2 ml of a 7.5% Ficoll 
buffer (7.5% (w/w) Ficoll, 0.32 M sucrose, 50 pM K+ EDTA; pH 7.4) placed 
on top of the suspension. Finally, 2 ml of isolation medium was layered on 
top. This gradient was centrifuged at 99, 000 x g for 30 minutes at 4°C. The 
pellet formed as a result of this process contained the free mitochondria. They 
were resuspended to a protein concentration of 2 mg/ml in a final incubation 
medium consisting of 0.32 M sucrose, 10 mM Tris-HCl and 0.5 mM EDTA 
(pH 7.4) and placed on ice until required.
7.3.2 Measurement o f enzyme activity
Analysis of glutamate dehydrogenase activity was carried out using a 
microplate reader and was integrated using Revelation (version 3.2) software. 
Absorbance readings at 340 nm were obtained every 10 seconds for 3 
minutes.
Drugs were dissolved in the final incubation medium described above. 
Mitchondria were incubated for three hours with the drug at room 
temperature. Control preparations were incubated with blank final incubation 
medium. Triton X-100 (2%) was also added to all samples to permeabilise the 
mitchondria. Enzyme activity in the direction of glutamate => a-KG 
(oxidative deamination) was measured in the following buffer -150 mM KC1, 
20 mM Tris HC1, 2 mM EGTA, 1 mM NAD+, 50 mM glutamate, 0.01 mM
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rotenone, 1.5 mM ADP (pH 7.6). Following incubation, 100 pi of the 
mitochondria was placed in a well of a 96-well plate with 900 pi of the assay 
buffer resulting in a final protein concentration o f200 pg/ml. The plate was 
immediately analysed for changes in absorbance at 340 nm over a 5 minute 
period.
Glutamate dehydrogenase activity in the direction of a-KG => glutamate 
(reductive amination) was measured in the following buffer- 150 mM KC1, 20 
mM Tris HC1, 0.16 mM NADH, 2 mM EGTA, 50 mM NH4CI, 1 mM 2- 
oxoglutarate (a-KG), 0.01 mM rotenone, 1.5 mM ADP (pH 7.6). Again, 100 
pi of the drug/medium incubated mitochondria was added to 900 pi of the 
assay buffer in a 96-well plate. The plate was immediately analysed for 
changes in absorbance at 340 nm over a 5 minute period.
7.4 Experimental protocol
Mitochondria, prepared from rat brain as described in section 7.3.1, were 
incubated for three hours with either RMD, DGR, CBZ or ARR-15896 (0 - 1000 
pM). Following the three hour incubation, glutamate dehydrogenase activity was 
assessed by the methods described in section 7.3.2. Each experiment was repeated 
on 5 separate occasions.
7.5 Data analysis and statistics
Changes in absorbance were calculated from an immediate first reading 
compared to one taken after 5 minutes. The results were compared to those
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obtained from non-drug containing control samples. Results for both 
directions of the reaction (reductive animation and oxidative deamination) are 
expressed as a mean percentage of control ± SEM. Results were compared to 
control by one-way analysis of variance with Dunnett correction for multiple 
comparisons.
7.6 Results
RMD, DGR and CBZ significantly (p < 0.05) decreased the conversion of a-KG 
to glutamate (reductive animation) to 60.5% (± 6.6; figure 35), 79.3% (± 3.5; 
figure 36) and 82.3% (±5.9; figure 37) of control, respectively. ARR-15896 was 
without effect at any of the concentrations studied (figure 38).
RMD and DGR significantly (p < 0.05) decreased the conversion of glutamate to 
a-KG (oxidative deamination) to 80.2% (± 3.0; figure 39) and 73.0% (± 7.2; 
figure 40) of control, respectively. CBZ and ARR-15896 significantly (p < 0.05) 
increased the rate of a-KG formation to 126.33% (± 9.85; figure 41) and 149.1% 
(± 9.0; figure 42) of control respectively.
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Figure 35: Effects of remacemide (0 - 1000 pM) on the reductive amination 
of a-ketoglutarate by glutamate dehydrogenase following a 3 
hour incubation. Results (n = 5) are expressed as a mean 
percentage of control activity with error bars representing the 
standard error of the mean. Statistical significance (*/? < 0.05) 
was determined by one way analysis of variance with Dunnett 
correction for multiple comparisons.
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Figure 36: Effects of desglycinyl-remacemide (0 - 1000 pM) on the 
reductive amination of a-ketoglutarate by glutamate 
dehydrogenase following a 3 hour incubation. Results (n = 5) are 
expressed as a mean percentage of control activity with error bars 
representing the standard error of the mean. Statistical 
significance (*/? < 0.05) was determined by one way analysis of 
variance with Dunnett correction for multiple comparisons.
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Figure 37: Effects of carbamazepine (0 - 1000 pM) on the reductive 
amination of a-ketoglutarate by glutamate dehydrogenase 
following a 3 hour incubation. Results (n = 5) are expressed as a 
mean percentage of control activity with error bars representing 
the standard error of the mean. Statistical significance (*p < 0.05) 
was determined by one way analysis of variance with Dunnett 
correction for multiple comparisons.
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Figure 38: Effects of ARR-15896 (0 - 1000 pM) on the reductive 
amination of a-ketoglutarate by glutamate dehydrogenase 
following a 3 hour incubation. Results (n = 5) are expressed as a 
mean percentage of control activity with error bars representing 
the standard error of the mean.
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Figure 39: Effects of remacemide (0 - 1000 pM) on the oxidative
deamination of glutamate by dehydrogenase activity following a 
3 hour incubation. Results (n = 5) are expressed as the mean 
percentage of control activity with error bars representing the 
standard error of the mean. Statistical significance (*/? < 0.05) 
was determined by one way analysis of variance with Dunnett 
correction for multiple comparisons.
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Figure 40: Effects of desglycinyl-remacemide (1 - 1000 pM) on the
oxidative deamination of glutamate by dehydrogenase activity 
following a 3 hour incubation. Results (n = 5) are expressed as 
the mean percentage of control activity with error bars 
representing the standard error of the mean. Statistical 
significance (*p < 0.05) was determined by one way analysis of 
variance with Dunnett correction for multiple comparisons.
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Figure 41: Effects of carbamazepine (1 - 1000 pM) on the oxidative
deamination of glutamate by dehydrogenase activity following a 
3 hour incubation. Results (n = 5) are expressed as the mean 
percentage of control activity with error bars representing the 
standard error of the mean. Statistical significance (*p < 0.05) 
was determined by one way analysis of variance with Dunnett 
correction for multiple comparisons.
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Figure 42: Effects of ARR-15896 (1 - 1000 pM) on the oxidative
deamination of glutamate by dehydrogenase activity following a 
3 hour incubation. Results (n = 5) are expressed as the mean 
percentage of control activity with error bars representing the 
standard error of the mean. Statistical significance (*p < 0.05) 
was determined by one way analysis of variance with Dunnett 
correction for multiple comparisons.
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7.7 Discussion
The role of glutamate in epilepsy is well documented (Greenamyre and Porter, 
1994). Compounds which mimic or increase glutamate levels have been 
shown to have seizure producing properties (Fisher, 1989) and human brain 
dialysis studies have shown that the extracellular glutamate concentration in 
the epileptic focus is markedly increased during seizures (Carlson et al, 1992; 
During and Spencer, 1993; Wilson et al, 1996). The homeostasis of 
glutamate, and indeed GABA, is therefore critical to the maintenance of 
normal brain activity.
The above study was designed to investigate the effects of RMD and DGR on 
the activity of GDH, the enzyme responsible for the formation of glutamate 
from a-KG (reductive amination) and also for the conversion of glutamate to 
a-KG (oxidative deamination).
RMD, DGR and CBZ significantly decreased the formation of glutamate from a- 
KG in the above study while ARR-15896 had no effect. RMD and CBZ were 
shown to have no effect at therapeutically relevant concentrations which are said 
to be between 1 and 10 pM for both compounds (McLean and Macdonald, 1986; 
Schachter and Tarsy, 2000). The formation of a-KG from glutamate was 
significantly reduced by RMD and DGR. However RMD had no effect at 
therapeutically relevant concentrations. CBZ and ARR-15896 significantly 
increased the conversion of a-KG to glutamate. Interestingly, DGR significantly 
decreased both actions of the GDH enzyme at 10 pM. In both cases the results
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obtained appeared to be against the general trend observed with other DGR 
concentrations. There is no clear reason for these findings and further experiments 
would be require to assess their integrity.
Previous studies have found that DGR significantly increases the activity of 
GABA-T following repeated administration (Leach et al, 1997d). The same study 
found that DGR had no effect on GABA or glutamine concentrations, however, a 
trend towards reduced brain glutamate levels was observed although this finding 
was not statistically significant. Further investigations (Fraser et al, 1999) revealed 
that DGR has no effect on the enzyme glutamine synthetase which indicates that 
the decrease in glutamate levels observed in the original study was not the result 
of an increase in the conversion of glutamate to glutamine. DGR has also been 
reported to decrease the activity of GAD, the enzyme responsible for the 
conversion of glutamate to GABA (Leach et al, 1997d; figure 34).
Limited work has been carried out to assess the effects of AEDs on the activity 
of GDH. One study (Hitchcock and Teixeira, 1982) found that chronic PHT 
decreased GDH levels although no measurements of activity were performed. The 
same study also stated that VPA increased GDH and GABA levels. More 
recently, GBP was found to increase the oxidative deamination of glutamate to 
342% of control (Goldlust et al, 1995).
In brain, the role of GDH has yet to be fully elucidated (Plaitakis et al, 2000).
There is a general consensus that formation of glutamate in cultured astocytes
occurs mainly via the actions of glutaminase (figure 34) rather than reductive
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amination by GDH (Yudkoff et al, 1991; McKenna et al, 1996; Westergaard et al, 
1996). However, the GDH reaction may account for some fraction of glutamate 
synthesised in nerve tissue under conditions of hyperammonemia (Kanamori and 
Ross, 1995) which can be caused by VPA treatment (Marescaux et al, 1983). This 
could account for the results obtained in previous studies with VPA (Hitchcock 
and Teixeira, 1982).
RMD and DGR were shown to have no effects on the activity of GDH at 
therapeutically relevant concentrations which are estimated to be between 1 and 
10 pM for both RMD and DGR (Schachter and Tarsy, 2000). This is in 
agreement with previous studies that suggested that acute DGR administration 
was without effects on other enzymes involved in GABA/glutamate homeostasis 
(Leach et al, 1997d). CBZ was shown to increase the conversion of glutamate to 
a-KG at therapeutic concentrations. These actions may contribute to the 
anticonvulsant properties of CBZ although further investigations are required. 
ARR-15896 significantly increased the conversion of glutamate to a-KG, which 
again may contribute to its anticonvulsant action. It may also have implications for 
its efficacy against stroke-induced ischemia.
An in vivo study measuring the effects of anticonvulsants on GDH activity would 
have been a useful follow-up study given more time. Chronic administration of 
compounds would perhaps validate the above results and give further insight into 
the possible implications of any observations.
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In conclusion, the activity of the enzyme GDH was measured in rat brain 
mitochondria with the effects of RMD, DGR, CBZ and ARR-15896 being 
investigated. RMD, DGR and CBZ all decreased the formation of glutamate from 
a-KG although none of the effects occurred at therapeutically relevant 
concentrations. ARR-15896 was found to have no effect. CBZ and ARR-15896 
increased the conversion of glutamate to a-KG which may contribute to their 
anticonvulsant effects by decreasing glutamate concentrations. The results may 
also be important for the use of ARR-15896 against stroke-induced ischaemia. 
Although the role of GDH in glutamate homeostasis remains to be fully elucidated 
it is possible that in disease states, such as epilepsy, glutamate regulation via the 
GDH system plays an important role. Further investigations are required to 
confirm the above findings in vivo and to assess the clinical importance of the 
results.
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Chapter 8
The effects of remacemide and desglycinyl-remacemide on 
monoamine uptake in rat brain synaptosomes
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8.1 Introduction
There is growing evidence to suggest that monoamines have an important role 
in epilepsy (Starr, 1996). The initial indication of the involvement of 
monoamines in the process of epileptogenesis was provided by studies 
employing reserpine, which, by depletion of neuronal monoamine levels, 
facilitates the onset of seizures in DBA/2 mice (Chen et al, 1954; Lehmann, 
1967; Chapman and Meldrum, 1989). Selective destruction of monoaminergic 
nerve terminals with 6-OHDA, or strategically placed electrolytic lesions in 
both genetic epilepsy models and non-epileptic mammals (Jobe et al, 1999), 
provides further evidence for the importance of monoamines in seizure 
suppression.
Synaptic inactivation of monoamine neurotransmitters occurs via a
combination of both neuronal and extraneuronal re-uptake and intracellular
enzymatic degradation (Rang et al, 1995). Re-uptake of monoamines from the
synaptic cleft is mediated via transporter proteins, belonging to the Na+- and
Cl'-dependent amine transporter family that exist in both neuronal and glial
cell membranes (Fleckenstein et al, 2000). In addition, within the nerve
terminals, vesicular monoamine transporters operate to sequester monoamines
into vesicles prior to release as neurotransmitters (Fleckenstein et al, 2000).
Drugs may act on these transporters to alter their activity and consequently
influence synaptic transmission (Haughey et al, 1999). Monoamine oxidase
(MAO) and catechol-O-methyl transferase (COMT) represent the degradative
enzymes responsible for the inactivation of monoamines following re-uptake
(Rang et al, 1995). Inhibition of these enzymes therefore increases synaptic
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monoamine concentrations. MAO inhibitors, such as clorgyline, increase 
monoamine levels in the synaptic cleft (Lehmann, 1967), with a resultant 
decrease in convulsion intensity in animal seizure models (Finberg et al, 1993; 
Mishra et al, 1993).
Fluoxetine (FLU), an antidepressant that acts selectively by 5-HT reuptake 
inhibition, produces dose dependent anticonvulsant effects in the GEPR 
(Dailey et al, 1992). These anticonvulsant effects can be correlated with 
increased extracellular 5-HT concentrations (Yan et al, 1994). Results 
obtained from experimental models of epilepsy (Alexander and Kopeloff,
1970; Kellogg, 1971; Racine and Coscina, 1979) support the involvement of 
serotonergic systems in inhibition of seizure activity. The absence of a steady 
state 5-HT level in animals susceptible to audiogenic seizures (Naffah- 
Mazzacoratti et al, 1996) and the ability of endogenous 5-HT to suppress 
picrotoxin induced epileptiform activity in Sprague-Dawley rats (Lu and 
Gean, 1998) provides further evidence.
There is, similarly, growing evidence to suggest that NE exerts an inhibitory
influence in the CNS, therefore enhanced NE transmission may limit the
spread of seizure discharges (Lehmann, 1967; Jobe et al, 1972; McIntyre et al,
1979; Applegate et al, 1986; Shouse et al 1996). Restoration of NE levels via
a foetal locus coeruleus graft (NE containing neurones), reverses this effect
(Kokaia et al, 1994), therefore indicating a NE involvement in seizure
suppression (McIntyre et al, 1979; Applegate et al, 1986; McIntyre and
Edson, 1989; Bengzon et al, 1992). In addition, tricyclic antidepressants, such
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as desipramine (DES), inhibit NE reuptake and increase both synaptic NE 
concentration and the seizure threshold (Wood et al, 1977). Confirmation of 
these effects in epileptic patients was achieved by electrical activation of the 
locus coeruleus through cerebellar stimulation, resulting in elevated NE levels 
in the CSF and an improvement in seizure tolerance (Wood et al, 1977; 
Bengzon et al, 1992).
Previous research has revealed reduced levels of homovanillic acid (HVA), a 
DA metabolite, in patients with temporal lobe epilepsy (Kresch et al, 1989), 
an effect that can be reversed by CBZ (Okada et al, 1997b). This suggests a 
role for DA in seizure susceptibility. Administration of levodopa, a precursor 
for both NE and DA, diminishes the occurrence of tonic extensor convulsions 
in audiogenic seizure susceptible DBA/2 mice, while increasing brain NE and 
DA concentrations (Dailey and Jobe, 1984). However, inhibition of the 
conversion of levodopa to NE, via DA p hydroxylase suppression, does not 
alter this anticonvulsant effect therefore indicating the importance of DA 
(Dailey and Jobe, 1984).
There is limited data to suggest that some drugs that block monoamine 
reuptake are effective anticonvulsants in man (Ojemann et al, 1983). Whether 
an action on monoamine reuptake is important in terms of RMD and currently 
used AEDs remains to be investigated.
8.2 Aims
The aim of these experiments was to determine whether inhibition of 
monoamine re-uptake might contribute to the antiepileptic actions of RMD 
and DGR. CBZ, PHT, LTG and ARR-15896 were included for comparative 
purposes.
8.3 Methods
8.3.1 Preparation o f synaptosomes
Adult male Sprague- Dawley rats (200 -  250 g) were sacrificed by cervical 
dislocation and the brain removed into ice-cold 0.9% saline. Brain regions 
were isolated according to the method of Glowinski and Iversen (1966). The 
cerebral cortex was employed for studies of 5-HT and NE uptake and the 
striatum for DA investigations. The tissue was weighed and homogenised in 
40 volumes of ice-cold 0.32 M sucrose solution using a motorised glass-teflon 
pestle. The homogenate was centrifuged at 1,000 x g for 10 minutes at 4°C to 
remove erythrocytes and cellular debris. The resulting supernatant was 
centrifuged for a further 20 minutes at 12,000 x g at 4°C. The final supernatant 
was discarded and the pellet resuspended in 35 ml Krebs solution (NaCl 125 
mM, KC1 3 mM, NaHCOs 22 mM, CaCl2.2H20  1.2 mM, MgS04.7H20  1.2 
mM, NaH2P04 1 mM, D-glucose 10 mM, ascorbic acid 1 mM) containing 
pargyline (100 pM). Pargyline was included to prevent MAO-mediated 
neurotransmitter degradation.
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8.3.2 Monoamine uptake assay
This technique was devised from modifications of the methods of Matsunaga 
and co-workers (1998) and Fleckenstein and colleagues (1999). A 400 jj.1 
aliquot of synaptosome suspension was incubated at 37°C for 10 minutes in 
the presence of 50 nM radiolabelled monoamine (specific activities: NE, 2.5 Ci 
/ mmol; DA, 1.22Ci / mmol; 5-HT, 2.53 Ci / mmol), and appropriate drug 
concentrations, in a final assay volume of 1 ml. Monoamine transport was 
determined in duplicate with a blank assay included for each sample. Blank 
assays contained an excess (200 pM) of unlabelled monoamine. After 10 
minutes, the reaction was terminated by rapid filtration through pre-wet 
Whatman GF/B glass-fibre filter paper followed by three washes with ice cold 
Krebs solution in a Brandel harvester. Filter papers were air dried and placed 
in Pony vials containing 4 ml of Ecoscint A. Samples were analysed in 
comparison to standards of known radioactive content, corrected for 
background and blank sample counts, and expressed in relation to protein 
concentration and reaction time. Protein concentrations were determined by 
the BIORAD method as described in section 2.2.2.
8.4 Experimental protocol
Pilot studies were performed with the recognised monoamine uptake inhibitors 
FLU (0 - 1000 nM), DES (0 -100 pM) and nomifensine (NOM; 0-10 pM) to 
validate the methodologies for 5-HT, NE and DA uptake, respectively. 
Thereafter, the effects of RMD, DGR, CBZ, ARR-15896, LTG and PHT (all 
0 - 1000 pM) on 5-HT, NE and DA uptake were investigated.
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8.5 Data analysis and statistics
Results were calculated as a percentage of the individual control values for 
each uptake assay. Group results (n = 6) were then expressed as the mean 
percentage ± SEM. Statistical differences from control were determined by 
one-way analysis of variance with a Dunnett correction for multiple 
comparisons.
8.6 Results
FLU, DES and NOM significantly ip < 0.05) reduced the reuptake of 5-HT, 
NE and DA, respectively, into the rat brain synaptosomes, thereby validating 
the methodologies (figure 43-45).
RMD significantly ip < 0.05) reduced the reuptake of 5-HT, NE and DA to 
37.8 % (± 5.4), 29.8 % (± 5.9) and 10.8% (± 3.2) of control, respectively 
(figure 46). DGR significantly ip < 0.05) reduced 5-HT, NE and DA reuptake 
to 8.6% (± 1.5), 23.4% (± 3.6) and 16.67% (± 6.7) of control, respectively 
(figure 47). CBZ significantly ip < 0.05) reduced the reuptake of 5-HT, NE 
and DA to 27.6% (± 3.1), 54.2% (± 5.6) and 30.4% (± 6.8) of control, 
respectively (figure 48). ARR-15896 significantly ip < 0.05) reduced 5-HT, 
NE and DA reuptake to 16.2% (± 6.9), 27.5% (± 3.1) and 14.0% (± 2.4) of 
control, respectively (figure 49). LTG significantly ip < 0.05) reduced 5HT 
and NE reuptake (± SEM) to 39.0% (± 4.1) and 49.4% (± 6.7) of control, 
respectively. LTG was without effect on DA reuptake at all the 
concentrations studied (figure 50). PHT significantly ip < 0.05) reduced DA
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Figure 46: The effects of remacemide on 5-hydroxytryptamine (5-HT),
norepinephrine (NE) and dopamine (DA) reuptake in rat cortical 
(5-HT, NE) and striatal (DA) synaptosomes. Results (n = 9) are 
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Error bars and indicators of significance have been omitted for 
ease of comprehension.
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Figure 47: The effects of desglycinyl-remacemide on 5-hydroxytryptamine 
(5-HT), norepinephrine (NE) and dopamine (DA) reuptake in rat 
cortical (5-HT, NE) and striatal (DA) synaptosomes. Results (n = 
9) are expressed as the mean percentage of individual control 
values. Error bars and indicators of significance have been 
omitted for ease of comprehension.
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Figure 48: The effects of carbamazepine on 5-hydroxytryptamine (5-HT), 
norepinephrine (NE) and dopamine (DA) reuptake in rat cortical 
(5-HT, NE) and striatal (DA) synaptosomes. Results (n = 9) are 
expressed as the mean percentage of individual control values. 
Error bars and indicators of significance have been omitted for 
ease of comprehension.
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Figure 49: The effects of ARR-15896 on 5-hydroxytryptamine (5-HT),
norepinephrine (NE) and dopamine (DA) reuptake in rat cortical 
(5-HT, NE) and striatal (DA) synaptosomes. Results (n = 9) are 
expressed as the mean percentage of individual control values. 
Error bars and indicators of significance have been omitted for 
ease of comprehension.
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Figure 50: The effects of lamotrigine on 5-hydroxytryptamine (5-HT),
norepinephrine (NE) and dopamine (DA) reuptake in rat cortical 
(5-HT, NE) and striatal (DA) synaptosomes. Results (n = 9) are 
expressed as the mean percentage of individual control values. 
Error bars and indicators of significance have been omitted for 
ease of comprehension.
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reuptake to 35.6% (± 8.0) of control (figure 51) but had no significant effect 
on 5-HT or NE reuptake processes.
(Percentage inhibition of control uptake)
DRUG CONCENTRATION 5-HT NE DA
RMD 1000 uM 37.8 29.8 10.8
DGR 1000 uM 8.6 23.4 16.6
CBZ 1000 uM 27.6 54.2 30.4
ARR-15896 1000 uM 16.2 27.5 14.0
LTG 1000 uM 39.0 49.4 NE
PHT 1000 uM NE NE 35.6
Table 3 Effects of anticonvulsants on monoamine uptake 
8.7 Discussion
The aim of the above investigations was to assess the effects of RMD and 
DGR on monoamine uptake in rat brain synaptosomes. CBZ, ARR-15896, 
LTG and PHT were employed for comparative purposes.
There is increasing evidence to suggest monoamines may contribute to the 
regulation of neuronal excitability and hence seizure susceptibility (Kresch et 
al, 1989). Experimentally induced decrements in monoamine levels have, in 
general, been demonstrated to precipitate seizures (McIntyre et al, 1979; 
Applegate et al, 1986; Browning et al, 1989; Shouse et al, 1996; Jobe et al, 
1999), whereas increasing monoamine levels are usually associated with a
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reduction in convulsion intensity (Lehmann, 1967; Finberg et al, 1993; Mishra 
et al, 1993). Therefore, potentially AEDs may enhance monoaminergic 
transmission as part of their anticonvulsant mechanisms of action.
RMD significantly reduced the reuptake of all the three monoamines 
investigated although none of these reductions were statistically significant ip 
< 0.05) from control at therapeutically relevant concentrations which are 
reported to be between 1 and 10 pM for both RMD and DGR (Schachter and 
Tarsy, 2000). DGR also significantly reduced all three reuptake processes but 
only those of 5-HT and NE were significantly (p < 0.05) affected at 
therapeutically relevant concentrations. CBZ significantly reduced all three 
monoamine uptake processes although only the reduction in 5-HT reuptake 
was significant (p < 0.05) at therapeutically relevant concentrations which 
again are reportedly between 1 and 10 pM (McLean and Macdonald, 1986). 
The experimental NMD A receptor antagonist, ARR-15896 reduced the 
reuptake of all three monoamines. Statistically significant ip < 0.05) reduction 
of all the reuptake processes was achieved at 30 pM ARR-15896, the 
concentration required to block NMDA-induced depolarisation in 
hippocampal slices (Palmer et al, 1999). LTG significantly reduced the 
reuptake of 5-HT and NE and PHT the reuptake of DA, although no 
statistically significant ip < 0.05) effect was seen at therapeutically relevant 
concentrations.
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Figure 51: The effects of phenytoin on 5-hydroxytryptamine (5-HT),
norepinephrine (NE) and dopamine (DA) reuptake in rat cortical 
(5-HT, NE) and striatal (DA) synaptosomes. Results (n = 9) are 
expressed as the mean percentage of individual control values. 
Error bars and indicators of significance have been omitted for 
ease of comprehension.
208
CBZ produces dose dependent anticonvulsant effects in both GEPRs (Yan et 
al, 1992) and outbred Sprague-Dawley rats (Dailey et al, 1997), with a 
corresponding increase in synaptic 5-HT (Yan et al, 1992; Dailey et al, 1996; 
Graumlich et al, 1999; Butler et al, 2000). TTX, despite reducing basal 5-HT 
release, did not alter the increase in synaptic 5-HT induced by CBZ, which 
implies the elevated 5-HT levels are independent of the nerve action potential 
(Dailey et al, 1997). Evidence suggests that the increased extracellular 5-HT 
is due to reuptake inhibition (Butler et al, 2000).
Depletion of 5-HT levels in GEPRs by prior administration of p- 
chloroamphetamine diminishes the anticonvulsant effect of CBZ (Yan et al, 
1992; Dailey et al, 1996; Lu & Gean, 1998). PHT, which has a similar clinical 
profile to CBZ, also produces dose related anticonvulsant effects in GEPRs 
and Sprague-Dawley rats but with no corresponding increase in extracellular 
5-HT (Dailey et al, 1996). The evidence suggests that several AEDs, notably 
CBZ, enhance monoaminergic neurotransmission, possibly by reuptake 
inhibition, and that these effects contribute to the antiepileptic actions of the 
drugs.
Previous work has suggested that LTG inhibits the reuptake of 5-HT, NE and 
DA in vitro (Southam et al, 1998). The findings presented above do suggest 
that LTG has an inhibitory effect on the reuptake of 5-HT and NE, however, 
a lack of action of therapeutically relevant concentrations questions the 
importance of such findings.
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In contrast to the above findings, suppression of NE uptake by PHT has been 
reported in several studies with the concentrations required well within the 
therapeutic range (Hadfield, 1972; Weinberger et al, 1976). However, other 
studies have indicated that PHT only exerts an effect on NE transmission at 
concentrations above the therapeutic range and even then not necessarily via 
an action on the reuptake process (Azzaro et al, 1973). Although the results 
reported above were not statistically significant, there was a trend towards 
inhibition of NE reuptake observed with PHT (figure 51). Due to the 
concentrations of PHT required to produce that effect it is suggested that 
synaptosomal toxicity and not a pharmacological effect is being observed.
Biochemical evidence for a DA system dysfunction in the brain of epileptic 
patients is not straightforward (Starr, 1996). Both increases and decreases in 
the concentrations of DA and its major metabolite, HVA, have been detected 
in the CSF of epilepsy patients. Traditionally, DA has been regarded as 
anticonvulsant, although experimental work has occasionally produced 
conflicting results, suggesting that there might be other factors involved 
(Starr, 1996). Some clinical evidence exists suggesting that DA has an 
anticonvulsant action in man (Starr, 1996). The prototypic non-selective 
D i/D2 receptor agonist apomorphine was first proposed to be an antiepileptic 
over a century ago, but only recently has its anticonvulsant profile in man 
been established (Starr, 1996). The use of apomorphine for epilepsy is 
restricted by the high incidence of side effects and short-lived action. Side 
effects include nausea and vomiting, which could be minimised by 
administration of a peripherally acting DA antagonist such as domperidone.
Early investigations (Hadfield, 1972) demonstrated a PHT mediated inhibition 
of DA uptake in the DA rich caudate putamen. However, statistical 
significance was not indicated, and so the clinical relevance of these results 
cannot be assessed. In contrast, recent studies using in vivo microdialysis 
(Okada et al, 1997c) have reported no change in DA uptake in the presence of 
PHT at therapeutic concentrations. With respect to CBZ, significantly 
increased levels of extracellular DA have been reported in the same model 
(Okada, 1997a). The results were attributed to CBZ acting as an adenosine A2 
receptor agonist. Adenosine is said to have a role as a homeostatic modulator 
for the release of various neurotransmitters. Therefore agonists at A2 
receptors are reported to potently increase the seizure threshold and it was 
suggested that this is one of the mechanisms by which CBZ operates (Okada 
et al, 1997b). As this study was solely concerned with the contribution of 
uptake blockade, an action on adenosine receptors cannot be validated or 
disputed.
Results from 5-HT reuptake experiments indicate that CBZ, DGR and ARR- 
15896 significantly effect the reuptake process at pharmacologically relevant 
concentrations. All three agents are chemically related to the amine 
compounds that are known to inhibit monoamine uptake, for example 
imipramine and amitriptyline (Stone, 1995). It is possible that CBZ, DGR and 
ARR-15896 block the biogenic amine transporters responsible for the removal 
of monoamines from the synaptic cleft by virtue of their structure. A similar 
hypothesis can be suggested for the results obtained from the NE reuptake
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analysis given that DGR and ARR-15896 were again the only compounds 
seen to have an affect at pharmacologically significant concentrations.
The contrasting effects of RMD and DGR presented above confirms that the 
two compounds have pharmacological differences. Whether the actions of 
DGR on 5-HT and NE reuptake are relevant to the antiepileptic properties of 
RMD requires further investigation.
Interestingly, the NMDA antagonist, ARR-15896 potently inhibited the 
reuptake of all three monoamines investigated most probably via an action on 
the amine transporter systems responsible for reuptake of monoamines. These 
findings suggest a previously undiscovered mechanism of action for this 
agent. Further studies are required to evaluate the importance of these 
findings to the anti-ischaemic actions of the compound.
The theoretical link between epilepsy and effective disorders is confirmed 
pharmacologically, because agents that elevate noradrenergic and/or 
serotonergic transmission, for example tricyclic antidepressants, are both 
anticonvulsant and antidepressant, whereas reserpine both induces depression 
and facilitates seizures (Yan et al, 1993; Moshe, 2000). AEDs such as CBZ 
and VPA are becoming increasingly prescribed prophylactically for mood 
stabilisation (Okuma, 1994; Post et al, 1996; Dunn et al, 1998; Jobe et al, 
1999), and recently the beneficial effects of LTG in depression and bipolar 
disorders have been reported (Bowden, 1998; Post et al, 1998; Southam et al,
1998). The above findings suggest that RMD and ARR-15896 could have a
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potential use against such disorders. Further investigations are required to 
confirm the actions of RMD, and therefore DGR, and ARR-15896 in this 
respect.
With hindsight, a greater accuracy of results could perhaps have been afforded 
with the use of pure, rather than crude, synaptosomes.
In conclusion, the above study investigated the effects of RMD and DGR on 
the reuptake processes of 5-HT, NE and DA. CBZ, ARR-15896, LTG and 
PHT were included for comparative purposes. RMD was found to have no 
significant effects at clinically relevant concentrations. CBZ, DGR and ARR- 
15896 were found to significantly reduce the reuptake of 5-HT perhaps via a 
simple blockade of the biogenic amine transporters responsible for the 
reuptake process. DGR and ARR-15896 were also found to inhibit NE 
reuptake, possibly by the same mechanism. Further investigations are required 
to assess the mechanism and importance of the results obtained to RMD 
pharmacology in terms of epilepsy and possibly affective disorders.
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Chapter 9
General discussion and conclusions
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RMD is a novel anticonvulsant that has been previously shown to be effective 
against MES-, kainate-, NMD A- and 4-AP induced seizures (Stagnitto et al, 
1990; Garske et al, 1991; Palmer et al, 1992; Palmer et al, 1993; Cramer et 
al, 1994). RMD and its active metabolite, DGR, have been shown to inhibit 
the sustained repetitive firing of cultured neurones, suggested an inhibitory 
action on voltage-gated Na+ channels with IC50 values of 7.9 and 1.2 pM 
reported, respectively (Wamil et al, 1996). Both RMD and its active 
metabolite, DGR, have an inhibitory effect on NMDA receptors with a low 
affinity for the receptor ion channel complex although DGR is more potent at 
this site with an IC50 value for [3H]MK801 displacement of 0.48 pM 
compared to 68 pM observed for RMD (Palmer et a l, 1992). Inhibition of 
NMDA-evoked currents in rat hippocampal neurones was achieved with 
RMD and DGR at IC50 values of 67 and 0.7 pM, respectively (Subramaniam 
et al, 1996). The same studies suggested that RMD has affinity for an 
alternative allosteric site on the NMDA receptor although the consequences 
of this are not clear (Subramaniam et al, 1996).
The aim of this project was to investigate the preclinical pharmacology of 
RMD and DGR. Particular emphasis was placed on the relative contribution 
of each moiety to the antiepileptic actions of the parent compound and the 
relative importance of individual mechanisms of action. In the development of 
RMD, it was assumed that its additional inhibitory effects at the NMDA 
receptor might confer advantages for the drug over standard Na+ channel 
blocking AEDs.
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During the conduct of this project, results emerged from clinical trials 
suggesting that while effective as add-on therapy (Richens et al, 2000), RMD 
was significantly inferior to the Na+ channel blocker, CBZ in monotherapy 
trials (Brodie et al, in prep). In fight of these observations, the preclinical 
pharmacological investigations described above assumed greater significance. 
An attempt was made to formulate a hypothesis to explain why RMD, a drug 
with a promising preclinical profile and recognised clinical efficacy as add-on 
treatment, performed so poorly as monotherapy.
The results presented above indicate that there are vital differences in the 
pharmacology of RMD and DGR. Investigations presented herein (section 
3.6) have demonstrated that DGR is the predominant moiety, in terms of 
pharmacokinetics, following administration of the parent compound. Various 
preclinical investigations, including those presented here, have shown that 
DGR is the more active compound pharmacologically (Stagnitto et al, 1990; 
Garske et al, 1991; Palmer et al, 1991; Palmer et al, 1992; Clark et al, 1995; 
Davies, 1997). Given that DGR exerts an effect on NMDA receptors at 
concentrations lower than those required to block Na+ channels, it is possible 
that the efficacy observed in the majority of animal models is the result of a 
reduction of NMDA receptor activity.
NMDA antagonists are effective anticonvulants in a wide variety of seizure
models (Anderson et al, 1986; Avoli et al, 1987; Mody and Lambert, 1987;
Aram et al, 1989). However, they are known to produce a variety of adverse
neurobehavioural effects in vivo (Rogawski, 1992). The challenge therefore
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has been to develop NMDA antagonists that not only have adequate 
bioavailability and appropriate pharmacokinetic properties, but which are also 
sufficiently free of side effects at anticonvulsant doses. There are several 
modulatory sites on the NMDA receptor (figure 1) which have been identified 
by a wide range of selective antagonists. Studies have suggested that there 
may be differences in the toxicity profiles of drugs acting selectively at these 
sites (Rogawski, 1992).
Investigations have been carried out to assess the therapeutic indices of a 
variety of selective NMDA antagonists (Ferkany et al, 1989; Rogawski et al, 
1989; Saywell et al, 1990; Thurkauf et al, 1990; Rogawski et al, 1991). The 
therapeutic index (TI) of each compound was determined as the ratio of 
TD50/ED50, where TD50 is the dose producing impaired motor performance in 
50% of animals, and the ED50 is the dose protecting 50% of the animals 
against THE in the MES-model. A TI of 1 indicates an equal potency for 
anticonvulsant activity and motor toxicity. High affinity uncompetitive 
NMDA antagonists such as MK801 and PCP were found to have TIs of < 1. 
However, low affinity uncompetitive antagonists, such as DGR, were found 
to have an average TI of 4. CBZ, which has no reported effects on NMDA 
receptors was found to have a TI of 6 (Rogawski, 1992). Although high 
affinity uncompetitive NMDA antagonists appear to have no future in epilepsy 
therapy (Sveinbjomsdottir et al, 1993), low affinity uncompetitive antagonists 
have shown promise. Preclinically, RMD and DGR displayed anticonvulsant 
activity with a much better therapeutic ratio than the high affinity antagonists
(Rogawski et al, 1991; Rogawski, 1996).
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As add-on therapy in clinical trials, RMD was shown to be effective at 
decreasing seizure frequency when compared to the first drug alone (Richens 
et al, 2000). It was noted that the vast majority of patients were taking CBZ, 
a known hepatic enzyme inducer as a concominant AED. Various clinical 
studies have demonstrated that RMD, and in particular DGR, are susceptible 
to the effects of hepatic enzyme induction (Leach et al, 1996a; Leach et al, 
1997a; Chadwick et al, 2000; Richens et al, 2000). The results presented 
above demonstrate that DGR is also more susceptible than RMD to the 
enzyme inducing effects of PB in mice.
Despite reported efficacy as adjunctive therapy, a recently conducted systemic 
review and meta-analysis of earlier placebo-controlled add-on trials indicates 
that RMD has a poor response rate as add-on therapy (Marson et al, 2001). 
The analysis indicated that doses of 300 - 600 mg RMD per day were no 
different from placebo. Regression analysis in the same study suggests that 
approximately 10% of patients would however see a significant improvement 
in seizure control on 800 - 1200 mg of RMD per day. Clinical studies have 
indicated that 1200 mg RMD daily, administered as adjunctive therapy to 
patients taking hepatic enzyme inducers, increases the incidence of NMDA 
associated side effects (Chadwick et al, 2001). If 1200 mg RMD was taken 
daily by patients who do not have enzyme induction, the incidence of adverse 
events would surely increase to unacceptable levels.
The clinical trial results described above are in complete contrast to what 
would be expected from preclinical data. As described, low affinity NMDA
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antagonists with acceptable pharmacokinetic profiles should be ideal 
candidates for antiepileptic therapy. A low affinity NMDA antagonist with an 
additional effect at voltage-gated sodium channels, on paper appears to be an 
ideal candidate for clinical efficacy. The fact that RMD does not significantly 
decrease seizure frequency raises a number of questions. Firstly the relevance 
of animal models in the development of AEDs. All preclinical information 
suggested that both RMD and DGR are anticonvulsant in a wide range of in 
vitro and in vivo models although in clinical practice neither compound 
appeared to have a significant effect on seizures. Perhaps the models that are 
utilised are more detached from the human condition as first thought. In 
addition, DGR levels in brain reported in the above studies appear to be much 
higher than those estimated for humans (AstraZeneca, unpublished results). It 
is possible that the kinetic differences between animal and man contribute to 
the lack of outcome correlation. Secondly, the findings question the entire 
concept of rational drug design. On paper, RMD was an ideal candidate for 
AED development. It is possible that the DGR was just too potent at the 
NMDA site. A number of successful AEDs, for example VP A, GBP, VGB, 
FBM and LEV, have a weak affinity for their respective sites of action 
although they are successful in the clinical setting.
In conclusion, the results presented herein suggest that there are differences in
the pharmacology of RMD and DGR which may possibly affect the clinical
profile of the parent drug. The studies confirm the reported differences in the
potencies of the two moieties at the known sites of action. Monotherapy trials
and meta-analysis of add-on trials indicate that RMD does not improve on the
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efficacy afforded by CBZ, a traditional Na+ channel blocker. These results 
suggest that NMDA receptor blockade is not as important a property for an 
antiepileptic compound as first believed. The lack of correlation between 
preclinical and clinical data questions the relevance of animal models to 
human epilepsy. This suggestion has possible implications for the future 
development of NMDA antagonists as AEDs.
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